Novartis Confidential Page 2
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 7
List of tables ........................................................................................................................ 7
List of abbreviations ............................................................................................................ 9
Glossary  of terms ............................................................................................................... 12
Protocol summary .............................................................................................................. 14
Amendment 04 (23
-Jan-2020)........................................................................................... 20
Amendment 03 (24
-Sep-2018) .......................................................................................... 23
Amendment 02 (16- Aug-2017) ......................................................................................... 25
Amendment 01 (19
-Dec-2016).......................................................................................... 29
1Background ................................ ................................ ................................ ........................ 33
1.1 Overview of disease pathogenesis, epidemiology and current treatment .............. 33
1.1.1 Role of the CDK4/6 pathway  in breast cancer...................................... 33
1.1.2 Role of estrogen pathway  in breast cancer ............................................ 35
1.2
Introduction to investigational treatment(s) and other study  treatment(s) ............. 37
1.2.1 Overview of Ribociclib ......................................................................... 37
1.2.2 Overview of Letrozole .......................................................................... 40
1.2.3
Low potential for interaction between ribociclib and letrozole ............ 41
1.2.4 Overview of LHRH agoni sts................................................................. 41
2Rationale ............................................................................................................................ 42
2.1 Study  rationale and purpose ................................................................................... 42
2.2 Rationale for the stud y design ............................................................................... 43
2.3 Rationale for dose and regimen selection .............................................................. 43
2.4 Rationale for choice of comparator drugs ............................................................. 44
2.5 Risks and benefits .................................................................................................. 44
3Objectives and endpoints ................................................................................................... 45
4Study  design ...................................................................................................................... 47
4.1 Description of stud y design ................................................................................... 47
4.2 Timing of interim anal yses and design adaptations ............................................... 49
4.3 Definition of end of study ...................................................................................... 49
4.4 Early study termination .......................................................................................... 50
5Population .......................................................................................................................... 50
5.1 Patient population .................................................................................................. 50
5.2 Inclusion criteria .................................................................................................... 50
5.3 Exclusion criteria ................................................................................................... 52

Novartis Confidential Page 3
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
6Treatment ................................ ................................ ................................ ........................... 54
6.1 Study  treatment ...................................................................................................... 54
6.1.1 Dosing regimen ..................................................................................... 55
6.1.2 Ancillary  treatments .............................................................................. 57
6.1.3
Rescue medication ................................................................................ 57
6.1.4 Guidelines for continuation of treatment .............................................. 57
6.1.5 Treatment duration ................................................................................ 57
6.2 Dose escalation guidelines ..................................................................................... 57
6.3 Dose modifications ................................................................................................ 57
6.3.1 Dose modification and dose delay ........................................................ 57
6.3.2 Follow -up for toxicities ......................................................................... 65
6.4
Concomitant medications ...................................................................................... 65
6.4.1 Permitted concomitant therap y
............................................................. 65
6.4.2 Permitted concomitant therap y requiring caution ................................. 66
6.4.3 Prohibited concomitant therap y
............................................................ 67
6.4.4 Drugs with QT prolongation ................................................................. 67
6.5
Patient numbering and treatment assignment........................................................ 68
6.5.1
Patient numbering ................................................................................. 68
6.5.2 Treatment assignment ........................................................................... 68
6.5.3 Treatment blinding ................................................................................ 68
6.6 Study  drug preparation and dispensation ............................................................... 68
6.6.1 Study  treatment packaging and la beling ............................................... 69
6.6.2 Drug supply  and storage ........................................................................ 69
6.6.3 Study  drug compliance 
and accountability ........................................... 70
6.6.4 Disposal and destruction ....................................................................... 70
7
Visit schedule and assessments ......................................................................................... 70
7.1 Study  flow and visit schedule ................................................................................ 70
7.1.1 Molecular 
pre-screening ........................................................................ 80
7.1.2 Screening ............................................................................................... 80
7.1.3 Run-in period ........................................................................................ 82
7.1.4 Treatment period ................................................................................... 82
7.1.5 Discontinuation of study treatment ....................................................... 82
7.1.6 Withdrawal of consent .......................................................................... 84
7.1.7 Follow up for safet y evaluations ........................................................... 85
7.1.8 Lost to f ollow-up................................................................................... 85
7.2 Assessment ty pes................................................................................................... 85

Novartis Confidential Page 4
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
7.2.1 Efficacy  assessments ............................................................................. 85
7.2.2 Safety  and tolerability  assessments ....................................................... 87
7.2.3 Patient reported outcomes ..................................................................... 90
8Safety  monitoring and reporting ........................................................................................ 91
8.1 Adverse events ....................................................................................................... 91
8.1.1
Definitions and reporting ...................................................................... 91
8.1.2 Laboratory  test abnormalities ................................................................ 93
8.2 Serious adverse events ........................................................................................... 93
8.2.1
Definitions............................................................................................. 93
8.2.2
Reporting............................................................................................... 94
8.3 Emergency  unblinding of treatment assignment ................................................... 95
8.4 Pregnancies ............................................................................................................ 95
8.5 Warnings and precautions ...................................................................................... 95
8.6 Data Monitoring Committee .................................................................................. 95
8.7 Steering Committee ............................................................................................... 95
9Data collection and management ....................................................................................... 96
9.1 Data confidentiality ............................................................................................... 96
9.2 Site monitoring ...................................................................................................... 96
9.3
Data collection....................................................................................................... 97
9.3.1 IRT data collection ................................................................................ 97
9.3.2 FACT -B questionnaire data collection .................................................. 97
9.4 Database management and quality  control ................................ ............................ 97
10Statistical methods and data anal ysis................................................................................ 98
10.1 Analy sis sets .......................................................................................................... 98
10.1.1 Full Anal ysis Set ................................................................................... 99
10.1.2 Safety  set in Core Phase ........................................................................ 99
10.1.3 Safety  Set in Extension Phase ............................................................... 99
10.1.4
Per-Protocol set ..................................................................................... 99
10.1.5 Dose -
determining anal ysis set............................................................... 99
10.1.6 Pharmacokinetic anal ysis set
................................................................. 99
10.1.7 Other anal ysis sets ................................................................................. 99
10.2 Patient demographics/other baseline characteristics
............................................. 99
10.3 Treatments (stud y treatment, concomitant therapies, compliance) ....................... 99
10.4 Primary  objective ................................................................................................. 100
10.4.1 Variable ............................................................................................... 100
10.4.2 Statistical hy pothesis, model, and method of analy sis........................ 100

Novartis Confidential Page 5
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
10.4.3 Handling of missing values/censoring/discontinuations ..................... 100
10.4.4 Supportive and Se nsitivity  analy ses.................................................... 100
10.5 Secondary  objectives ........................................................................................... 101
10.5.1 Secondary  objective(s) ................................ ................................ ........ 101
10.5.2 Other secondary  efficacy objectives ................................................... 101
10.5.3
Safety objectives ................................................................................. 101
10.5.4
Patient- reported outcomes ................................................................... 103
10.6 Exploratory  objectives ................................ ................................ ......................... 104
10.7 Interim anal ysis.................................................................................................... 104
10.8
Sample size calculation........................................................................................ 104
10.9 Power for anal ysis of key secondary  variables
.................................................... 105
11Ethical con siderations and administrative procedures ................................ .................... 105
11.1 Regulatory and ethical compliance ...................................................................... 105
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... 105
11.3 Informed consent procedures
............................................................................... 105
11.4 Discontinuation of the study ................................................................................ 106
11.5 Publication of study  protocol and results ............................................................. 106
11.6 Study  documentation, record keeping and reten
tion of documents ..................... 106
11.7 Confidentiality  of study  documents and patient records ..................................... 107
11.8
Audits and inspections......................................................................................... 107
11.9 Financial disclosures ............................................................................................ 107
12Protocol adherence .......................................................................................................... 108
12.1 Amendments to the protocol ................................................................................ 108
13References (available upon request) ................................................................................ 109
14Appendices ...................................................................................................................... 113
14.1 Appendix 1 
- Concomitant Medications.............................................................. 113
14.2 Appendix 2 – Patient Reported Outcomes FACT -B ........................................... 117
14.3 Appendix 3 
-Guidelines for response, dur ation of overall response, TTF, 
TTP, progression- free survival and overall survival (based on RECIST 1.1) .....120
14.3.1 Introduction ......................................................................................... 122
14.3.2 Efficacy  assessments ........................................................................... 122
14.3.3
Definitions........................................................................................... 122
14.3.4 Disease measurability .......................................................................... 122
14.3.5 Eligibility  based on measurable disease .............................................. 123
14.3.6 Methods of tumor measurement -general guid
elines ......................... 123
14.3.7 Baseline documentation of target and non -target lesions ................... 125

Novartis Confidential Page 6
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
14.3.8 Follow -up evaluation of target and non -target lesions ........................ 126
14.3.9 Follow -up and recording of lesions ..................................................... 126
14.3.10 Non-
nodal lesions................................................................................ 126
14.3.11 Nodal lesions ....................................................................................... 127
14.3.12 Determination of target lesion response .............................................. 127
14.3.13 Determination of non -target lesion response ...................................... 129
14.3.14 New lesions ......................................................................................... 130
14.3.15 Evaluation of overall lesion response ................................................. 130
14.3.16 Efficacy  definitions ............................................................................. 131
14.3.17 Best overall response ........................................................................... 131
14.3.18 Time to event variables ....................................................................... 134
14.3.19 Progression
-free survival .................................................................... 134
14.3.20 Overall survival ................................................................................... 134
14.3.21 Time to progression ............................................................................. 134
14.3.22 PFS2 .................................................................................................... 135
14.3.23 Time to treatment failure ..................................................................... 135
14.3.24 Duration of response ........................................................................... 135
14.3.25 Time to response ................................................................................. 136
14.3.26 Definition of start and end dates for time to event variables .............. 137
14.3.27 Handling of patients with non -measurable disease only  at baseline ...138
14.3.28 Sensitivity  analy ses............................................................................. 139
14.3.29 Data handling and programming rules ................................................ 141
14.3.30 Study /project specific decisions .......................................................... 142
14.3.31 End of treatment phase completion ..................................................... 142
14.3.32 End of post -treatment foll ow
-up (study  phase completion) ................ 142
14.3.33 Medical validation of programmed overall lesion response ............... 143
14.3.34 Programming rules .............................................................................. 143
14.3.35
Calculation of ‘time to event’ variables.............................................. 144
14.3.36 Incomplete assessment dates ............................................................... 144
14.3.37 Incomplete dates for last known date patient alive or death ............... 144
14.3.38 Non-target lesion response .................................................................. 144
14.3.39 Study /project specific programming ................................................... 144
14.3.40 Censoring reason ................................................................................. 144
14.3.41 References (available upon request) ................................................... 145
14.4 Appendix 4 
-Bone Marrow Reserve in Adults ................................................... 146

Novartis Confidential Page 7
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
List of figures
Figure 1 -1 Regulation of cell cy cle checkpoint control .......................................... 35
Figure 4 -
1 Study  design .......................................................................................... 48
Figure 6 -
1 Men / Premenopausal regimen .............................................................. 55
Figure 6 -
2 Postmenopausal regimen ....................................................................... 56
List of tables
Table 1
-1 Goserelin and third generation AIs in metastatic premenopausal 
BC patients ............................................................................................ 36
Table 3
-1 Objectives and related endpoints .......................................................... 46
Table 6
-1 Dose and treatment schedule................................................................. 55
Table 6
-2 Ribociclib Dose Modification Guidelines ............................................. 58
Table 6
-3 Ribociclib dose reduction/interruption and management 
recommendations for hematological adverse drug reactions 
(CTCAE v4.03)................................ ................................ ..................... 59
Table 6-4 Ribociclib dose reduction/interruption and management 
recommendation for hepatic toxicities (CTCAE v4.03) ....................... 60
Table 6-5 Ribociclib dose adjustment and management recommendation for 
QTcF prolongation ................................................................................ 63
Table 6
-6 Ribociclib dose adjustment and management recommendation for   
ILD/pneumonitis ................................................................................... 64
Table 6
-7 Ribociclib dose reduction/interruption and management 
recommendation f or all other adverse reactions ................................... 64
Table 6
-8 Packaging and labeling ......................................................................... 69
Table 6
-9 Supply  and storage of study  treatments ................................................ 69
Table 7
-1 Visit evaluation schedule (Core Phase) ................................................. 72
Table 7
-2 Visit evaluation schedule (Extension Phase) ........................................ 78
Table 7
-3 Imaging Assessment Collection Guid ance............................................ 85
Table 7
-4 ECOG performance status ..................................................................... 88
Table 7
-5 Local Clinical lab oratory parameters collection plan ........................... 89
Table 7-6 Patient reported outcomes collection plan ................................ ............ 91
Table 10-1 Confidence Intervals associated with AEs of interest for subgroups ..104
Table 14-1 List of prohibited medications during study  drug treatment ............... 113
Table 14-2 List of medicat ions to be used with caution during study  drug 
treatment .............................................................................................. 115
Table 14
-3 Response criteria for target lesions ................................ ..................... 127
Table 14-4 Response criteria for non -target lesions ................................ .............. 129
Table 14-5 Overall lesion response at each assessment ................................ ........ 131

Novartis Confidential Page 8
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Table 14-6 Overall lesion response at each assessment: patients with non -
target disease onl y............................................................................... 138
Table 14
-7 Options for event dates used in PFS, TTP, duration of response ........ 139
Table 14-8 Bone Marrow Reserve in Adults......................................................... 146

Novartis Confidential Page 9
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
List of abbreviations
aBC
AEAdvanced Breast Cancer
Adverse Event
AI Aromatase Inhibitors
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
ANC Absolute Neutrophil Count
ALP Alkaline Phosphatase
ASCO American Society of Clinical Oncology
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
ATC Anatomical Therapeutic Chemical
AUC Area Under the Curve
aBC Advance dBreast Cancer
BC Breast Cancer
BCRP Breast Cancer resistance protein
BSEP
CBDBile export salt pump
Cannabidiol
CBR Clinical Benefit Rate
CCND1 Cyclin D1
CDK4/6 Cyclin -Dependent Kinases 4 and 6
CMO&PS
CLChief Medical Officer and Patient Safety
Clearance
CNS Central Nervous System
Cmax Maximum Plasma Concentration
COA Clinical Outcome Assessment
eCOA Electronic Clinical Outcome Assessment
CR Complete Response
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
CSR Clinical study report
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrome P450
DDI Drug -Drug Interaction
DFS Disease Free Survival
DHEA Dehydroepiandrosterone
DI Dose Intensity
DILI Drug -Induced Liver Injury
DS&E Drug Safety and Epidemiology
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF
EDCElectronic Case Report Form
Electronic Data Capture
EOT End of Treatment
ER Estrogen Receptor
ET Endocrine Therapy
FACT-B Functional Assessment of Cancer Therapy -Breast
FAS Full Analysis Set

Novartis Confidential Page 10
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
FDA Food and Drug Administration
FMO3 Flavin -containing Monooxygenase 3 
FPFV First Patient First Visit
FSH Follicle Stimulating Hormone
G3/4 Grade 3/4
GCP Good Clinical Practice
GI Gastrointestinal
HER2 Human Epidermal Growth Factor Receptor 2
HIV Human Immunodeficiency Virus
HR+ Hormone Receptor Positive
IA Interim Analysis
IB Investigator ’s Brochure
IC50 Inhibitory Concentration, where 50% inhibition is observed
ICF Informed Consent Form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IHC
ILDImmunohistochemistry
Interstitial Lung Disease
IN Investigator Notification
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
IUD Intrauterine Device
LDH Lactate Dehydrogenase
LFT Liver Function Test
LHRHa Luteinizing Hormone -Releasing Hormone agonist
LLN Lower Limit of Normal
LPFV Last Patient First Visit
MATE1 Multidrug And Toxin Extrusion protein-1
NCCN National Comprehensive Cancer Network
NSAI Nonsteroidal Aromatase Inhibitors
NSCLC Non-Small Cell Lung Cancer
OCT2 Organic Cation Transporter 2
OFS Ovarian Function Suppression
ORR Overall Response Rate
OS Overall Survival
PAS PRO Analysis Set
PD
P-gPProgression of Disease
Permeability -glycoprotein
PFS Progression Free Survival
PgR Progesterone receptor
PHI Protected Health Information
PK Pharmacokinetics
pRb Retinoblastoma Protein
PR Partial Response
PRO Patient -Reported Outcomes

Novartis Confidential Page 11
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
PS
PSDSPerformance Status
Post-Study Drug Supply
PT
PTAProthrombin Time
Post Trial Access
PVC Premature Ventricular Contractions
QD Quaque Die (every day)
QTcF QT corrected interval using Fridericia
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
Rb Retinoblastoma Protein
REB Research Ethics Board
RECIST Response Evaluation Criteria in Solid Tumors
RT RadioTherapy
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SBP Systolic Blood Pressure
SC Steering Committee
SD Stable Disease
SERM Selective ER Modulators
SmPC
SUSARSummary of Product Characteristics
Suspected Unexpected Serious Adverse Reaction
T1/2 Half-life
TBIL Total Bilirubin
TdP
TEN
THCTorsades d e Pointe s
Toxic Epidermal Necro lysis
tetrahydrocannabinol
TTP Time To Progression
ULN Upper Limit of Normal
US United States
VES Visit Evaluation Schedule
WBC White Blood Cell

Novartis Confidential Page 12
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Glossary  of terms
Assessment A procedure used to generate data required by the study
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e. 
treatment group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g.: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.)
Enrollment Point/time of patient entry into the study; the point at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described in the 
protocol)
Investigational drug The study treatment whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is synonymous with
“investigational new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indication/approved dosage, or that are 
tested in a fixed combination. Investigational treatment generally does not 
include other study treatments administered as concomitant background therapy 
required or allowed by the protocol when used in within approv ed 
indication/dosage
Medication number A unique identifier on the label of each study treatment package which is linked 
to one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study pro cedures 
that was not included in the investigational treatment
Premature patient withdrawal Point/time when the patient exits from the study prior to the planned completion 
of all study treatment administration and/or assessments; at this time all study 
treatment administration is discontinued and no further assessments are 
planned, unless the patient will be followed for progression and/or survival
Randomization number A unique treatment identification code assigned to each randomized patient, 
correspond ing to a specific treatment arm assignment
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of the 
tumor, whether lymph nodes contain cancer, and whether the cancer has 
spread from the original site to other parts o f the body
Stage related to study 
timelineA major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient (subject) as part of the required study procedures, inc luding placebo and 
active drug run -ins.
In specific examples, it is important to judge investigational treatment 
component relationship relative to a study treatment combination; study 
treatment in this case refers to the investigational and non -investigat ional 
treatments in combination.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any 
reason.
Subject Number A unique identifying number assigned to each patient/subject/healthy volunteer 
who enrolls in the study
Supportive treatment Refers to any treatment required by the exposure to a study treatment, e.g. 
premedication of vitamin supplementation and corticosteroid for pemetrexed 
disodium.

Novartis Confidential Page 13
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Treatment group A treatment group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts. Cohorts are not expanded, new cohorts are 
enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specifie d timepoints
Withdrawal of Consent Withdrawal of consent occurs only when a patient does not want to participate in 
the study any longer, and does not want any further visits or assessments, and 
does not want any further study related contact

Novartis Confidential Page 14
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Protocol summary
Title An open -label, multicenter, Phase IIIb study to assess the safety and efficacy of 
ribociclib (LEE011) in combination with letrozole for the treatment of men and 
pre/postmenopausal women with hormone receptor-positive (HR+) HER2 -
negative (HER2 -) advanced breast cancer (aBC) with no prior hormonal therapy 
for advanced disease
Brief title Study to assess the safety and efficacy of ribociclib (LEE011) in combination with 
letrozole for the treatment of men and pre/postmenopausal women with HR + 
HER2 -aBC in a broader population
Sponsor and
Clinical PhaseNovartis
Phase IIIb
Investigation ty pe Drug
Study  type Interventional
Purpose and rationale The purpose of this Phase IIIb study is to collect additional safety and efficacy 
data for the combination of ribociclib + letrozole in a broad erpopulation of 
patients with HR+HER2 - aBCin comparison with other Phase III studies with 
ribociclib .
Primary  Objective(s) and 
Key Secondary  ObjectiveToevaluate the safety and tolerability of ribociclib with letrozole in men and 
pre/postmenopausal women with HR+, HER2- aBC who received no prior 
hormonal therapy for advanced disease
Note: Throughout this document , perimenopausal and premenopausal status will 
be grouped together and referred as “Premenopausal”
Secondary  Objectives ●To assess the clinical efficacy of ribociclib + letrozole measured by Time -to-
Progression (TTP) and tumor response by overall response rate (ORR) a nd 
clinical benefit rate (CBR)
● To assess treatment impact on patient reported outcome (PRO) measured by 
variations of Functiona l Assessment of Cancer Therapy - Breast ( FACT-B)
questionnaire scores
●To evaluate long -term safety of ribociclib + letrozole during Extension Phase
●To evaluate clinical benefit of ribociclib + letrozole as assessed by 
investigator during Extension Phase
Study  design This open -label, single arm, multi -center Phase IIIb study will evaluate the overall 
safety and tolerability and clinical efficacy of ribociclib in combination with 
letrozole in men and pre/postmenopausal women with HR+, HER2 -aBC and no 
prior hormonal treatment for advanced disease. A total of approximately 3 ,000 
patients will be enrolled fo r treatment with Letrozole (2.5 mg once daily) + 
Ribociclib (LEE011) 600 mg (day 1 to 21 in a 28 day cycle) ; goserelin (3.6mg as 
injectable subcutaneous implant every 28 days) or leuprolide (7.5mg 
intramuscular injection every 28 days) will be used in men and premenopausal 
women patients .
The study will be composed of 2 phases: Core Phase (from FPFV to 18 months 
after LPFV) and Extension P hase ( 18 months from LPLV of the Core Phase ). 
During the Core Phase, safety and efficacy data (including ePRO in selec ted 
countries ) will be collected. In the event that patients are still deriving benefit at 
the end of the Core phase and ribociclib is not approved or available and 
reimbursed, patients may be transitioned to the Extension Phase and continue to 
receive studytreatment until progression, intolerance, death or physician/patient 
decision. Only safety and clinical benefit (as assessed by investigator ) data will 
be collected in the Extension Phase
During theExtension Phase, if ribociclib is approved and reimbursed, patients 
will be trans itioned to prescription or drug access/support program(s) according 
to local laws and regulations . 
The study wi ll end after completion of the Extension P hase and all remaini ng 
patients will discontinue from the study . Patients who complete this Extension 
Phase, and continue to derive clinical benefit from the treatment based on the 
investigator’s evaluation will receive ribociclib from prescription (if approve dand 

Novartis Confidential Page 15
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
reimbursed ), another Post -Trial Access (PTA) program, or other drug 
access/support program(s).
Population This study includes men and pre/postmenopausal women with HR+, HER2- aBC 
who had not received any prior hormonal agent for treatment of advanced 
disease

Novartis Confidential Page 16
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Inclusion criteria 1. Patient is an adult, male or female ≥ 18 years old at the time of informed 
consent
2. Male or female with advanced (locoregionally recurrent or metastatic) breast 
cancer not amenable to curative therapy.
3. In the case of women, both pre/perimenopausal and postmenopausal 
patient s are allowed to be included in this study; menopausal status is 
relevant for the requirement of goserelin or leuprolide to be used 
concomitantly with ribociclib and letrozole.
a)Postmenopausal status is define d either by:
i)Prior bilateral oophorectomy
OR
ii)Age ≥60
OR
iii)Age<60 and amenorrhea for 12 or more months (in the absence of 
chemotherapy, tamoxifen, toremifen, or ovarian suppression) and FSH 
and estradiol in the postmenopausal range per local normal range . If 
patient is taking tamoxifen or toremifene and age <60, then FSH and 
plasma estradiol levels should be in post-menopausa l range per local 
normal range.
Note: For women with therapy -induced amenorrhea, serial measurements 
of FSH and/or es tradiol are needed to ensure menopausal status.
b)Premenopausal status is defined as either:
i)Patient had last menstrual p eriod within the last 12 months
OR
ii)If on tamoxifen or toremifene within the past 14 days, plasma 
estradiol and FSH must be in the premenopaus al range per local 
normal range
OR
iii)In case of therapy induced amenorrhea, plasma estradiol and/or FSH 
must be in the premenopausal range per loca l normal range.
c)Perimenopausal status is define as neither p remenopausal nor 
postmenopausal
Note: Throughout this document, perimenopausal a nd premenopausal status 
is grouped together and referred as “Premenopausal”
4. Patient has a histologically and/or cytologically confirmed diagnosis of 
estrogen -receptor positive and/or progesterone receptor positive breast 
cancer by local laboratory. A confirmatory biopsy is not required.
5. Patient has HER2 -negative breast cancer defined as a negative in situ
hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in 
situhybridization (FISH, CISH, or SISH) test is required by local laboratory 
testing.
6. Patient has an Eastern Cooperative Oncology Group (ECOG) performance 
status ≤ 2
7. Patient has adequate bone marrow and organ function as defined by ALLof
the following laboratory values (as assessed by local laboratory):
●Absolute neutrophil count ≥ 1.5 × 10 9/L
●Platelets ≥ 100 × 10 9/L
●Hemoglobin ≥ 9.0 g/dL
●Potassium, sodium, calcium corrected for serum albumin and 
magnesium within normal limits or corrected to within normal limits with 
supplements before first dose of the study medication
●INR ≤1.5
●Serum creatinine <1.5 mg/dl or creatinine clearance ≥ 50 mL/min

Novartis Confidential Page 17
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
●In absence of liver metastases, alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) should be <2.5 × ULN. If the patient 
has liver metastases, ALT and AST should be < 5 × ULN.
●Total bilirubin < ULN except for patients with Gilbert’s syndrome who
may only be included if the total bilirubin is ≤ 3.0 × ULN or direct 
bilirubin ≤ 1.5 × ULN .
8.Patient must have a 12 -lead ECG with ALLofthe following parameters at 
screening:
●QTcF interval at screening < 450 msec (using Fridericia’s correction)
●Resting heart rat e ≥ 50 bpm
9.Patient must be able to swallow ribociclib and letrozole tablets
10.Patient has signed informed consent obtained before any trial-related 
activities and according to local guidelines
11.Patients must be able to communicate wi th the investigator and comply with 
the requirements of the study procedures
Exclusion criteria 1. Patient has a known hypersensitivity to any of the excipients of ribociclib or 
letrozole , including peanut and soy
2. Patient who received any CDK4/6 inhibitor
3. Patient who received any prior systemic hormonal therapy for advanced 
breast cancer; no more than one prior regimen of chemotherapy for the 
treatment of metastatic disease is permitted
Note :
●Patients who received (neo) adjuvant therapy for b reast cancer are 
eligible. If the prior neo (adjuvant) therapy included letrozole or 
anastrozole the disease free interval must be greater than 12 months 
from the completion of treatment until study entry.
●Patients who received ≤ 28 days of letrozole or anastrozole for 
advanced disease prior to inclusion in this trial are eligible.
4. Patient is concurrently using other anti-cancer therapy
5. Patient has had major surgery within 14 days prior to starting study drug or 
has not recovered from major side eff ects
6. Patient who has not had resolution of all acute toxic effects of prior anti -
cancer therapy to NCI CTCAE version 4.03 Grade ≤1 (except alopecia or 
other toxicities not considered a safety risk for the patient at investigator's 
discretion)
7. Patient who has received extended -field radiotherapy ≤ 4 weeks or limited 
field radi otherapy for palliation ≤ 2 weeks prior to start of treatment , and who 
has not recovered to grade 1 or better from related side effects of such 
therapy (with the exception of alopecia) and/or from whom ≥ 25% (Ellis RE 
1961 ) of the bone marrow has been previously irradiated are also excluded .
(see Appendix 14.4 )
8. Patient has a concurrent malignancy or malignancy within 3 years prior to 
starting study drug, with the exception of adequately treated, basal or 
squamous cell carcinoma, non -melanomatous skin cancer or curatively 
resected cervical cancer
9.Patient with central nervous system (CN S) metastases unless they meet 
ALL of the following criteria:
●At least 4 weeks from prior therapy for CNS disease completion 
(including radiation and/or surgery) to starting the study treatment.
●Clinically stable CNS lesions at the time of study treat ment initiation and 
not receiving steroids and/or enzyme-inducing anti -epileptic medications 
for the management of brain metastases for at least 2 weeks.
10. Patient has impairment of gastrointestinal (GI) function or GI disease that 
may significantly al ter the absorption of the study drugs (e.g., uncontrolled 

Novartis Confidential Page 18
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption 
syndrome, or small bowel resection)
11. Patient has a known history of HIV infection (testing not mandatory)
12. Patient h as any other concurrent severe and/or uncontrolled medical 
condition that would, in the investigator’s judgment, cause unacceptable 
safety risks, contraindicate patient participation in the clinical study or 
compromise compliance with the protocol: (e.g. c hronic pancreatitis, chronic 
active hepatitis, active untreated or uncontrolled fungal, bacte rial or viral 
infections, etc.)
13. Clinically significant, uncontrolled heart disease and/or cardiac 
repolarization abnormalities, including but not limited to any of the following:
●History of acute coronary syndromes (including myocardial infarction, 
unstable angina, coronary artery bypass grafting, coronary angioplasty, 
or stenting) or symptomatic pericarditis within 6 months prior to 
screening
●History of d ocumented congestive heart failure (New York Heart 
Association functional classification III -IV)
●Documented cardiomyopathy
●Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), 
complete left bundle branch block, high -grade AV block (e.g. bifascicular 
block, Mobitz type II and third -degree AV block)
●Long QT syndrome or family history of idiopathic sudden death or 
congenital long QT syndrome, or any of the following:
i.Risk factors for Torsades de Pointe (TdP) including uncorrected
hypokalemia or hypomagnesemia, history of cardiac failure, or 
history of clinically significant/symptomatic bradycardia.
ii.Concomitant use of medication(s) with a known risk to prolong the 
QT interval and/or known to cause Torsades de Pointe that cannot
be discontinued (within 5 half -lives or 7 days prior to starting study 
drug) or replaced by safe alternative medication
iii.Inability to determine the QT cF(Fridericia’s correction) interval on 
screening
●Systolic blood pressure (SBP) >160 mmHg or <90 m mHg at screening
14. Patient is currently receiving any of the following medications and cannot be 
discontinued 7 days prior to starting Cycle 1 Day 1 :
●Concomitant medications, herbal supplements, and/or fruits (e.g. 
grapefruit, pumeloes, star fruit, Sev ille oranges) and their juices that are 
known strong inducers or inhibitors of CYP3A4/5 (See Appendix 14.1 )
●Medications that have a narrow therapeutic window and are 
predominantly metabolized through C YP3A4/5
15. Patient is currently receiving or has received systemic corticosteroids ≤ 2 
weeks prior to starting study drug, or who have not fully recovered from side 
effects of such treatment. Note: The following uses of corticosteroids are 
permitted: sing le doses, topical applications (e.g., for rash), inhaled sprays 
(e.g., for obstructive airways diseases), eye drops or local injections (e.g., 
intra-articular )
16. Participation in a prior investigational study within 30 days prior to 
enrollment or within 5-half -lives of the investigational product, whichever is 
longer
17.  Pregnant or nursing (lactating) women
Note: W omen of child -bearing potential isdefined as all women 
physiologically capable of becoming pregnant, unless they are using highly 
effective methods of contraception during dosing and for 21 days after 
stopping your study medication.
Highly effective contraception methods in clude :
●Total abstinence, when this is in line with the preferred and usual 
lifestyle of the patient . Periodic abstinence (e.g. calendar, ovulation, 

Novartis Confidential Page 19
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
symptothermal, post -ovulation methods ), and withdrawal are not acceptable 
methods of contraception
●Female sterilizatio n (have had surgical bilateral oophorectomy with or 
without hysterectomy) , total hysterectomy (surgical removal of the uterus 
and cervix) or tubal ligation (getting the “tubes tied”) at least 6 weeks 
before taking study treatment. In case of oophorectom y alone, only when 
the reproductive status of the woman has been confirmed by follow up 
hormone level assessment
● M ale partner steriliz ation (at least 6 months prior to screening). For 
femal e patients on the study the vas ectomized male partner should be the 
sole partner for that patient
Placement of an intrauterine device (IUD) or intrauterine system (IUS) 
Note: Use of oral (estrogen and progesterone), transdermal, injected ,
implantedhormon e containing intrauterine (IUS) or any other hormonal
methods of contraception is not allowed in this study
Investigational and 
reference therapyRibociclib 600mg oral daily (3 weeks on/ 1 week off) in combination with letrozole 
2.5 mg oral once daily ; goserelin 3.6mg (as injectable subcutaneous implant 
every 28 days) orleuprolide 7.5mg (as injectable intramuscular depot every 28 
days) will be used in men and premenopausa lwomen patients 
Safety  assessments ●Physical examinations
●ECOG performance status
●Weight and vital signs
●12 lead ECGs (assessed locally)
● Laboratory assessments including hematology, chemistry and INR (assessed 
by local lab)
● Adverse Events (AE s) collection
Efficacy  assessments Clinical efficacy will b e assessed by the investigator
Tumor assessments will be performed according to the current standard of care 
(every 12 weeks until dise ase progression is recommended)
Other assessments Patient Reported Outcomes FACT -B Questionnaire (See Appendix 14.2 )
Data analy sis The data will be summarized with respect to demographic and baseline 
characteristics, and safety observations and efficacy measurements. Categorical 
data will be presented as frequencies and percentages. For continuous data, 
mean, standard deviation, median, minimum, and m aximum will be presented.
Time to progression (TTP) is defined as time from date of start of treatment to 
the date of event defined as the first documented progression or death due to 
underlying cancer ( Appendix 14.3 :Novartis RECIST Guideline v 3.2 ). ORR and 
CBR will be calculated and summarized based on investigators’ assessment 
(according to RECIST 1.1).
For PROs, descriptive statistics will be used to summarize the subscale and 
overall scores at each scheduled assessment time point. Additionally, change 
from baseline at the time of each assessment will be summarized.
Key words HR-positive, HER2 -negative, advanced breast cancer, LEE011, ribociclib, 
letrozole, goserelin, leuprolide, CDK, CDK4, CDK6, CDK4/6, Phase IIIb, ER-
positive, PR -positive, premenopausal, postmenopausal , male breast cancer

Novartis Confidential Page 20
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Amendment 04 (23- Jan-2020)
Amendment Rationale
The study  was initiated in November, 2016 and 3,246 subjects were treated. The Core Phase 
was completed (Last Patient Last Treatment occurred on 09- Oct-2019 and Last Patient Last 
Visit occurred on 08- Nov- 2019). A total of 415 subjects have been transitioned tothe Extension 
Phase of the study .
The current amendment is intended to incorporate the u pdated safet y information on  ribociclib 
in alignment with LEE011 (Ribociclib) Investigator’s Brochure (IB), Edition 14 (release date: 
28-Nov- 2019) andtodefine the duration of the Extension Phase and transition plan for patients 
during and at the end of the study  .
Interstitial Lung 
Disease (ILD)/pneumonitis has been observed with CDK4/6 inhibitor 
treatment as a class effect and was requested by  FDA to be added to US label (Please refer 
to IB Edition 14 for more information). A new Table 6-6, Ribociclib dose adjustment and 
management recommendation for ILD/pneumonitis has been added 
Toxic Epidermal Necrolysis (TEN) has been reported in the post-marketing setting in a 
well-
documented literature case report. No case was observed in the clinical trials.  (Pl ease 
refer to IB Edition 14 for more information). Protocol section 6.3.1.3.5, Guidance for all 
other adverse reactions was updated with clear guidance to discontinue ribociclib if TEN is 
diagnosed
Updated recommended tables relating to Hepatic and Cardiac QTc Monitoring
Clarified Contraceptive methods allowed during study
Updated the list of prohibited medications during study  treatment, and co-medication 
considerations
Updated the list of medications to be used with caution during study  drug treatment
Updated the language regarding Extension Phase duration and transition plan
Editorial and ty pographical changes throughout the document
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The changes being made to the protocol due to this amendment are incorporated in the following 
sections:
Protocol Summary  Exclusion criterion 17 clarified the info rmation provided on acceptable 
male and f emale contraception methods by:
a.Removal of the needed combination of an IUD/IUS with an occlusive cap or condom 
with spermicidal foam/gel/film/vaginal suppository
b.Additional methods of hormone contraceptives not allow ed in 
the study
Section 4.3 was updated to clarify  the end of the Extension Phase and transition plan
Table 6-3 was updated by removal of Grade 3 ANC without fever or signs of infection on 
Day 14 of the first 2 cy cles

Novartis Confidential Page 21
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Table 6- 3 Title was updated with CTCAE v4.03 grading
Table 6-4 Title was updated with CTCAE v4.03 grading and clarification of bi -weekl y to 
every  two weeks
Table 6 -5 was updated with instructions on how to manage Grade 2 QTc prolongation with 
instructions to repeat ECG within one hour of first QTcF ≥ 481 ms
Section 6.3.1.3.4 and Table 6 -6 Ribociclib dose adjustment and management 
recommendation for ILD/pneumonitis was added in.
Former section 6.3.1.3.4 Guidance for all other adverse reactions was renumbered to 
6.3.1.3.5
Former Table 6 -6 was renumber ed to 
Table 6 -7 Ribociclib dose reduction/interruption and 
management recommendation for all other adverse reactions
Table 6
-7Ribociclib dose reduction/interruption and management recommendation for all 
other adverse reactions include language referring to Toxic Epidermal Necrosis (TEN)
was modified
Section 6.4.1 updated the text with with prohibited medications and the list of use with 
cautions with citations for Appendices
Section 6.4.1.3 Palliative Radiotherap y wording clarified that RT should not be used on 
target lesions and the 
total cumulative doses should not encompass >25% of irradiated 
bone marrow
Section 6.4.1.3 text moved to the Section 6.4.4 ie, ‘Refer to the rib ociclib [Investigator’s 
Brochure] and letrozole, goserelin, and leuprolide drug package insert and Appendix 14.1
for information on possible interactions with other drugs’
Former Table 6 -7 was renumbered to Table 6 -8 Package and labeling
Former Table 6 -8 was renumbered to Table 6 -9 Supply  and Storage of Study  Treatment
Table 7-2 Extension Phase Visit Evaluation Schedule was revised to label visits E -C1D1, 
E-C4D1, E-C7D1, and E-C1D1 and subsequent cycles and goser elin/leuprolide dose 
administration updated to monthly
Section 7.1.5 was updated to describe discontinuation of study  treatment from the Extension 
Phase
Section 8.4 Pregnancies was updated to remove the timeframe for outcome collection for 
pregnant partners of male patients
Section 14.1 - Appendix 1 cited source changed from ‘Oncology  Clinical Pharmacology 
guidance ’ to ‘Novartis PK Science Memorandum’ and the release updated to Jan 2018
Table 14- 1 was updated with the most current prohibited medications
Table 14- 2 was updated with the most current medications to be used with caution
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

Novartis Confidential Page 22
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 23
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Amendment 03 (24-Sep-2018 )
Amendment Rationale
The study  was initiated in November, 2016 and enrollment has been completed (last Patient 
First Visit occurred on March 22, 2018). 3255 patients have been enrolled in the study .
The current amendment is intended to incorporate updated ribociclib program information .
A summary  of the k
ey changes in this amendment is listed below:
Updated the language regarding early  study  termination by  the sponsor
Updated withdrawal of consent language with the new Global Data Protection 
Requireme nts
Update dthe dose adjustment and management recommendations for QTcF prolongation. 
Analy ses of preclinical and clinical data with ribociclib have demonstrated that ribociclib 
prolongs the QT interval in a concentration -dependent manner. Moreover, based on the 
ribociclib exposure -ΔQTcF relationship and the clinical experience in studies 
CLEE011A2301 (MONALEESA -2), CLEE011F2301 (MONALEESA -3) and 
CLEE011E2301 (MONAL EESA -7), ribociclib dose reduction is an effective strategy  for 
managing ribociclib therapy  in patients experiencing QTcF prolongation. Therefore, in 
order to reduce the risk of subsequent QTcF prolongation in patients experiencing a QTcF 
between 481-500 msec, ribociclib dosing should be reduced by 1 dose level with the first 
occurrence of QTcF ≥ 481 msec. As a result, this amendment includes an update to the 
dosage management guidance for patients who experience QTc prolongation.
Updated the list of prohibited medications during study  treatment, and co-medication 
considerations
Updated the list o f medications to be used with caution during study  drug treatment
Clarified that paper PROs may  be used if ePRO is unavailable
Editorial and ty pographical changes throughout the document
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The changes being made to the protocol due to this amendment are incorporated in the following 
sections:
Protocol Summary  inclusion criterion 1removed the need for men to use a condom while 
taking drug and for 21 days after stopping medication, whether they are vasectomized or 
not.
Protocol Summary  exclusion criterion 17 expanded the information provided on acceptable 
female contraception methods
Section 4.4 updated the language regarding the reasons why the study  may be terminated 
early by the sponsor and what actions are needed in that case
Section 5.2 inclusion criterion 1removed the need for men to use a condom while taking 
drug and for 21 day s after stopping medication, whether they  are vasectomized or not.

Novartis Confidential Page 24
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Section 5.3 exclusion criterion 17 expanded the information provided on acceptable female 
contraception methods
Sections 6.1.1.1 and 6.4.3 updated to clarify  that herbal or dietary  supplements with a known 
risk of QT prolongation are not permitted
Section 
6.4.1.4 updated to indicate that potential drug interactions are possible between 
ribociclib and antiemetics.
Section 6.4.2 clarified the information provided regardi ng renal transporters MATE1, OCT2 
and BCRP.
Section 6.4.3 was updated to clarify  that both herbal medications and dietary  supplements 
that are strong inhibitors of CYP3A4/5 or those known to cause QT prolongation are 
prohibited.
Section 7.1 and table 7.5 w ere updated to clarif y that absolute lymphocyte count is required 
when reporting hematology -related lab results
Section 7.1.6 was updated with updated language regarding actions needed when a patient 
withdraws their consent to participate in the trial
Section 7.2.3 was updated to clarify  the timing of the PRO administration
Section 8.1.3 was removed due to redundancy  as AESI  review information is also included 
in section 
10.4.1
Section 9.3.2 was updated to allow for use of paper PROs when the ePRO is unavai lable, 
and to clarify  that questionnaires should be administered in the patient’s local language
Table 6- 5 was updated with instructions on how to manage QTcF prolongation
Table 14-1 was updated with the most current prohibited medications
Table 14- 2 was updated with the most current medications to be used with caution
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 25
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Amendment 02 (16- Aug-2017 )
Amendment rationale
The study  was initiated in Nov ember, 2016 and enrollment is currently  ongoing. As of Aug 8, 
2017, 1008 patients have been enrolled in the study.
The current amendment is intended to update the existing information on ribociclib and clarif y 
specific aspects of amendment 01, based on feedback and communications received from 
investigators and the Study Steering Committee. This will result in enhanced clarity  for patient 
eligibility  and quality  of data collection.
A summary  of the k
ey changes in this amendment is listed below:
Information from the pivotal study  CLEE011A2301 (MONALEESA -2) supporting the use 
of ribociclib + letrozole in aBC has been upda ted to strengthen the study  rationale
Standard language around contraception was updated in the inclusion/exclusion criteria
Recruitment duration was adjusted according to the expected recruitment figures and 
required follow -up to adequately address the pr imary  and secondary objectives of the stud y
Clarifications on assessments performed during the Core Phase and the Extension Phase
Expansion of another monthly -based dosing LHRH agonist (leuprolide) in addition to 
goserelin, based on NCCN Breast Cancer Gui delines 2017
Removal of requirement for prior anti -cancer therapy  5
 half-lives washout period ,given the 
low probability  of drug-drug interactions and the urgency  to treat patients with advanced 
breast cancer who are progressing
Clarified radiotherap y windo ws and rationale
Additional clarification and updated wording on prohibition of herbal products
Update d wording on allowance of local/regional sub -studies/analy sisstudies
Clarification about ribociclib administration and assessments schedule due to drug 
interruptions from adverse events
Clarification of the sample size calculation. Three thousand (3,000) patients are planned to 
be enrolled in this study  to detect rare AEs (frequency  ~0.1%) with high probability . This 
will allow for a greater precision when reporting rare, but clinicall y meaningful AEs (e.g. 
febrile neutropenia, QT prolongation, renal insufficiency , thromboembolic events, etc.) and 
will allow for a meaningful safet y analysis of specific patient subgroup sof particular 
interest
Amendment 02 also includes minor editorial changes and additional clarifications to address 
investigators’ questions as described in the list of changes below.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version ofthe 
protocol using strike through red font for deletions and red underlined for insertions.
The changes being made to the protocol due to this amendment are incorporated in the following 
sections:

Novartis Confidential Page 26
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Cover page authorship was removed according toNovartis Oncology  Protocol template, 
version 06- Apr-2017
Summary  section of the protocol has been updated to maintain consistency  with the main 
body  of the protocol
Section 1.1.1 updated current preclinical and clinical data supporting CDK4/6 pathway  in 
breast cancer
Section 1.1.3 role of Cyclin D kinases inhibitor in breast cancer was deleted as updated 
information was provided in Section 1.1.1
Section 1.2.1 overview of ribociclib was updated with newly  reported results on non- clinical 
data, clinical safet y, clinical efficacy , clinical pharmacokinetics, and clinical experience
Section 
1.2.4 summary  of results from study  CLEE011X2107 and Section 1.2.5 summary 
of results from study  CLEE011A2301 was removed as the updated information has been 
provided in the updated Sect ion 1.2
Section 1.2.6 was updated with LHRH agonists information and was renumbered as Section 
1.2.4
Section 1.2.7 was removed
Section 2.4 (previous) was deleted and merged with Section 2.3: rationale for dose and 
regimen selection updated; added leuprolide to the combination of ribociclib+letrozole to 
achieve adequate hormonal suppression in men/premenopausal women
Section 2.6 renumbered as Section 2.5: added ribociclib approval by US FDA on Mar 13, 
2017
Section 4.1 updated to allow the use of leu prolide; removed expected Core Phase duration 
of 36 months; allowed local/regional sub-studies/anal ysis to be conducted in patient 
population enrolled in LEE011A2404 study ; Figure 4 -1 study  design was updated to allow 
the use of leuprolide for ovarian supp ression
Section 4.3 revised definition of end of study
Section 5.2 inclusion criterion 4 clarified that a confirmatory  biopsy  is not required
Section 5.2 inclusion criterion 7 clarified the laboratory  values required for total bilirubin 
and direct bilirubin
Section 5.3 exclusion criterion 3 removed requirement of stopping any  prior (neo)adjuvant 
anti-cancer therapy  or prior chemotherap y for metastatic disease at least 5 half-lives or 7 
days before study  entry
Section 5.3 exclusion criterion 7 clarified the criterion on prior radiotherap y
Section 5.3 exclusion criterion 14 clarified prohibition of herbal products
Section 5.3 exclusion criterion 17 updated highl y effective contraception methods
Section 6.1, Section 6.1.1, Table 6-1, Figure 6-1, and Section 6.1.1.1 updated with 
leuprolide dose and treatment information
Section 
6.1.5 Treatment Duration was revised to remove the 18 month sof recruitment 
period after FPFV
Section 6.3.1 clarified dose modifications and discontinuations guides for ribociclib, 
letrozo le, and goserelin/leuprolide

Novartis Confidential Page 27
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Section 6.3.1.2 updated dose information and monitoring of post-menopausal status of 
patient given LHRH agonists
Section 6.3.1.3 Table 6-2 Dose Modification Guideline: Letrozole and Goserelin columns 
were removed from table; cl arified 
seven consecutive re st day s needed prior to reinitiating
ribociclib
Section 6.3.1.3.1 Added Recommendations on Adjustment of Ribociclib Treatment Cy cles 
in the Case of Dose Interr uptions/ Re
initiation
Section 6.3.1.3.2 Follow up on potential drug-induced liver injury  (DILI) cases was 
renumbered from former Section 6.3.1.3.1
Section 6.3.1.3.3 Additional follow -up for QTc prolongation was renumbered from former 
Section 6.3.1.3.2
Table 6-3 clarified dose adjustment and management recommendation on Abso lute 
Neutrophil Count (ANC) Grade 4 toxicity
Table 6-4 modified dose reduction/interruption and management recommendation for 
Grade 2 and 3 hepatotoxicity  and note section
Section 
6.1.3.4 adjustment of starting dose in special populations was removed as this 
protocol is not intended to investi gate the combination of ribocic lib + letrozole in the special 
populations
Section 6.4.1 clarified requirement of documenting dose schedule change of concomitant 
medications
Section 6.4.1.2 clarified that the proph ylactic use of WBC growth factors with ribociclib is 
not recommended as ASCO guidelines recommendations regarding the use of WBC growth 
factors is for chemotherapy induced neutropenia
Section 6.4.1.4 added the use of antiemetic medications
Section 6.4.2 updated the use of permitted concomitant therap y requiring caution
Section 6.4.3 clarified the use of prohibited concomitant therapy
Section 6.4.4 updated the use of drugs with QT prolongation as concomitant medications
Section 
6.6 added leuprolide informa tion on drug dispensing, packaging and labeling, and 
drug suppl y and storage
Section 7.1 clarified direct bilirubin required to be assessed at screening and during 
treatment only if clinically  indicated; clarified that study  visits should be adjusted accor ding 
to treatment cy cle in the case of ribociclib being withheld
Section 7.1.2 updated to allow bloodwork completed during regular work -up as standard 
practice within 5 calendar days prior to signing ICF to be considered as screening 
assessments
Section 7.1.4 updated with leuprolide information
Section 7.1.5 clarified patients’ withdrawal/discontinuation criteria and EOT visit schedule
Section 
7.2.2.5.4 r enamed section Pregnancy  and Hormonal Levels and clarified FSH and 
Estradiol local collection (not colle cted on eCRFs) at screening for confirmation on 
menopausal status

Novartis Confidential Page 28
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Table 7-1 Visit Evaluation Schedule updated Chemistry  and Coagulation reference link to 
Table 7-5; added leuprolide to table; for hematology and chemistry  assessments during 
screening ,added text “
-14 days to Day 1”. This 14 day period was already  part of the 
protocol in Section 7.2.2.5
Table 7-5 clarified direct bilirubin required only if clinically indicated, added note to clarify 
that electrol ytes are required to be monitored but not enter ed on the eCRF
Table 7-6 clarified FACT -B questionnaires collection plan to include End of Treatment visit
Sections 8.2.2 and 8.4 replaced “Novartis Drug Safet y and Epidemiology  (DS&E)” with 
“Novartis Chief Medical Office and Patient Safet y (CMO&PS)”
Secti on 8.4 replaced “must” with “should” for collection of pregnancy  outcomes of female 
partners’ of male participants
Section 10.1.3 added to clarify  safety  set in Extension 
Phase
Section 10.3 clarified safety  set anal ysis in Core Phase and Extension Phase respectivel y
Section 10.5.3.1 clarified safet y set used for safety  analysis in Core Phase and Extension 
Phase respectively  during pre -treatment, on- treatment, and post -treatment period
Section 10.7 clarified interim anal ysis plan
Section 10.8 clarified sam ple size calculation
Table 10-1 added to show confidence intervals associated with AEs of interest for subgroups
Section 
14.1 Prohibited Concomitant Medications and Concomitant Medication use with 
Caution medications were updated; Website www.qtdrugs.org w as updated to 
www.crediblemeds.org
References section updated
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 29
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Amendment 01 (19- Dec-2016 )
Amendment rationale
The study  was initiated in Nov, 2016 and enrollment is currentl y ongoing with First Patient 
First Visit ( FPFV ) on 30- Nov- 2016.
The current amendment is intended to update the existing information about ribociclib, clarify 
specific aspects of the original protocol and expand the 
patient population to also include 
premenopausal women in use of ovarian suppression with goserelin. A summary  of the key 
changes proposed in this amendment is listed below:
Ribociclib information was updated based on the data available on the current IB version 
(v10, release date: Oct- 10-2016; safet y cut -off date: Jul-5-2016)
Detailed information from the pivotal study  CLEE011A2301 (MONALEESA -2) 
supporting the use of ribocic lib + letrozole in aBC has been included to strength enthe study 
rational e
Premenopausal patients (receiving concomitant ovarian suppression with goserelin) are 
allowed to be included in the study , based on current treatment guidelines suggesting similar 
treatment strategies in premenopausal patients with ovarian suppression as post-menopausal 
patients and data from another CDKi (palbociclib) demonstrating similar efficacy  of CDKi 
+ ET in prepost-menopausal patients (PAL OMA -3 Study ).Standard language aroun d 
contraception was added to the inclusion/exclusion criter ia as of result of this change
Male patients entering the study  will also be required to use goserelin concurrentl y with 
ribocicli b+ letrozole based on the current standard of care in this patient population and to 
avoid potential increase of FSH and testosterone (increasing potential substrates for 
aromatization) which could be associated with prolonged administration of AIs
Recruit ment duration and follow -up duration were adjusted according to the expected 
recruitment period and required follow -up to adequately address the primary and secondar y 
objectives of the study
Recruitment will be completed 18 months after FPFV or when 3,000 patients are 
enrolled, whichever occurs firs t
Core Phase of the stud y will be completed 18 months after LPFV
Core Phase (from FPFV to 18 months after L ast Patient First Visit (L PFV) ) and Extension 
Phase (18 months after LPFV to Last Patient Last V isit (L PLV))of the study  is defined
Clarifications on assessments performed during the Core Phase and the Extension Phase
Clarifications around the use of denosumab and bisphosphonates, which are now allowed 
together with ribociclib + letrozole accor ding to investigator’s judgment
Adjustments of VES requiring study  visits every 2 months after 6 months of treatment 
(starting on C6), and every  3 months after 12 months of treatment (starting on C12).
Amendment 01also includes minor editorial changes and additio nal clarifications to address 
investigators’ questions as described in the list of changes below.

Novartis Confidential Page 30
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The changes being made to the protocol due to this amendment are incorporated in the following 
sections:
Throughout the document: Addition of language to refer to most recent version of the 
LEE011 Investigator ’sBrochure and minor text editorial changes
Throughout the document: Premenopausal and perimenopausal status is grouped together 
and referred as “Premenopausal”
Throughout the document: Ty pographical and grammatical corrections
Section 1: Updated based on ne w data from ongoing and completed trials with L EE011.
Section 1.1.2: Updated to include data on clinical benefit of AIs in combination with ovarian 
function suppression (OFS) in premenopausal patients with breast cancer in neoadjuvant, 
adjuvant and advance d settings ; Rationale for inclusion of male patients is further clarified .
Section 1.2.5: Added to provide CL EE011A2301 (MONALEESA- 2) trial key  efficacy  and 
safet y results o f pre-planned interim anal ysis.
Section 1.2.6 and Section 1.2.7: Added to provide information on Goserelin (Zoladex®) 
overview and drug -drug-interactions.
Section 2: Added rationale on inclusion of pre menopausal patients with appropriate ovarian 
suppression (with the use of goserelin) in this trial. Study  rationale was updated with 
CLEE011A2301 (MONAL EESA -2) positive interim result to reinforce the activit y of the 
combinati on of ribociclib and letrozole.
Section 2.4: 
Addition of rationale for the standard dose of goserelin.
Section 2.5: Addit ion of rationale for non -compa rative design.
Section 2.6: Risks and benefits section was updated in relation to CLEE011A2301 
(MONALEESA -2) positive interim result and addition of goserelin to premenopausal/ male 
patients.
Section 3 Table 3-1: updated to add secondary  objective for Extension Phase and the 
associated end points.
Section 4.1: Updated to define Core and Extension Phase of the study ; added Extension 
Phase to allow patients who still derive benefit of ribociclib -based treatment however 
without access to ribociclib to continue to receive treatment until EOT; updated to clarify 
that goserelin is added to the treatment regimen in men/premenopausal 
women patients. 
Clarification was provided to allow country to stop recruitment after the planned number of 
patients is reached in respe ctive country  during the study .
Figure 4-1: Updated to add Extension Phase of the study ; updated to add goserelin to the 
study  treatment (ribociclib+l etrozole+goserelin) for male and premenopausal patients
. 
“Study  treatment” was updated as appropriate throughout the document.
Section 4.3: Definition of end of study  was revised to clarify  on recruitment period (18 
months) and end of Core Phase (18 months after LPFV) .

Novartis Confidential Page 31
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Section 5.2: I nclusion criterion #3 was updated to include pre/perimenopausal women with 
premenopausal status defined; additionally , postmenopausal status is further clarified in the 
case of age < 60 if patient is taking tamoxifen or toremife ne.
Section 5.3: Exclusion criterion #17 was added to require premenopausal women to use 
highl y effective contraception method during the study
.
Section 6.1 and Section 6.1.1: Updated to add goserelin to study  treatment for men and 
premenopausal women. Fig ure 6 -1 dosing regimen was updated to include goserelin.
Section 6.1.5: Treatment duration was updated and further clarified in relation to Core Phase 
and Extension Phase of the study.
Section 6.3.1: Clarified that dose reduction is not permitted for letrozole and goserelin. 
Robociclib dose modification guidelines were clarified to ensure seven (7) consecutive rest 
days and avoid overdose.
Section 6.3.1.3.4: Updated dose modification guidelines on adjustment of starting dose in 
renal impairment and hepatic impairment populations.
Table 6- 2: Goserelin was added to Table 6 -2 Dose Modification Guidelines
Table 6 -3: Ribociclib dose redu ction/interruption guidelines updated for G3 neutropenia on 
Day 14 of the first 2 cy cles.
Section 6.4.1.1: Clarified that the use of denosumab and bisphosphonates together with 
ribociclib+ letrozole is allowed according to investigator’s judgement.
Section 6.6: Updated to include goserelin information on study  drug preparation and 
dispensation, study  treatment packaging and la belin g, and drug suppl y and storage.
Table 7-1 Visit Evaluation Schedule (VES) was updated as Core Phase VES. Other 
clarifica tions and updates include: clarification sof pregnancy  test requirement, adjustments 
on the schedule of ribociclib IRT dispensing, ePRO, vital sign and weight, ECOG, and 
physical exam assessment schedules were adjusted to monthly  for C1-C5, every  2
 months 
for C6-C11, and every  3 months from C12 onwards; updates onthe requirement of EOT 
visit completion within 7 days from the last ribociclib based treatment.
Section 7.1.4: Added Extension Phase .
Section 7.1.5: Added discontinuation information on Core Phase.Table 7-2: Added 
Extension Phase VES.
Section 7.1.7: Follow -up for safety  evaluation was updated to clarify  the req uirement after
EOT of Core and E xtension 
Phase.
Section 7.2.1: Clarification on no centra l review of imaging assessments; Confirmation of 
Clinical Benefit is required during the Extension Phase.
Section 7.2.2: Addition of safet y assessments re quired during Extension Pha se.
Section 7.2.3: Clarified that FACT -B is collected electronically  in selected countries and it 
is not collected onmale patients.
Section 7.2.2.5.4: Pregnancy section is added.
Table 7
-5: Pregnancy  test is added.
Section 10: Updated to add data summary  at Extension Phase and details in subgroup 
analysis.

Novartis Confidential Page 32
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Section 10.4.1: Updated to clarify  the variables to evaluate the primary  objective.
Section 10.5.1: updated to add secondary  objective for Extension Phase.
IRBs /IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
Some changes herein affect the Informed Consent. S ites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 33
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
1.1.1 Role of the CDK4/6 path way in breast cancer
While endocrine therapy  (ET) is effective in treatment of HR-positive advanced BC, 
approximately  30-50% of patients may not respond to it due to a primar y resistance. Moreover, 
many  advanced BC patients with initial response to ET will acquire secondary  resistance to 
these agents ( Bachelot et al 2012 ; Nichols 2015). Co -targeting the estrogen receptor (ER) with 
other key intracellular proliferation and cell survival signaling pathway s, such as mechanisms 
responsible for cell cycle regulation and progression, may enhance first-line endocrine 
responsiveness of BC tumors by preventing or delaying the development of acquired r esistance 
for endocrine treatments.
Cell cycle progression is regulated by cyclin -dependent serine -threonine protein kinases 
(CDKs). Extracellular growth and adhesion signals increase the level and function of cy clin D 
proteins within the cell. In turn, the cyclin D proteins associate with and activate CDK4 and 
CDK6 (Musgrove et al 2011 ). CDK4 and CDK6 phosphory lation leads to inactivation of the 
retinoblastoma protein (Rb) and thus releases E2F, which inturn leads to the transcription 
initiation of proteins involved in cell cycle propagation and proliferation (Figure 1-1) . The 
luminal A and B subtypes of BC (85% of which are ER-positive and HER2- negativ e) have high 
rates 
of cyclin D/CDK activation; in the luminal A and B subty pes, cyclin D1 (CCND1) 
amplifications were observed in 29% and 58%, and CDK4 amplifications were observed in 14% 
and 25%, respectively  (Holm et al 2012; The Cancer Genome Atlas Network 2012). Luminal 
A subty pe tumors also have loss of CDKN2A, which encodes p16INK4A, a CDK inhibitor 
(Beroukhim et 
al 2010 ). The luminal subty pes 
also maintain expression of Rb, which is essential 
for benefit from treatment with a CDK4/6 inhibitor ( Thangavel et al 2011 ).
Dysregulation of cell cyclecheckpoints is common in BC, and in all cancers in general, and 
may have clinical and therapeutic significance. For example, patients with HR-positive BC 
exhibiting a gene expression signature of Rb loss had a shorter recurrence -free survival 
following adjuvant tamoxifen (Bosco et al 2007). A tumor gene expression signature of E2F 
activation is also associated with higher residual tumor cell proliferation following neoadjuvant 
AI therap y. Therefore, activation of the CDK4/6 -Rb-E2F pathway  promotes endocrine 
resistance, and treatment with a CDK4/6 inhibitor or knockdown of CDK4 expression leads to 
reactivation of Rb, binding back of E2F and subsequent cell cycle arrest ,thus abrogating 
endocrine -resistant 
cell proliferation.
Selective inhibitors of CDK4/6, such as palbociclib and ribociclib, inhibit proliferation and 
induce apoptosis in preclinical models of endocrine -resistant breast cancer (Miller et al2011 ;
Thangavel et al 2011; ribociclib [Investigator’s Brochure ] . Both palbociclib and ribociclib 
demonstrated synergy  with endocrine treatments in preclinical studies and efficacy  in clinical 
studies in patients with HR- positive, HER2 -negative advanced BC (Finn et al 2009 ; ribociclib 
[Investigator’ s Brochure ]). Addition of palbociclib to letrozole improved median progression-
free survival (PFS) from 10.2 months to 20.2 months (hazard ratio 0.49, 95% CI: 0.32- 0.75, 
p=0.0004) in a randomized, open -label, multicenter phase II study  (Finn et al 2015) and from 

Novartis Confidential Page 34
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
14.5 to 24.8 months (hazard ratio 0.58, 95% CI: 0.46-0.72, p=0.0001) in a phase III study  in 
systemic non- adjuvant treatment -naïve postmenopausal women with ER-positive, HER2-
negative advanced BC (Finn et 
al 2016). In addition, in a phase III study in 521 pre-and 
postmenopausal patients with advanced HR-positive, HER2- negative BC that had relapsed or 
progressed during prior ET, addition of palbociclib to fulvestrant (with ovarian suppression in 
premenopausal women in both arms) improved median PFS from 3.8 months to 9.2 months 
(hazard ratio 0.42; 95% CI
: 0.32 -0.56; p<0.001) ( Turner et al 2015 ).
In the subgroup analy sis of this study , the palbociclib -containing regimen has similar efficacy 
in pre-/perimenopausal vs post-menopausal women and PFS results were not significantl y 
associated with plasma estrogen (E2) levels ( Loibl et al 2016 ), supporting use of palbociclib in 
pre-/perimenopausal wo men.
Efficacy  and safet y of the combination of ribociclib and letrozole as first line treatment was 
evaluated in 668 postmenopausal women with HR- positive, HER2 -negative advanced BC in a 
phase III study  
(CLEE011A2301) . Ribociclib significantly  improved PFS (hazard ratio 0.56, 
95% CI : 0.43 -0.72, p = 0.00000329) ( Hortobagy i et al 2016 ).
Refer to the most recent ribociclib [Investigator’s Brochure ] for more details.
An update to this study with anaddition al11 months of follow -up reported aconsistent 
improvement in PFS in comparison with the interim analy sis. Median PFS was prolonged by 
9.3 mo, from 16.0 mo (95% CI
: 13.4 –18.2) in the placebo + letrozole arm to 25.3 mo (95% CI: 
23.0–30.3) in the ribociclib +letrozole arm (hazard ratio 0.568, 95% CI: 0.457- 0.704, 
p=0.0000000963). 24-mo PFS rates were 54.7% vs 35.9%. The investigator -reported overall 
response rate was 42.5% (95% CI: 37.2%
-47.8%) in the ribociclib arm and 28.7% (95% CI: 
23.9%- 33.6%) in the placebo arm (in the full analysis set ); and 54.5% (95% CI: 48.4%, 60.6.%) 
and 38.8% (95% CI: 32.7%, 44.9%) in patients with measurable disease at baseline ( Hotobagy i 
et al, ASCO 2017 ).
Considering demonstrated efficacy  of CDK4/6 inhibitors in the HR-positive, HER2- negative 
advanced BC, co-targeting the CDK4/6
-Rb-E2F pathway  with CDK4/6 inhibitors may be a 
viable strategy  to enhance endocrine responsiveness and prevent or delay  the development of 
acquired resistance.

Novartis Confidential Page 35
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
Figure 1-1 Regulation of cell cy cle checkpoint control
Adapted from Lange and Yee 2011 .
Refer toribociclib [ Investigator ’s Brochure ] fo r more details.
1.1.2 Role of estrogen pathway  in breast cancer
Expression of the estrogen receptor (ER) and/or progesterone receptor (PgR) is one of the most 
important prognostic factors in invasive breast cancer and is detected in approximately  70% of 
cases. Estrogen deprivation therap y is the core treatment modality in patients with hormone 
receptor positive (HR+) advanced breast cancer.
Endocrine therapy  options for postmenopausal women with ER+ advanced breast cancer 
(locally  advanced, recurrent, or metastatic breast cancer) include selective ER modulators or 
SERM (tamoxifen), ER antagonists (fulvestrant), nonsteroidal aromatase inhibitors (NSAI ; 
anastrozole and letrozole) and steroidal aromatase inhibitors (exemestane). Blocking estrogen 
signaling with tamoxifen has been the main approach in treatment for ER+breas t cancer for 
over 35 years. In postmenopausal women, aromatase inhibitors (AI) reduce peripheral estrogen 
synthesis by blocking the conversion of androgens to estrogens in non-ovarian tissues; synthesis 
in these tissues is the primary source of estrogens i n postmenopausal women. AIs are generall y 
used as the first line of therap y for women with HR+ breast cancer (Beslija 2009 ; NCCN 
2.2017).
In premenopausal patients without previous exposure to an antiestrogen, initial treatment of 
advanced/metastatic disease involves the use of a selective ER modulator alone or ovarian 
suppression/ablation plus endocrine therapy  as for postmenopausal women. In premenopausal 
women 
who received a prior endocrine therapy  within 12 months, the preferred therap y involves 
ovarian ablation or suppression + endocrine therapy  -such as aromatase inhibitors (AIs) -as 
for post- menopausal patients . (NCCN Breast Cancer Guidelines, version 2.2017).
Based on the clinical benefit shown in postmenopausal patients , AIs in combination with 
ovarian function suppression (OFS) have been investigated in premenopausal patients with 

Novartis Confidential Page 36
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
breast cancer in neoadjuvant, adjuvant and advanced settings. Results from the randomized 
phase III trials SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and 
EXemestane Trial) showed that adjuvant treatment with exemestane+OFS as compar ed with 
tamoxifen+OFS, significantly  reduced recurrence in premenopausal women with HR+ early 
breast cancer. Results from both trials (N=5,738) showed statisticall y significant differences in 
disease free survival (DFS) at 5 years (91.1% in exemestane + OFS vs 87.3% in tamoxifen + 
OFS) and rate of freedom from breast cancer at 5 years (92.8% in exemestane+OFS vs 88.8% 
in tamoxifen+OFS) (Pagani 2014). Studies exploring the combination of third generation AIs 
and goserelin in metastatic premenopausal BC patients
are shown below in Table 1-1. 
(Montagna 2013 )
Table 1
-1 Goserelin and third generation A Is in metastatic premenopausal BC 
patients
Study N AI+goserelin (G)ORR 
(CR+PR) (%)CB 
(CR+PR+SD) 
(%)TTP 
(months)First line 
endocrine 
therapy
(Forward 2004 ) 16 Anastrozole+G 6.2 75 N/R No
(Cheung 2010 ) 36
13Anastrozole+G
Exemestane+G*36
N/R67
3812
N/RYes
No
(Carlson 2010 ) 35 Anastrozole+G 37 72 8.3 Yes
(Park 2010 ) 35 Letrozole+G 46 77 9.5 Yes
(Yao 2011 ) 52 Letrozole+G 21 71 10 Yes/No
(Roche 2009 ) 33 Anastrozole+G 55 64 13 Yes
(Nishimura 2012 )37 Anastrozole+G 19 62 7.2 Yes/No
ORR=Objective response rate, CR=Complete response, PR=Partial response, CB=Clinical benefit, SD=Stable 
disease, PD=Progressive disease, TTP=Time to progression, N/R=Not reported
*In study by Cheung et al, patients received treatment with exemestane after they received treatment with 
anastrozole.
Although data are limited (Montagna 2013), clinical benefit of the combination of AIs and OFS 
in premenopausal women with advanced ER+ breast cancer has been shown in small phase II 
studies with letrozole and anastrozole. In one study  (Cheung 2010), patients received 
exemestane, but only after they had received anastrozole, so the effect of single –agent 
exemestane has not been well characterized. Lastly , novel therapeutic approaches targeting 
promising pathway s should be explored to further improve efficacy  in premenopausal women 
with advanced HR+ breast cancer.
Male breast cancer is rare, with less than 1% 
of all breast carcinomas occurring in men 
(Giordano 2005). The pathology  is similar to that of female breast cancer, and infiltrating ductal 
cancer is the most common tumor type. Male breast cancers have 
high rates of hormone -
receptor expression, with approximately  90% 
of male breast cancers expressing estrogen 
receptor, and 81% expressing progesterone receptor.
In general, the approach to the treatment of metastatic breast cancer is similar in male and 
female patients with breas t cancer, with hormonal therap y being the often the first approach. 
Although, historically , surgical ablative therapies such as orchiectom y, adrenalectom y, and 
hypophy sectomy  have been used effectivel y to control metastatic breast cancer in male patients, 
these surgical procedures are rarel y used toda y and have been supplanted b y additive hormonal 
therapies. Tamoxifen has established efficacy  in metastatic male breast cancer, with an 

Novartis Confidential Page 37
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
approximate 50% response rate, and is considered an acceptable treatment option. Luteinizing 
hormone –releasing hormone agonists, with or without antiandrogens, have also been reported 
to be effective in male breast cancer. There have 
been case reports of responses to a wide variety 
of hormonal therapies including progestins, androgens, steroids, aminoglutetha mide, estrogens, 
and letrozole.
Since the hormonal environment in male patients differs from that observed in female patients, 
the role of AIs in male patients may be different (Doyen J 2010). In men, 80% of circulating 
estrogens are derived from peripheral aromatization of testicular and adrenal androgens, with 
direct production from the testes accounting for the remaining 20%. Studies in men patients had 
demonstrated that non-steroidal AIs lead to a decrease in plasma E2 levels, but these levels can 
still be detectable in some patients, potentiall y because of the baseline levels of peripheral 
androgens (with 
are subtracts for aromatization) and the testicular production of estrogens, 
which is not inhibited by NSAIs. Additionall y, the use of NSAIs can be associated with 
feedback loop leading to increase of LH and FSH, which can lead of additional production of 
androgens, with increased availability  of subtracts for aromatizat ion. All these elements 
converge to a suboptimal suppression of estrogen production in male patients submitted to 
treatment with monotherapy  AI, and create a rational for the combined use of these agents 
together with LHRH.
The use of aromatase inhibitors together with LHRH was studied as first-or second -line therapy 
for male patients with HR+ metastatic breast cancer (Giordano SH 2005) ; 19 patients were 
evaluated with promising results: 2 patients (10.5 %) had complete response, 7 patients (36.8 %) 
experienced a partial response, 7 patients (36.8 %) had stable disease lasting ≥6 months, and 3 
patients (15.8 %) had progressive disease. Overall, the disease control rate was 84.2 %. Median 
progression- free survival was 12.5 months (95 % CI 8.2–16.9), median overall survival was 
35.8 months (95 % CI 24.4–49.2), 1-and 2-year survival rates were 89.5 and 67 %, respectivel y. 
Safety  profile was expected and manageable, with no grade 3/4 adverse events
1.2 Introducti on to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  ofRibociclib
Ribociclib is an orally bioavailable and highl y selective small molecule 
inhibitor with highly 
specific nanomolar inhibitory  activity  against CDK4/cy clin-D1 and CDK6/cy clin-D3 enzy me 
complexes with I C50’s of 0.01 and 0.039 µM in biochemical assay s, respectively .
1.2.1.1 Non- clinical data
Ribociclib inhibits the phosphorylation of Rb at CDK4/6
-binding sites with an average IC50 of 
60 nM in Jeko-1 MCL  cells that overexpress cyclin D1. Regardless of the various genetic 
aberrations that may be present in the cancer cells, the anti -tumor activity  of ribociclib requires 
the presence of functional pRb.
Cardiac safety  studies in vivo demonstrated QT prolongation with the potential to induce 
premature ventricular contractions (PVCs) at higher exposure levels. The effects of ribociclib 
on the bone marrow (hypocellularity ), lymphoid system (lymphoid depletion), intestinal 
mucosa (atroph y), the kidney  (concurrent degeneration and regeneration of tubular epithelial 

Novartis Confidential Page 38
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
cells), skin (atrophy ), bone (decreased bone formation) and testes (atrophy ) are considered to 
be related to the pharmacological inhibition of cell replication in these tissues due to CDK4/6 
inhibition. The hepatobiliary system (proli ferative changes, cholestasis, sand-like gallbladder 
calculi and inspissated bile) was identified as an additional target organs of toxicity that are not 
likely  related to the primary  pharmacology  of ribociclib. Generall y, all these effects of ribociclib 
demonstrated either reversibility  or a clear trend towards reversibility . Ribociclib did not show 
an indication for a genotoxic potential. Reproductive studies in animals have demonstrated that 
ribociclib is embry otoxic, fetotoxic and teratogenic.
In vitro
, ribociclib was a reversible inhibitor of human cytochrome P450 (CYP) enzymes 
CYP1A2, CYP2E1 and CYP3A4 and a time-dependent inhibitor of CYP3A4. Under 
therapeutic conditions, inhibition of CYP3A4 is likely  to occur, while inhibition of CYP1A2 or 
CYP2E1 is not expected. The in vitro inhibitory  potency  of ribociclib for the transporters breast 
cancer resistance protein (BCRP), organic cation transporter 2 (OCT2), multidrug and toxin 
extrusion protein-1 ( MATE1 ), and bile salt export pump (BSEP) may translate into clinically 
relevant inhibition at therapeutic doses.
Elimination of ribociclib is dominated by oxidative metabolism mainly  via CYP3A4 with a 
minor contribution by flavin -containing monooxygenase 3 (FMO3). Although ribociclib is a 
substrate of the P-glycoprotein (P-gp) efflux transporter, this process is likely  not clinicall y 
relevant due to the high passive permeability  of ribociclib.
Refer to the most recent ribociclib [Investigator’s Brochure ]for additional details .
1.2.1.2 Clinical experience
Ribociclib i s currently  being investigated in patients with breast cancer and other solid tumors 
in multiple clinical trials at different phases of development. Refer to the most recent ribociclib 
[Investigator’s Brochure ] for details on clinical studies with ribocicl ib.
1.2.1.2.1 Clinical safety of ribociclib
Clinical safety  of ribociclib with endocrine agents such as letrozole, tamoxifen, exemestane and 
fulvestrant has been evaluated in several phase I and III combination trials. The recommended 
dose of ribociclib in combinati on with these agents was declared as 600 mg qd on a 3 weeks 
on/1 week off schedule.
The safety profile of ribociclib in combination with letrozole was investigated in a randomized 
clinical trial of ribociclib and letrozole versus placebo and letrozole (CLEE011A2301) in 668 
treatment -naive postmenopausal women with HR-positive, HER2- negative, advanced BC. 
Most common treatment -
emergent AEs reported in the ribociclib arm in this study  occurring 
in >30% of patients were neutropenia (74.3%), nausea (51.5%), infections (50.3%), fatigue 
(36.5%), diarrhea (35.0%), alopecia (33.2%) and leukopenia (32.9%). The most common grade 
3 or 4 AEs reported in ≥5 % of patients in the ribociclib arm were neutropenia (59.3%), 
leukopenia (21.6%), hypertension (9.9%), increased alanine aminotransferase (9.3%), 
lymphopenia (6.9%) and increased aspartate aminotransferase (5.7%). Febrile neutropenia 
occurred in 1.5% of the patients in the ribociclib arm. Blood creatinin e increases were reported 
in 6.9% of patients. Four patients (1.2%) met the biochemical and clinical criteria for H y’s Law 
with 3 reported as treatment -related and all 4 returning to normal values after treatment 

Novartis Confidential Page 39
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
discontinuation. Eleven patients (3.3%) presented on treatment QTcF prolongation >480 msec. 
Serious AEs we re reported in 21.3% of patients in the ribociclib arm with 7.5% of serious AEs 
deemed by investigators as treatment -related. There were 3 fatal events in the ribociclib arm 
(disease progression, sudden death, unknown cause) with 1 AE (sudden death) reported as 
treatment -related in a patient that had grade 3 hypokalemia and grade 2 QTcF prolongation (483 
msec). Neutropenia, QT interval prolongation and hepatobiliary  toxicity  are considered to be
important identified risks for ribociclib which appear to be manageable and reversible with 
adequate monitoring, interruption and/or reduction of ribociclib dosing.
For a comprehensive review of safet y profile of ribociclib in combination with endocrine agents 
refer to the most recent ribociclib [Investigator’s Brochure] .
1.2.1.2.2 Cl
inical efficacy with ribociclib
In a phase III randomized clinical trial of ribociclib and letrozole versus placebo and letrozole 
(CLEE011A2301) in 668 treatment -naive postmenopausal women with HR-positive, HER2-
negative, advanced BC, ribociclib im
proved PFS (hazard ratio 0.56, 95% CI: 0.43- 0.72, 
p=0.00000329). The investigator -reported overall response rate was 40.7% (95% CI: 35.4%
-
46.0%) in the ribociclib arm and 27.5% (95% CI: 22.8%- 32.3%) in the placebo arm 
(p=0.000155) in the full anal ysis set; and 52.7% (95% CI : 46.6%, 58.9%) and 37.1% (95% CI : 
31.1%, 43.2%) (p=0.00028) in patients with measurable disease at baseline (Hortobagy i et al 
2016).
An update to this study with an additional 11 months of follow -
up reported a consistent 
improvement in PFS in comparison with the interim analy sis. Median PFS was prolonged by 
9.3 mo, from 16.0 mo (95% CI: 13.4 –18.2) in the placebo + letrozole arm to 25.3 mo (95% CI: 
23.0–30.3) in the ribociclib + letrozole arm (hazard ratio 0.568, 95% CI: 0.457 -0.704, 
p=0.0000000963). 24-mo PFS rates were 54.7% vs 35.9%. The investigator -reported overall 
response rate was 42.5% (95% CI: 37.2%
-47.8%) in the ribociclib arm and 28.7% (95% CI: 
23.9%- 33.6%) in the placebo arm (in the full analysis set); and 54.5% (95% CI: 48.4%, 60.6.%) 
and 38.8% (95% CI: 32.7%, 44.9%) in patients with measurable disease at baseline (Hortoby agi 
et al, ASCO 2017 ).
Refer to the most recent ribociclib [Investigator’s Brochure] for additional details 
on efficacy 
profile of ribociclib.
1.2.1.2.3 Clinical Pharmacokinetics of ribociclib
Following oral dosing of the capsule formulation at 600 mg, ribociclib is rapidly absorbed with 
median Tmax of 2.40 h (range: 0.683 to 7.82 h). Steady -state plasma Cmax ranges from 606-
6170 ng/mL  (geometric mean: 1820 ng/mL or 4.1 µM) and AUC0 -
24h ranges from 6770- 90600 
ng*h/mL (geometric mean: 23800 ng*h/mL). The effective T1/2 of ribociclib is 32.0 h (range: 
8.06 to 97.9 
h). Inter-patient variability  in Cmax and AUC is 62% and 66%, respectively , as 
assessed b y geometri c coefficient of variation
. LEQ803, an active metabolite of ribociclib, has 
similar PK characteristics as parent drug. At the 600 mg dose level, LEQ803 accoun ts for 
approximately  8% of parent exposure after single and multiple doses. Neither ribociclib nor 
LEQ803 accumulate substantially following repeated daily  administration.

Novartis Confidential Page 42
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
suppress ovarian function in premenopausal women in this study  as the 3-month depot 
formulations do not reliably  suppress estrogen levels in all patients ( Gradishar et al 2016
).
The most common AEs occurring of women treated with LHRH agonists included hot flushes, 
headache, sweating, acne, emotional lability , depression, decreased libido, vaginitis, breast 
atrophy , seborrhea and peripheral edema.
The most common AE occurring of men treated with LHRH agonists include a transitory 
elevation in testosterone levels can occur in men after the first few doses, followed by the 
expected decrease of these hormonal levels; as a result, the most commonly  observed adverse 
reactions, which occurred in at least 1 out of every 10 men (10%) who participated in clinical 
trials, are hot flashes, sexual dysfunction, decreased erections and lower urinary  tract symptoms 
(for example, urinary  urgency , cystitis, blood in your urine). Some patients may experience a 
temporary  increase in bone pain.
Refer to the most recent 
regional prescribing information and/or clinical guidelines for more 
information on LHRH agonists.
2 Rationale
2.1 Stud y rationale and purpose
Approximately  75% of breast cancer sexpress estrogen receptor (ER) and/or progesterone 
receptor (PgR) and are dependent of estrogen for growth. Studies of ER+ breast cancer cell 
lines indicate that estrogens and antiestrogens act in early  to mid-G1 phase, via cyclin D1 
expression. G1/S transition is under the control of CDKs, particularly  CDK4, CDK6 and CDK2. 
CDK4 and CDK6 are activated by binding to D-type cyclins and act early in G1 phase. The 
interplay  between the ER pathway  and the cell cycle control machinery  –particularly  the control 
of G1-S transition mediated by cyclin d and CDK 4/6 – provides a strong rational for the 
combined use of interventions designed to control both nodes as a way  to stop the HR+ breast 
cancer proliferation. This mechanistic approach is corroborated by preclin ical evidence of 
synergistic activity  of CDK inhibitors and hormonal agents against HR+ breast cancer in cell 
lines and animal models and also clinical superiority  with the combination (CDKi + hormonal 
agents) vs. endocrine therap y alone in recent phase II/III trials (PALOMA -1/2/3 with 
palbociclib; MONALEESA -2 with ribociclib).
Ribociclib (L EE011) is an oral selective inhibitor of CDK 4/6 which has demonstrated activity 
in HR+BC cell lines in combination with multiple hormonal partners, as well as in clinic al 
studies. While studies in combination with fulvestrant (MONALEESA -3) and NSAI /tamoxifen 
in premenopausal patients (MONALEESA -7) are ongoing, the phase III trial MONALEESA -2 
(ribociclib + letrozole vs. letrozole) was declared as a positive study  in an interim assessment , 
with clinically  and statistically meaningful benefit observed with the combination (ribociclib + 
letrozole) vs letrozole monotherap y in major endpoints (PFS and tumor response); the 
combination treatment had demonstrated amanageable safet y profile based on dose 
interruptions and/or reductions . These results reinforc ethe activity  of this combination for the 
treatment of HR+ advanced breast cancer. This trial will support the first authorization granted 
in the United States (US).

Novartis Confidential Page 43
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
The purpose of this study is to further evaluate the overall safet y and tolerability  and clinical 
efficacy  of ribociclib in combination with letrozole in a large cohort of patients with HR+, 
HER2- aBC who have not received prior hormonal treatment f or advanced disease.
This study  will collect additional safety , tolerability , and efficacy  data in a larger and broader 
patient population including certain clinical situations not included in the phase III trials (e.g., 
patients treated with prior chemoth erapy for advanced disease, ECOG PS 2.)Premenopausal 
patients with appropriate ovarian suppression achieved with the use of goserelin
,will be 
included in this trial, since the treatment of these patients is quite similar towhat 
postmenopausal women typically  receive . In this trial, perimenopausal patients can be included 
(see Section 5 for definition) and should be treated with goserelin as prem enopausal patients. 
The results from the phase III PALOMA -3 trial with palbociclib + fulvestrant had demonstrated 
similar superior efficacy  vs. fulvestrant monotherapy  in both premenopa usal (+goserelin) and 
post-menopausal patients (premenopausal, N=72; median Progression Free Surviv al (
mPFS) : 
9.5 months (95% CI : 7.4-NE); pos t-menopausal, N=275; mPFS: 9.9 months (95% CI  8.5-11.0)
(Cristofanilli, Lancet Oncology  2016). The trial will also include males with HR+, HER2- aBC, 
which will generate data about the use of this combination in a very rare patient population with 
the 
rational to explore the activity  of letrozole +LHRH agonists (as hormonal suppressant)
together with ribociclib, given the observed benefit of CDKi when added to standard hormonal 
therapy in women wit h HR+ advanced breast cancer.
The results from this trial will provide arelevant set of information to the medical community 
about the activity  of ribociclib + letrozole in HR+ aBC and potentiall y generate additional 
hypothesis to be explored in future tr ials.
2.2 Rationale for the study  design
This is an open -label, single arm, multi
-center Phase IIIb study  to evaluate the overall safety 
and tolerability  and clinical efficacy  of ribociclib in combination with letrozole in men and 
pre/postmenopausal women with HR+, HER2- advanced breast cancer who have not received 
prior hormonal treatment for advanced 
disease.
The study  design will allow an adequate characterization of the safety  profile of this 
combination (primary  objective); efficacy  parameters will also becollected in all patients
during study  participation, which will provide additional information about the combination 
activity  in a broad erpatient population with aBC.
2.3 Rationale for dose and regimen selection
The dose (oral administration of 600 mg daily) and regim en (Day s 1-21 of a 28 day cycle) of 
ribociclib was selected for this study ,since this dose and regimen were shown to be tolerable 
and efficacious when combined with ET in clinical trials in patients with HR-positive, HER2 -
negative advanced BC ( see Section 1.2.1).
Data from ribociclib [MONALEESA -
2]trial (Hortobagy i 2016 )and palbociclib ([PALOMA-
1]and [PALOMA - 2]studies) demonstrated clinical benefit ,when used in combination with the 
non-steroidal aromatase inhibitor letrozole , significantly  prolonging progression free survival 
in postmenopausal women with HR+, HER2 -negative advanced breast cancer when compared 
with letrozole alone ( Finn 2015, Finn 2016, Hortobagy i 2016 ).

Novartis Confidential Page 44
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
In this study , we propose to use the same approach, combining ribociclib with letrozole 
(+LHRH agonists to achieve adequate hormonal suppression in men/premenopausal women )
in HR+, HER2- negative men and pre/postmenopausal women with advanced breast cancer who 
have received no prio
r therap y for advanced disease.
The standard dose sof goserelin (3.6 mg subcutaneously  every  28 day s)andleuprolide (7.5mg 
intramusc ularlyevery  28 days
)will be used in this study  as goserelin or leuprolide arenot 
expected to affect the metabolism of nor be affected by  co-administration of other drugs.
2.4 Rationale for choice of comparator drugs
This is a non-comparative study .The purpose of this trial is to further evaluate the overall 
safet y/tolerability  and 
clinical efficacy  of ribociclib in combination with letrozole in a more 
diverse population in comparison with the existing phase III study  with this combination. Given 
the positive results from MONALEESA -2 (and also available data with other CDK 4/6 
inhibit ors), the combination of ribociclib (a CDK 4/6 inhibitor) + letrozole demonstrated 
superior efficacy  in comparison with monotherapy  with letrozole, and this treatment is now an 
accept edstandard of car e for the treatment of HR+ aBC.
For this reason, the trial is designed as a single -arm, non-comparative study  to allow all patients 
on the study  to be treated with this regime nwhile relevant information about its safety  and 
efficacy  will be collected and anal yzed.
2.5 Risks and benefits
The treatment landscape inHR+, HER2- aBC has evolved during recent years, with the 
characterization that CDK 4/6 inhibitors may play an important role in controlling the disease 
and prolonging PFS in comparison to NSAI  alone. Many treatment guidelines have alread y 
incorporated CDK i as a treatment choice and palbociclib (the first commerciall y available 
CDKi) is alread y approved in many countries around the world. On March 13, 
2017 , the US 
Food and Drug Admin istration approved Kisqali®(ribociclib) ,a cyclin-dependent kinase 4/6 
inhibitor, in combination with an aromatase inhibitor as initial endocrine -based therapy  for the 
treatment of postmenopausal women with hormone receptor (HR) -positive, human epidermal 
growth factor receptor 2 (HER2) -negative advanced or metastatic breast c ancer .
Ribociclib ,a selective CDK 4/6 inhibitor , has been evaluated in patients with HR+ HER 2-aBC, 
supported by strong preclinical data showing activity  against HR+ luminal breast cancer cell 
lines and synergistic activity  with hormonal agents in preclin ical models. Study 
[CLEE011X2107 ]was the first one to demonstrate activity  of ribociclib in combination with 
letrozole in aBC patients that were treatment -naïve for their advanced disease, with adequate 
tumor control based on ORR and CBR. Treatment was generall y well-tolerated and emerging 
toxicities were appropriately managed with dose reductions/interruptions. The pivotal phase III 
trial ([MONAL EESA -
2]) comparing ribociclib + letrozole with letrozole in a similar patient 
population as [CLEE011 X2107
]was declared positive in a preplanned interim analy siswith 
clinically  and statistically  meaningful benefit observed with the combination (ribociclib + 
letrozole) vs letrozole monotherap y in major endpoints (PFS and tumor response); the 
combination treatment had demonstrated a manageable safet y profile based on dose 
interruptions and/or reductions.

Novartis Confidential Page 45
Amended Protocol Version 04 (Clean)              Protocol No. CLEE011A2404
This proposed trial is intended to expand the available information about ribociclib inHR+, 
HER2- aBC either in terms of safety  as well as efficacy . The p opulation to be included in this 
trial is slightly  broader than those included in the pivotal phase III trials(e.g. PS 0-2, prior 
treatment with chemotherap y for advanced disease, premenopausal women andmen), which 
will allow the generation of data in a larger patient population in comparison with other Phase 
III trials .
Patients included in this trial will potentially  benefit from an effective treatment
,based on the 
results from phase I and phase III trials; since all patients included in this trial will rece ive the 
combination of ribociclib + letrozole, no ethical issues are expected from this perspective . 
Patients will continue to receive treatment until disease progression, death, unacceptable 
toxicity , physician’s decision, subject/guardian’s decision, protocol deviation, study 
termination by  sponsor, lost to follow -up, technical problems or until 18months after L PFV in 
the Core Phase , whichever event occurs first. Patients may be transitioned to the Extension 
Phase and continue to receive the drugs until progression, intolerance, death or 
physician/patient decision.
Ribociclib + letrozole treatment is associated with potential AEs, including reversible 
cytopenias (neutropenia, anemia and thrombocy topenia), GI toxicities (nausea, vomiting, and 
diarrhea), fa tigue, alopecia, elevation in liver enzymes and QT prolongation; some of them can 
be serious. These toxicities can be managed with appropriate monitoring, dose 
reductions/interruptions and symptom -related treatments. These risks can be appropriatel y 
mitiga ted in this protocol with clear guidance about eligibility  criteria, monitoring of potential 
toxicities and strategies for therap y management (including instructions related to dose 
adjustments/interruptions).
The addition of goserelin or leuprolide to premenopausal women /male patients is not expected 
to affect the metabolism of nor be affected by co-administration of the other drugs (ribociclib 
and letrozole), so no additional safet y risks are expected with this combination.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3
-1below.

Novartis Confidential Page 46
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary
To evaluate the safety and tolerability of ribociclib + letrozole in men 
and pre / postme nopausal women with HR+, HER2 - aBC who 
received no prior hormonal therapy for advanced disease
Note: Throughout this document , perimenopausal a nd 
premenopausal statu s is grouped together and referred as 
“Premenopausal”●AEs, Grade 3/4 AEs & SAEs during treatment with ribociclib 
+ letrozoleRefer to Section 10.4
Secondary
To assess the clinical efficacy and patient reported outcomes of 
ribociclib + letrozole in the patient population as described above
To evaluate long -term safety of ribociclib + letrozole during Extension 
Phase
To evaluate clinical benefit of ribociclib + letrozole as assessed by 
investig ator during Extension Phase●Time -to-Progression (TTP) (RECIST 1.1), based on 
investigators’ assessment
●Overall response rate (ORR) as defined by RECIST 1.1 for 
patients with measurable disease
●Clinical Benefit Rate (CBR) as defined by RECIST 1.1 
(including patients with CR, PR, SD, NCRNPD >24 weeks)
●Patient Reported Outcome (PRO) using FACT -B 
questionnaire
● F requency and severity of AEs & SAEs during Extension 
Phase
● Proportion of patients with clinical benefit as assessed by 
investigator dur ing Extension PhaseRefer to Section 10.5.1

Novartis Confidential Page 47
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
4 Study  design
4.1 Description of study  design
This is an open -label, single arm, multi- center Phase IIIb study  to evaluate the overall safety 
and tolerability  and clinical efficacy  of ribociclib in combination with letrozole in men and 
pre/postmenopausal women with HR+, HER2- aBC and no prior hormonal treatment for 
advanced disease. Gonadal suppression is achieved with either goserelin or leuprolide in men
and premenopausal women patients
.
The stud y will be composed of 2 phases:
Core Phase: from FPFV to 18 months after L PFV. During the Core P hase, safet y and 
efficacy  data (including PROs in selected countries) will be collected ;
Extension P hase: from the end of the Core P hase to L PLV. In the event study  patients are 
still deriving benefit at the end of the Core Phase and ribociclib is not approved or 
available and reimbursed , patients may be transitioned to this Extension Phase and 
continue to receive the drugs until progression, intolerance, death or phy sician/patient 
decision
;only safet y and clinical benefit (as assessed by  investigator ) data will be 
collected.
Approximately  3,000 patients across a diverse number of sites, countries, and regions are 
expected to be enrolled in this trial. Study  treatment of the Core Phase will be provided until 
disease progression, death, unacceptable toxicities, physician’s decision, subject/guardian’s 
decision, 
protocol deviation, study  termination by sponsor, lost to follow -up, technical problems 
or until 18months after LPFV , whichever event occurs first (See Figure 4 -1).
Enrollment inthis trial i
snot competitive, with the purpose to include a diverse patient 
population in terms of sites, countries and regions. Each participating cou ntry will be assigned 
a predefined number of patients (based on number of participating sites and available patient 
population); once this number is achieved, countries may  stop enrollment while the study  will 
continue to enroll in other countries/regions. Safety  data collected will include all AEs and 
SAEs including grade 3/4 AEs, events of special interest (Neutropenia including febrile 
neutropenia, QT prolongation, hepatobililary  toxicity ),AEs leading to permanent treatment 
discontinuation or death, vit al signs, physical examination, variation of the ECOG performance 
status, and selected hematology /chemistry  parameters at study  visits while the patient remains 
on study  and for 30 day s after discontinuation.
Time to Tumor Progression (TTP) and overall tumor response (ORR/CBR) will be assessed by 
the investigator using RECI ST v1.1 criteria. Tumor assessments should be performed every 
12 weeks (recommended timeframe) or according to the current standard of care (as per 
local requirements) during treatment phase and at end of treatment (EOT). It is strongl y 
recommended that a tumor assessment is performed before the patient is switched to a new 
antineoplastic therap y.
Local/regional sub-studies/anal ysis can be conducted in the patient population enrolled in 
[CLEE011A2404 ](CompL EEment -1) study . These sub-studies can be designed to explore 
additional aspects of ribociclib treatment in HR+HER2- advanced breast cancer, which are not 

Novartis Confidential Page 48
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
assessed in the current CLEE011A2404 protocol. Examples of sub-studies include biomarker 
analysis (correlative science studies), additional patient -reported outcome (PRO) evaluations or 
any other relevant assessments that are not currently  evaluated during CLEE011A2404 study. 
Sub-study  protocols must follow the current Novartis process for review and approval of 
sponsored clinical trials, and should be reviewed and approved by the relevant regulatory 
authorities and Ethics Committees before implementation.
Figure 4-1 Study  design

Novartis Confidential Page 49
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
4.2 Timing of interim analy ses and design adaptations
Interim analy ses (IA) may be performed periodically .The first IA is planned to be performed 
about 12 months after FPFV, and periodicall y, if needed, to fulfill regulatory requests, safet y 
updates, or for publication purposes.
4.3 Definition of end of study
Study  recruitment will stop when approximately  3,000 patients are enrolled .
The planned overall study  duration of the Core Phase will befrom FPFV to18 months after 
LPFV. At the t ime of Core Phase endif patients are still deriving clinical benefit and ribociclib 
is not approved or available and reimbursed
, patients may be transitioned to the Extension Phase 
trial period and continue to receive the drugs until progression, intolerance, death or 
physician/patient decision, but only safety and clinical benefit as assessed by investigator will 
be collected during the E xtension Phase.
The duration of the Extension Phase will be 18 months from LPLV of the Core Phase. During 
the Extension Phase, if ribociclib is appro ved and reimbursed, patients willbe trans itioned to 
prescription or drug access/support program(s) according to local laws and regulations. 
The study will end after completion of the Extension Phase and all remaining patients will 
discontinue from the study .Patients who complete the Extension Phase, and continue to derive 
clinical benefit from the treatment based on t
he investigator’s evaluation willreceive ribociclib 
from prescription (if approved and reimbursed), another Post-Trial Access (PTA) progra m,or 
other drug access/support program (s).
Post-Trial Access (PTA) means the provision of treatment to trial participants following their 
completion of trial participation. PTA will be provided until one of the following is met:  patient 
no longer derives clinical benefit, investigator discontinues treatment, launch or reimbursement 
(where applicable), treatment fails to achieve registration in the trial participant’s country , or 
the clinical program is discontinued for an y other reason.  
The mechanism of PTA for this Extension Phase is provision of the Novartis investigational 
product in a non -trial setting (known as post -study drug supply [PSDS]) whe n no further safet y 
or efficacy  data are required, or an y other mechanism appropriate for the country .  
This PTA mechanism must comply  with local laws and regulations in the participating trial 
countries.  If Novartis discontinues the PSDS for this trial, Novartis will work with investigators 
to transition patients onto locally available alternative treatment, or standard of care.
The expected median follow -up at the time of study  completion will be around 24 months, 
which is sufficient to provide adequate information about the safety  and efficacy  of ribociclib 
+ letrozole in the population under investigation. According to data from Study  
CLEE011A2301 (MONAL EESA -2), G rade 3/4 (G3/4) AE of special interest (neutropenia, QT 
prolongation and liver enzy me elevations) were observed during the first cycles of treatment 
(QTc prolongation observed during the first 2 cycles; 83.8% of the LFT elevations had been 
observed during the first 6 cycles; 85% of the G3/4 neutropenia events were observed during 
the first 12 m onths of treatment), so a minimal period of 18 months of follow -up seems 
sufficient to capture these events as part of the primary  endpoint of the study . Additionally , 

Novartis Confidential Page 50
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
patients entering in the Extension Phase will continue to have safet y/tolerability  monitored, 
which will generate relevant data about the long -term safet y of this regimen.
4.4 Early study  termination
The study  can be terminated by  Novartis at any time for any  reason. This may  include reasons 
related to the benefit/ risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
Novartis will alway s consider the subject welfare and safet y. Should early  termination be 
necessary , subjects must be seen as soon as possible (provide instruction for contacting the 
subject, when the subject should stop taking drug, when the subject should come for a final visit) 
and treated as a prematurely  withdrawn subject. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the 
protection of the subject’s interests. The investigator or sponsor depending on the local 
regulation will be responsible for informing IRBs/IECs of the early termination of the trial.
5 Population
5.1 Patient population
This trial will be conducted in men and pre/postmenopausal women with HR+, HER2- aBC 
who ha ve
not received any  prior hormonal agent for the treatment of advanced disease.
Approximately  3,000 patients are expected to be enrolled in this trial.
Patients enrolled in this protocol are not permitted to participate in additional parallel 
investigational dr ug(s)studies while on treatment.
The investigator or designee must ensure that only patients who meet allthe following inclusion 
and none of the exclusion criteria are offered treatment in the study .
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all of the following criteria:
1.Patient is an adult, male or female ≥ 18 years old at the time of informed consent
2.Male or female advanced (locoregionall y recurrent or metastatic) breast cancer not 
amenable to curative therapy
.
3.In the case of women, both pre/perimenopausal and postmenopausal patients are allowed to 
be included in this study ; menopausal status is relevant for the requirement of goserelin or 
leuprolide to be used concomitantly with ribociclib and letrozole.
a.Postmenopausal status is defined either by :
1.Prior bilateral oophorectomy
OR
2.Age ≥ 60
OR

Novartis Confidential Page 51
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
3.Age < 60 and amenorrhea for 12 or more months (in the absence of chemotherap y, 
tamoxifen, toremifen, or ovarian suppression) and FSH and estradiol in the 
postmenopausal range per local normal range . If patient is taking tamoxifen or 
toremifene and age <60, then FSH and plasma estradiol levels should be in post -
menopausal range per local normal range (NCCN Guidelines Version 2.2017).
Note: For women with therap y-induced amenorrhea, serial measurements of FSH 
and/or estradiol are needed to ensure menopausal status.
b.Premenopausal status is defined as either:
1.Patient had last menstrual period within the last 12 months,
OR
2.If on tamoxifen or toremifene within the past 14 days, plasma estradiol and FSH
must be in the premenopausal range per local normal range,
OR
3.In case of therap y induced amenorrhea, plasma estradiol and/or FSH must be in
the premenopausal range per local normal range.
c.Perimenopausal status is define as neithe r premenopausal nor postmenopausal
Note: Throughout this document, perimenopausal and premenopausal status is
grouped together and referred as “Premenopausal”
4.Patient has a histologically  and/or cytologically  confirmed diagnosis of estrogen -receptor 
positi ve and/or progesterone receptor positive breast cancer by local laboratory .A 
confirmatory  biops y is not required.
5.Patient has HER2- negative breast cancer defined as a negative in situhybridization test or 
an IHC status of 0, 1+ or 2+. If IHC is 2+, a neg ative 
in situ hybridization (FISH, CI SH, or 
SISH) test is required by  local laboratory  testing.
6.Patient has an Eastern Cooperative Oncology  Group (ECOG) performance status ≤ 2
7.Patient has adequate bone marrow and organ function as defined by ALL ofthe following 
laboratory  values (as assessed by  local laboratory):
Absolute neutrophil count ≥ 1.5 × 109/L
Platelets ≥ 100 × 109/L
Hemoglobin ≥ 9.0 g/dL
Potassium, sodium, calcium corrected for serum albumin and magnesium within 
normal limits or corrected to within normal limits with supplements before first dose of 
the study  medication
INR ≤ 1.5
Serum creatinine < 1.5 mg/dl or creatinine clearance ≥ 50 mL /min
In absence of liver metastases, alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) should be below 2.5 × ULN. If the patient has liver metastases, 
ALT and AST should be < 5 × ULN.
Total bilirubin < ULN except for patients with Gilbert’s syndrome who may only be 
included if the total bilirubin is ≤ 3.0 × UL N ordirect bilirubin ≤ 1.5 × ULN
8.Patient must have a 12 -lead ECG with ALL of the following parameters at screening:
QTcF interval at screening < 450 msec (using Fridericia’s correction)

Novartis Confidential Page 52
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Resting heart rate ≥ 50 bpm
9. Patient must be able to swallow ribociclib and letrozole tablets
10.Patient has signed informed consent obtained before any trial-related activities and 
according to local guidelines
11.Patients must be able to communicate with the investigator and comply  with the 
requirements of the study procedures
5.3 Exclusion criteria
Patients el igible for this study  must not meet anyof the following criteria:
1.Patient has a known hypersensitivity  to any of the excipients of ribociclib or letrozole
including peanuts and soy
2.Patient who received an y CDK4/6 inhibitor
3.Patient who received any prior systemic hormonal therap y for advanced breast cancer; no 
more than one prior regimen of chemotherap y for the treatment of metastatic disease is 
permitted
Note:
Patients who received (neo) adjuvant therapy  for breast cancer are eligible. If the prior 
neo (adjuvant) therapy  included letrozole or anastrozole the disease free interval must 
be greater than 12 months from the completion of treatment until study  entry .
Patients who received ≤ 28 day s of letrozole or anastrozole for advanced disease prior 
to inclusion in this trial are eligible.
4.Patient is concurrentl y using other anti -cancer therapy
5.Patient has had major surgery  within 14 days prior to starting study  drug or hasnot 
recovered from major side effects
6.Patient who has not had resolution of all acute toxic effects of prior anti-cancer therap y to 
NCI CTCAE version 4.03 Grade ≤ 1 (except alopecia or other toxicities not considered a 
safet y risk for the patient at investigator's discretion)
7.Patient who has received extended- field radiotherapy  ≤ 4 weeks or limited field 
radiotheraph yfor palliation ≤ 2 weeks prior to start of treatment , and who has not recovered 
to grade 1 or better from related side effects of such thera py (with the exception of alopecia
or other toxicities not considered a safet y risk for the patient at the investigator’s discretion )
. 
Patients from whom ≥ 25% (Ellis RE 1961) of the bone marrow hasbeen previously
irradiated are also excluded
.See Appendix 14.4
8.Patient has a concurrent malignancy  or malignancy  within 3 years prior to starting study 
drug, with the exception of adequately  treated, basal or squamous cell carcinoma, non-
melanomatous skin cancer or curativel y resected cervical cancer.
9.Patient with central nervous system (CNS) metastases unless they meet ALL of the 
following criteria:
At least 4 weeks from prior therap y for CNS disease completion (including radiation 
and/or surgery ) to starting the study  treatment

Novartis Confidential Page 53
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Clinically  stable CNS lesions at the time of stud y treatment initiation and not receiving 
steroids and/or enzy me-inducing anti-epileptic medications for the management of 
brain metastases for at least 2 weeks
10.Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly  
alter the absorption of the study  drugs (e.g., uncontrolled ulcerative diseases, uncontrolled 
nausea, vomiting, diarrhea, malabsor ption sy ndrome, or small bowel resection)
11.Patient has a known history  of HIV infection (testing not mandatory )
12.Patient has any other concurrent severe and/or uncontrolled medical condition that would, 
in the investigator ’s judgment, cause unacceptable safety risks, contraindicate patient 
participation in the clinical study  or compromise compliance with the protocol (e.g. chronic 
pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or 
viral infections, etc.)
13.Clinically  significant, uncontrolled heart disease and/or cardiac repolarization abnormalities, 
including but not limited to any of the following:
History  of acute coronary syndromes (including myocardial infarction, unstable angina, 
coronary  artery  bypass grafting, coronary  angioplasty , or stenting) or symptomatic 
pericarditis within 6 months prior to screening
History  of documented congestive heart failure (New York Heart Association 
functional classification III -IV)
Documented cardiom yopathy
Clinically  significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left 
bundle branch block, high -grade AV block (e.g. bifascicular block, Mobitz ty pe II and 
third-degree AV block)
Long QT s yndrome or family history of idiopathic sudden death or congenital long Q T 
syndrome, or an y of the following:
1.Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or 
hypomagnesemia, history  of cardiac failure, or history  of clinically 
significant/s ymptomatic brady cardia
2.Concomitant use of medication(s) with a known risk to prolong the QT interval 
and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 
half-lives or 7 days prior to starting study  drug) or replaced by safe alternative 
medication
3.Inability  to determine the QTcF (Fride ricia’s correction )interval on screening
Systolic blood pressure (SBP) >160 mmHg or <90 mmHg at screening
14.Patient is currently  receiving any  of the following medications and cannot be discontinued 
7 day s prior to Cy cle 1 Day  1:
Concomitant medications, herbal supplements, and/or fruits (e.g. grapefruit, pomelos, 
star fruit, Seville oranges) and their juices that are known strong inducers or inhibitors 
of CYP3A4/5 (See Appendix 14.1 )
Medications that have a narrow therapeutic window and are predominantl y metabolized 
through CYP3A4/5

Novartis Confidential Page 54
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
15.Patient is currently  receiving or has received systemic corticosteroids ≤ 2 weeks prior to 
starting study  drug, or who have not fully recovered from side effects of such treatm ent. 
Note: The following uses of corticosteroids are permitted: single doses, topical applications 
(e.g., for rash), inhaled spray s (e.g., for obstructive airway s diseases), eye drops or local 
injections (e.g., intra -articular)
16.Participation in a prior inv estigational stud y within 30 days prior to enrollment or within 5 -
half-lives of the investigational product, whichever is longer
17.Pregnant or nursing (lactating) women
Note : Women of child- bearing potential, defined as all women physiologically  capable of 
becoming pregnant, unless they  are using highl y effective methods of contraception during 
dosing and for 21 day s after stopping 
the study  medication.
Highl y effective contraception methods include:
Total abstinence when this is in line with thepreferred and usual lifesty leof the patient . 
Periodic abstinence (e.g. calendar, ovulation, s ymptothermal, post -ovulation methods)
and withdrawal are not acceptable methods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or witho ut 
hysterectom y), total hysterectomy or tubal ligation at least 6 weeks before taking stud y 
treatment. In case of oophorectom y alone, only when the reproductive status of the 
woman has been confirmed by  follow up hormone level assessment .
Male partner sterilization (at least 6 months prior to screening) . For female patients on 
the study  the vasectomized male partner should be thesole partner for that patient.
Placement of an intrauterine device (IUD) or intrauterine s ystem (IUS)
Note: Use of oral (estrogen and progesterone), transdermal, injected ,implanted hormone
containing intrauterine systems (IUS) or any other hormonal methods of contraception is 
not allowed in this study
6 Treatment
6.1 Stud y treatment
For this protocol, the term “inve stigational drug” refers to the Novartis study  drug ribociclib. 
The other drug sto be used in this study  areletrozole and either goserelin or leuprolide (for men 
/premenopausal women ). “Study  treatment” in this protocol refers to the combination of drugs
and includes investigational drug (ribociclib) as well as letrozole and goserelin or leuprolide (if 
applicable) .
Ribociclib will be supplied by Novartis or its designee as 200 mg tablets as individual patient 
supply  packaged bottles. Letrozole (Femara or generic equivalent) , goserelin and leuprolide
will be procured locally  by Country  Pharm a Organization or local institution as it is 
commerciall y available in each participating country  according to local practices and 
regulations. Storage conditions are described in the medication label. Medication labels will 
comply  with the legal requirements of each country  and be printed in the local language.
All dosages prescribed and dispensed to the patient and all dose changes during the study must 
be recorded on t he Dosage Administration Record in the eCRF.

Novartis Confidential Page 55
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
6.1.1 Dosing regimen
Ribociclib (LEE011) will be given orally once a day on days 1-21 of each 28-day cycle. On 
days 22
-28 ribociclib will not be given (“rest days”).Letrozole will be given orally  as per SmPC 
once a day on a continuous daily  schedule (day s 1-28 of each 28 -day cycle). There will be no 
“rest” in the letrozole schedule. For men and premenopausal women, either goserelin will be 
given as an injectable subcutaneous implant orleuprolide will be given as anintramuscular 
injection. Either goserelin or leuprolide is recommended to be administered on da y 1 starting at 
Cycle 1 and then every  28 day s.Goserelin or leuprolide must be given as the monthly  injection
dosage form ,as the 3 -month depot dosage forms donot reliably  suppress hormonal levels in all 
patients (NCCN ver. 2 2017 ).If a patient is already  receiving goserelin or leuprolide before 
C1D1, a 28 day sschedule should be maintained based on the pre -existing dosing schedule .
See Table 6-
1and Figure 6 -1for details.
Table 6-1 Dose and treatment schedule
Study  
treatmentsPharmaceutical form and 
route of administration DoseFrequency  and/or 
Regimen
Ribociclib Tablet for oral use 600 mg (3 tablets of 200 
mg)Daily on D1 -D21
(28 day cycles)
Letrozole Tablet for oral use 2.5mg Continuous Daily 
Goserelin Injectable Subcutaneous 
implant3.6 mg Every 28 day s
(only for men and 
premenopausal women )
Leuprolide Injectable Intramuscular
Depot7.5 mg Every 28 days
(only for men and 
premenopausal women)
Figure 6-1 Men / Premenopausal regimen

Novartis Confidential Page 56
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Figure 6-2 Postmenopausal regimen
The study  treatment will be administered as a flat-fixed dose (Starting doses: Ribociclib 600
mg QD 3 weeks on/1 week off; l etrozole 2.5 mg QD continuously ), and not by  body  weight or 
body  surface area.
The investigator or responsible site personnel should instruct the patient to take the study 
treatment as per protocol (emphasizing the importance of compliance). Drug accountability 
must be performed on a regular basis. Patients will be instructed to return unused study 
treatment to the site at the end of each cycle. The site personnel will ensure that the appropriate 
dose of each stud y treatment is provided at each visit.
6.1.1.1 Ribociclib and Letrozole Dosing
Ribociclib and letrozole should be taken as follows:
Ribociclib is dosed for the first 21 day s out of the 28 -day cy cle.
Patientsshould be instructed to take the stud y treatment combination of ribociclib and 
letrozole together with a large glass of water (~250 mL  or ~8 oz) at the same time each 
day. Evening dose s are strongl y not recommended.
Ribociclib and letrozole can be adm inistered with or without food.
Patients should be instructed to swallow the ribociclib and letrozole tablets whole and not 
chew, crush or open them.
For men and premenopausal women , either goserelin or leuprolide must be administered by 
injection every  28days in accordance with the local prescribing information.
If vomiting occurs during the course of treatment, no re- dosing of the patient is allowed 
before the next scheduled dose. The occurrence and frequency  of any  vomiting during a 
treatment cy cle must be noted in the adverse events section of the eCRF.
Any doses that are missed (not taken within 6 hours of the intended time) should be 
skipped and should not be replaced or made up on a subsequent day .
Patients must avoid consumption of grapefruit, grape fruit h ybrids, pummelos, star -fruit, 
Seville oranges or products containing the juice of each during the entire study  and 
preferabl y 7 da ys before the first dose of study  medication, due to potential CYP3A4 
interact ion with the study medications. These foo ds are known as CYP3A4 inhibitors and 
have a potential to increase exposure to ribociclib.

Novartis Confidential Page 57
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Note: Orange juice is allowed
Herbal or die tary supplements known as strong inhibitors or inducers of CYP3A4 /5or 
those with a known risk of QT prolongation are not permitted. Multivitamins are 
permitted. If the potential for interactions are unknown, then the herbal / dietary 
supplements should be avoided. (See Appendix 14.1 )
6.1.2 Ancillary  treatments
Not Applicable .
6.1.3 Rescue medication
Not Applicable .
6.1.4 Guidelines for continuation of treatment
Refer to Section 6.3 Dosing Modification for guidelines for continuation of treatment.
6.1.5 Treatment duration
The planned overall study  duration of the Core Phase will befrom FPFV to 18 months after 
LPFV.
The study  treatment during the Core Phase will be provided until disease progression, death, 
unacceptable toxicities, physician’s decision, subject/guardian’s decision, protocol deviation,
study  termination by sponsor, lost to follow -
up, technical problems or up to 18 months after 
LPFV.
At the time of Core Phase end, if patients are still deriving benefit and ribociclib is not approved
or available and reimbursed, patients may be transitioned to the Extension Phase and continue 
to receive the drugs until progression, intolerance, death or physician/patient decision, but onl y 
safet y and clinical benefit as assessed b y investigator will be collected .
6.2 Dose escalation guideline s
Not Applicable .
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose interruptions 
and/or reductions are either recommended or mandated in order to allow patients to continue 
the study  treatment. These dose modifications are summarized in Table 6-2, Table 6-3, Table 
6-4, Table 6-5, Table 6 - 6, and Table 6-7. No dose re -escalation is permitted.
Clinical judgment of the treating physician should guide the management plan of each patient 
based on individual benefit/risk assessment. However, for events requ iring a discontinuation in 
Table 6-3, Table 6 -4 , Table 6 -5, Table 6-6, and Table 6 - 7or listed in Section 7.1.5 ., treatment 
must be discontinued. If dosing was interrupted for >28 day s due to ribociclib related toxicity , 
ribociclib must be discontinued.

Novartis Confidential Page 58
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Dose reductions are not permitted for letrozole, goserelin or leuprolide .
Any changes to ribociclib dose or interruption of the study  treatment must be recorded on the 
Dosage Administration Record eCRF. All patients will be followed for (S)AEs for 30 days 
following the last dose of ribociclib.
6.3.1.1 Letrozole
The established clinical dose of letrozole (2.5 mg/day ) will be used and no dose modification 
of letrozole is planned in this study . The letrozole SmPC should be consulted regarding full 
prescribing information , monitoring, and management of adverse events.
In the case where letrozole is required to be permanently  discontinued the patient must be 
discontinued from study .
6.3.1.2 Goserelin and leuprolide
The established clinical dose of goserelin or leuprolide will be used in men and premenopausal 
women patients and no dose modification is planned in this study . Patients receiving LHRH 
agonists will be monitored regularly  per local institutional clinical guidelines to confirm a post-
menopausal status, according to local laboratory  ranges of FSH and estradiol le vels.
Refer to the most recent regional prescribing information and/or clinical guidelines for more 
information on LHRH agonists.
6.3.1.3 Ribociclib
Ribociclib should not be used as monotherap y.
Management of severe or intolerable adverse reactions requires dose reduction, temporary 
interruption, and/or discontinuation of ribociclib therap y. Refer to Table 6 -2for guidance .
Table 6-2 Ribociclib Dose Modification Guidelines
Ribociclib
Dose Number of tablets and strength
Starting dose 600 mg 3 x 200 mg tablets
First dose reduction 400 mg 2 x 200 mg tablets
Second dose reduction 200 mg 1 x 200 mg tablets
Recommendations for dose reduction, interruption or discontinuation of ribociclib in the 
management of study  drug related adverse reactions are summarized in Table 6-3, Table 6-4, 
Table 6-5, Table 6 -6, and Table 6 -7.
Clinical judgment of the treating physician should guide the management plan of each patient 
based on individual benefit/risk assessment. However, for events requiring a discontinuation in 
Table 6-3, Table 6 -4, Table 6-5,  Table 6-6, and Table 6-7or listed i n Section 7.1, treatment 
must be discontinued.
If a patient inadvertentl y doses ribociclib on a rest day (e.g. days 22-28 of any given cycle), 
ribociclib should be interrupted to ensure 7 consecutive res
t days and avoid overdose. The visit 
schedule will be adjusted accordingl y.

Novartis Confidential Page 59
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
6.3.1.3.1 Recommendations on Adjustment of Ribociclib Treatment Cycles in the 
Case of Dose Interruptions / Reinitiation
Delay edstart of a cycle:
In the case of ribociclib being withheld at C ycle (x) D1 based on investigator’s judgement , the 
patient should reinitiate ribociclib on a 3 week ON/ 1 week OFF schedule once the assessment(s) 
are within acceptable levels according to Section 6.3 Dose Modifications. The visit schedule 
should be adjusted based on the ribociclib treatment schedule.
Mid-cycle dose interruption:
In the case of ribociclib being withheld for < 7 daysduring any cycle, patient should reinitiate 
ribociclib to complete the 21 calendar day treatment (3 weeks ON) followed by 1 week OFF 
schedule .
In the case of ribociclib being withheld for ≥ 7 day sduring any cycle, patient should reinitiate 
ribociclib to a 
new 28 calendar day treatment schedule (3 weeks ON/ 1 week OFF) once the 
assessment(s) are within acceptable levels according to Section 6.3 Dose Modifications. The 
visit schedule should be adjusted based on the ribociclib treatment schedule .
Table 6-3 Ribociclib dose reduction/interruption and management 
recommendations for hematological adverse drug reaction s(CTCA E 
v4.03)
Toxicity /Grade Dose Adjustment and Management Recommendations
Thrombocy topenia
Grade 1( ≥75 x 109/L) No dose adjustment required.
Grade 2 ( ≥50 x 109/L –<75 x 109/L) Dose interruption until recovery to grade 1.
Re-initiate ribociclib at the same dose.
Grade 3 ( ≥25 x 109/L -<50 x 109/L) Dose interruption until recovery to grade 1.
Re-initiate ribociclib at the same dose level.
If toxicity recurs at grade 3: temporary dose interruption until 
recovery to grade 1 and reduce ribociclib to the next lower 
dose level.
Grade 4(<25 x 109/L) Dose interruption until recovery to grade 1.
Re-initiate ribociclib at the next lower dose level.
If toxicity recurs at grade 4: discontinue ribociclib
Absolute neutrophil count (ANC)
Grade 1 ( ≥1.5 x 109/L) No dose adjustment required.
Grade 2 ( ≥1.0 -<1.5 x 109/L) No dose adjustment required.
Grade 3 ( ≥0.5 -<1.0 x 109/L) Dose interruption until recovery to ≥1.0 x 109/L.
Re-initiate ribociclib at the same dose level.
If toxicity recurs at grade 3: temporary dose interruption until 
recovery to ≥ 1.0 x 109/L.
If resolved in ≤7 days, then maintain dose level.
If resolved in >7 days, then reduce ribociclib dose to the next 
lower dose level.
Grade 4 (<0.5 x 109/L) Dose interruption until recovery to ≥ 1.0 x 109/L.
Re-initiate ribociclib at the next lower dose level.

Novartis Confidential Page 60
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Toxicity /Grade Dose Adjustment and Management Recommendations
Febrile neutropenia
Grade 3
ANC <1.0 x 109/L with a single temperature 
of >38.3 ºC (101 ºF) or a sustained 
temperature of ≥38 ºC (100.4 ºF) for more 
than one hourDose interruption until improvement of ANC ≥ 1.0 x 109/L and no 
fever. Restart at the next lower dose level.
If febrile n eutropenia recurs, discontinue ribociclib.
Grade 4
Life-threatening consequences;
urgent intervention indicatedDiscontinue ribociclib.
Anemia
(Hemoglobin)
Grade 1 ( ≥10.0 –LLN g/dL) No dose adjustment required.
Grade 2 ( ≥8.0 –<10.0 g/dL) No dose adjustment required.
Grade 3 (<8.0 g/dL) Dose interruption until recovery to grade 2.
Re-initiate ribociclib at the same dose.
Grade 4
Life-threatening consequences;
urgent intervention indicatedDiscontinue ribociclib.
Table 6-4 Ribociclib dose reduction/interruption and management 
recommendation for hepatic toxicities (CTCA E v4.03)
HEPATOTOXICITY (BILIRUBIN, SGPT/ALT, SGOT/AST)
TOTAL BILIRUBIN without ALT/AST increase above baseline value
Grade 1 (> ULN –1.5 x ULN)
(confirmed 48 -72h later)Maintain dose level with LFTs monitored every two weeks
Grade 2 (> 1.5 –3.0 x ULN) Dose interruption of ribociclib 
If resolved to ≤ grade 1 in ≤ 21 days , then maintain dose 
level 
If resolved to ≤ grade 1 in > 21 -28 days or toxicity recurs, 
then reduce 1 dose level
Repeat liver enzyme and bilirubin tests twice weekly fo r 2 
weeks after dose resumption
If toxicity recurs after two dose reductions, or recovery to ≤ 
grade 1 is > 28 days, discontinue ribociclib
Grade 3 (> 3.0 –10.0 x ULN) Dose interruption of ribociclib , until
resolved to ≤ grade 1 , then lower 1 dose level of ribociclib
Repeat liver enzyme and bilirubin tests twice weekly fo r 2 
weeks after dose resumption
If resolved to ≤ grade 1 in > 28 days or toxicity recurs, 
discontinue ribociclib 
Grade 4 (> 10.0 x ULN) Discontinue ribociclib 
Confounding factors and/or alternative causes for increase of total bilirubin should be excluded b efore dose 
interruption/reduction. They include but are not limited to: evidence of liver metastases evidence of obstruction, 
such as elevated ALP and GGT typical of gall bladder or bile duct disease, hyperbilirubinemia due to the 
indirect component only ( i.e. direct bilirubin component ≤ 1 x ULN) due to hemolysis or Gilbert ’sSyndrome, 
other pharmacologic treatment, viral hepatitis, alcoholic or autoimmune hepatitis, other hepatotoxic drugs.
For patients with Gilbert ’sSyndrome, these dose modifications ap ply to changes in direct bilirubin only.
Bilirubin will be fractionated if elevated.

Novartis Confidential Page 61
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
AST or ALT
AST or ALT without bilirubin elevation > 2 x ULN
Same grade as baseline or increase from 
baseline grade 0 to grade 1
(confirmed 48 –72 h later)No dose adjustment required with LFTs monitored per 
protocol if same grade as baseline or every two weeks in 
case of increase from baseline grade 0 to 1
Increase from baseline grade 0 or 1 to grade 2 
(> 3.0 –5.0 x ULN)Dose interruption of ribociclib 
Ifresolved to ≤ baseline grade in ≤ 21 days, then maintain 
dose level
If resolved to ≤ baseline grade in > 21 days or toxicity recurs, 
then reduce 1 dose level
Repeat liver enzyme and bilirubin tests twice weekly for 2 
weeks after dose resumption
If toxici ty recurs after two dose reductions or recovery to ≤ 
baseline grade is > 28 days, discontinue ribociclib
Increase from baseline grade 0 or 1 to grade 3 
(> 5.0 –20.0 x ULN)Dose interruption of ribociclib until resolved to ≤ baseline 
grade, then l ower 1 d ose level of ribociclib
Repeat liver enzyme and bilirubin tests twice weekly fo r 2 
weeks after dose resumption
If recovery to ≤ baseline grade is > 28 days, discontinue 
ribociclib
If toxicity recurs, discontinue ribociclib
Increase from baseline grade 2 to grade 3 (> 
5.0 –20.0 x ULN)Dose interruption of ribociclib until resolved to ≤ baseline 
grade, then l ower 1 dose level of ribociclib
Repeat liver enzyme and bilirubin tests twice weekly for 2 
weeks after dose resumption
If toxicity recurs after two d ose reductions or recovery to ≤ 
baseline grade is > 28 days, discontinue ribociclib.
Grade 4 (> 20.0 x ULN) Discontinue ribociclib 
AST or ALT and concurrent Bilirubin
For patients with normal ALT and AST and 
total bilirubin at baseline: AST or ALT >3.0 x 
ULN combined with total bilirubin > 2 x ULN 
without evidence of cholestasis
Or
For patient with elevated AST or ALT or total 
bilirubin at baseline: baseline: [AST or ALT >2 
x baseline AND >3.0x ULN] OR [AST or ALT 
8.0 x ULN] -whichever is lower -combined with
[total bilirubin > 2 x baseline AND >2.0 x ULN]Discontinue ribociclib
Confounding factors and/or alternative causes for increased transaminases should be excluded before dose 
interruption/reduction. They include but are not limited to: concomitant medications, herbal preparations or 
dietary supplements, infection, hepato -biliary disorder or obstruction, new or progressive liver metastasis, and 
alcohol intake. 

Novartis Confidential Page 62
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
6.3.1.3.2 Follow up on potential drug -induced liver injury (DILI) cases
Patien ts withtransaminase increase combined with total bilirubin (TBIL) increase may be 
indicative of drug -induced liver injury  (DILI), and should be considered as clinically  important 
events.
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
For patients with normal ALT and AST and TBIL value at baseline: AST or AL T > 3.0 x 
ULN combined with TBIL > 2.0 x UL N
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.0 x ULN] OR [AST or ALT > 8.0 x ULN], , combined with [TBIL > 2 
x baseline AND > 2.0 x ULN]
Medical review needs to ensure that liver test elevations are not caused by  cholestasis, defined 
as: Alkaline Phosphatase (ALP)elevation > 2.0 x ULN with R value < 2 in patients without 
bone metastasis, or elevation of AL P liver fraction in patients with bone metastasis.
Note: The R value is calculated by  dividing the ALT by  the ALP, u sing multiples of the ULN 
for both values. Itdenotes the relative pattern of ALT and/or ALP elevation is due to cholestatic
(R ≤ 2), hepatocellular (R ≥ 5), or mixed (R > 2 and < 5) liver injury .
In the absence of cholestasis, these patients should be imm
ediately  discontinued from study  
drug treatment, and repeat L iver Function T estsas soon as possible, preferably within 48 hours 
from the awareness of the abnormal results. The evaluation should include laboratory  tests, 
detailed history , physical assessme nt and the possibility  of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
Hepatic toxicity  monitoring includes the following LFTs: albumin, ALT, AST, total bilirubin, 
direct and indirect bilirubin, alkaline phosphatase (fractionated if alkaline phosphatase is grade 
2 or higher), creatine kinase, prothrombin time (PT) or INR and GGT. For patients with 
Gilbert ’sSyndrome: total and direct bilirubin must be monitored, intensified monitoring applies 
to changes in direct bilirubin only .
Close observation is recommended in case of AST, ALT, and/or bilirubin increase requiring 
dose interruption, which involves:
Repeating liver enz yme and serum bilirubin tests two or three times weekly . Frequency  
of re-testing can decrease to once a week or less if abnormalities stabil ize or return to 
normal values.
Obtaining a more detail
ed history  of current sy mptoms.
Obtaining a more detailed history  of prior and/or concurrent diseases, including history  of 
any pre-existing liver conditions or risk factors.
Obtaining a history  of concomitant drug use (including non -prescription medications, 
herbal and dietary  supplements), alcohol use, recreational drug use, and special diets.
Ruling out acute viral hepatitis ty pes A, B, C, D, and E; hepatotropic virus infe ctions 
(CMV, EBV or HSV); autoimmune or alcoholic hepatitis; NASH; hy poxic/ischemic 
hepatopath y; and biliary  tract disease.

Novartis Confidential Page 63
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Obtaining a history  of exposure to environmental chemical agents.
Obtaining additional tests to evaluate liver function, as appropri ate (e.g., INR, direct 
bilirubin).
Considering gastroenterology  or hepatology  consultations.
Assessing cardiovascular dy sfunction or impaired liver oxy genation, including 
hypotension or right heart failure as possible et iologies for liver dy sfunction.
Consider a l iver biopsy  as clinically  indicated to assess pathological change and degree of 
potential liver injury
All cases of DILI confirmed on repeat testing meeting the laboratory  criteria defined above, 
with no other alternative cause for LFT abnormalitie s identified, should be considered as 
“medicall y significant”, thus meetingthe definition of SAE (Section 8.2.1 ), and must be 
reported as SAE using the term “potential drug-induced liver injury ”. All events must be 
followed up with the outcome clearl y documented .Results of tests as well as other clinicall y 
important information will be recorded in the eCRF.
6.3.1.3.3 Additional follow -up for QTc prolongation
Table 6
-5 Ribociclib dose adjustment and management recommendation for 
QTcFprolongation
Grade Dose Modification
For All Grades 1.Check the quality of the ECG and the QT value and repeat if needed.
2.Perform analysis of serum electrolytes (K+, Ca++ correct for albumin , 
Phos, Mg++). If outside of the normal range, interrupt ribociclib 
administration, correct with supplements or appropriate therapy as soon 
as possible, and repeat electrolytes until documented as normal.
3.Review concomitant medication usage forthe potential to inhibit 
CYP3A4 and/or to prolong the QT interval.
4.Check compliance with correct dose and administration of ribociclib.
1
QTcF450-480 msPerform steps 1 -4 as directed in “For All Grades.” No dose adjustment 
required.
2
QTcF481-500 msInterrupt ribociclib. Perform steps 1 -4 as directed in “For All Grades.”
Perform a repeat ECG within one hour of the first QTcF of ≥ 481 ms.
Repeat ECG as clinically indicated until the QTcF returns to < 481 ms. R estart 
ribociclib withdose reduced by 1 dose level. Refer to Table 6 -2for dosing 
schedule.
If QTcF ≥ 481 ms recurs , 
ribociclib should be reduced again by 1 dose level.
Repeat ECG 7 days and 14 days after dose resumption (then as clinically 
indicated) for any patients who had therapy interrupted due to QTcF ≥ 481 ms
3
QTcF≥ 501 ms on at least 
two separate ECGsInterrupt ribociclib. Perform steps 1 -4 as directed in “For All Grades.”
Perform a repeat ECG within one hour of the first QTcF of ≥ 501 ms.
If QTcF remains ≥ 501 ms, consult with a cardiologist (or qualified specialist) 
and repeat cardiac monitoring as indicated until the QTcF returns to < 481 ms.
If QTcF returns to < 481 ms, ribociclib will be reduced by 1 dose level. 
Refer to Table 6 -2for dosing schedule.
If QTcF remains ≥ 481 ms after performing steps 1 -4 as directed in “For All 
Grades,” disco ntinue ribociclib.
Repeat ECG 7 days and 14 days after dose resumption (then as clinically 
indicated) for any patients who had therapy interrupted due to QTcF ≥ 501 ms
If QTcF of ≥ 501 ms recurs, discontinue ribociclib.

Novartis Confidential Page 64
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Grade Dose Modification
4
[QT/QTc F≥ 501 or > 60 ms 
change from baseline]
and
[Torsades de pointes or 
polymorphic ventricular 
tachycardia, or 
signs/symptoms of serious 
arrhythmia]Discontinue ribociclib. Perform steps 1 -4 as directed in “For All Grades.”
●Obtain local cardiologist (or qualified specialist) consultation and repeat 
cardiac monitoring as indicated until the QTcF returns to <481 ms.
6.3.1.3.4 Additiona l follow -up for Interstitial Lung Disease (ILD)/pneumonitis (CTCAE 
v4.03)
Table 6-6 Ribociclib dose adjustment and management recommendation for   
ILD/pneumonitis
Grade Dose Adjustment and Management Recommendations
1
(asymptomatic)No dose adjustment required. Initiate appropriate medical therapy and monitor as clinically 
indicated .
2
(symptomatic)Interrupt ribociclib dose until recovery to Grade ≤1, then resume ribociclib at the next lower 
dose level*. 
3 and 4
(severe)Discontinue ribociclib
* An individualized benefit -risk assessment should be performed before resuming ribociclib 
6.3.1.3.5 Guidance for all other adverse reactions
Consider performing an analysis of serum potassium, calcium, and magnesium for all adverse 
reactions that are potentially  associated with electroly te imbalance. If electroly te values are 
outside of the normal range, interrupt ribociclib administration, correct electrol ytes with 
supplements or appropriate therap y as soon as possible, and repeat electroly te testing until 
docume nted normalization of the electroly tes.
For all other adverse events, including Toxic Ep idermal Necrol ysis (TEN), which isa grade -4
event b y CTCAE, please follow recommendations in Table 6-7.
Table 6-7 Ribociclib dose reduction/interruption and management 
recommendation for all other adverse reactions
Grade Dose Adjustment and Management Recommendations
1 No dose adjustment recommended. Initiate appropriate medical therapy and monitor.
2 Dose interruption until recovery to grade 1. Initiate appropriate medical therapy and monitor.
Re-initiate ribociclib at the same dose.
If the same toxicity recurs at grade 2, interrupt ribociclib until recovery to grade 1. Re -initiate 
ribociclib at the next lower dose level.

Novartis Confidential Page 65
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
6.3.2 Follow -up for toxicities
Patients who complete treatment or whose treatment is interrupted or permanently  discontinued 
due to an adverse event or clinically  significant laboratory  value, must be followed at least once 
a week (or more frequently if required by institutional practices, or if clinically  indicated) for 4 
weeks, and subsequentl y at approximately  4-week intervals, until resolution or stabilization of 
the event, whichever comes first. Appropriate clinical experts such as ophthalmologist, 
endocrinologist, dermatologist, psy chiatrists etc. should be consulted as deemed necessary .
All patients will be followed up for adverse events and serious adverse events for 30 days 
following the last dose of study  treatment. Patients stopping study  treatment but still receiving 
ribociclib outside of this trial (e.g., commercial supply ) will be followed up for safet y up to 30 
days independentl y of resolution/stabilization of AEs. Further reports of AEs after 30 days of 
EOT should follow local pharmacovigilance practices.
6.4 Concomitant medications
6.4.1 Permitted concomitant therapy
Medications required to treat AEs, manage cancer symptoms, concurrent diseases and 
supportive care agents, such as pain medications, anti-emetics and anti-diarrheal sare allowed.
Please consult the list of prohibited medications and the list of use with caution medications for 
further guidance (see Table 14 - 1 and Table 14 -2in Appendix 14.1).
The patient must be told 
to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug) and significant 
non-drug therapies (including physical therapy , herbal/natural medications and blood 
transfusions) administered during the study  must be listed on the Prior and Concomitant 
Medications or the Surgical and Medical Procedures eCRF.
If patients take concomitant medications chronically, an y change in thedose or schedule of any 
concomitant medication throughout the stud y period should be clearl y documented
6.4.1.1 Bisphosphonates and denosumab
Bisphosphonates and denosumab are generally  allowed with the following comments:
Bisphosphonate/denosumab therap y for the treatment of osteopo rosis is permitted.
Bisphosphonate/denosumab therap y for the prevention of skeletal related events for 
patients with bone metastases is permitted.
Chronic concomitant bisphosphonate/denosumab therap y for the prevention of bone 
metastasis is permitted.3 Dose interruption until recovery to grade 1. Initiate appropriate medical therapy and monitor.
Re-initiate rib ociclib at the next lower dose level.
If toxicity recurs at grade 2: temporary dose interruption until recovery to grade 1 and reduce 
ribociclib dose the next lower dose level.
If toxicity recurs at grade 3, discontinue ribociclib.
4 Discontinue ribocicl ib and treat with appropriate medical therapy.

Novartis Confidential Page 66
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Patients taking concomitant medication chronically should be maintained on the same dose and 
dose schedule throughout the study  period, as medically  feasible.
6.4.1.2 Hematopoietic growth factors
Prophy lactic use of WBC growth factors with ribociclib is not recommende d.
6.4.1.3 Palliative radiotherapy
Palliative radiation is permitted . It should not be delivered to target lesion. Cumulative courses 
of RT should not encompass  >25% of irradiated bone marrow (see Appendix 14.4 ).
If palliative radiotherap y is initiated after the start of study  treatment, the reason for its use must 
be clearly  documented and progression must be ruled out.
No dose modification of study  treatment is needed during palliative radiotherap y.
6.4.1.4 Use of ant iemetic medications
Ribociclib has low to minimal emetogenic potential according to the definition of antineoplastic 
agent emetogenicit y (Grunberg et al 2010). Antiemetic therap y can be used according toclinical 
guidelines for antineoplastic medications with low to minimal emetogenic potential for 
treatment and/or prevention of nausea and vomiting as a result of study  treatment (NCCN 
Clinical Practice Guidelines in Oncology . Antiemesis, 2017; Roila F et al 2016 ).
Potential drug intera ction between ribociclib and antiemetic medications should alway s be 
taken into consideration
. Example of a prohibited antiemetic medication is ondansetron that in 
combination with ribociclib may precipitate TdP. Refer to Appendix 1for list of medications 
that are prohibited or allowed to be used with ribociclib .
6.4.2 Permitted concomitant therapy  requiring caution
Medications to be used with caution during combined ribociclib and letrozole (+/-goserelin or 
leuprolide) in this study  are listed below (see Table 14-2 in Appendix 14.1).This list is not 
comprehensive and is only meant to be used as a guide. Please contact the medical mon itor 
with any questions . These medications should be excluded from patient use if possible. If they 
must be given based on the investigator’s judgment, then use with caution and consider a 
ribociclib interruption if the concomitant medication is only  neede d for a short time.
Moderate i
nhibitors or inducers of C YP3 A4/5(may increase or decrease ribociclib exposure, 
respectively )
Sensitive sub stratesofCYP3A4 /5 thatdo not have na rrow ther apeu tic index (ribociclib 
may increase exposure to these medications)
Str
ong inhibitors of BSEP (Bile Salt Export Pump) (based on in vitro data co -
administration with ribociclib may  lead to intrahepatic cholestasis)
Med
ications that carry a possible risk for QT prolon gat ion(may  precipitate QT 
prolongation and TdP)
Sensitive substrates of the renal transporters, MATE1 and OCT2 (has a potential to 
increase exposure to substrates of these transporters, although no animal or clinical data 
are available to support these statements)

Novartis Confidential Page 67
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Sensitive substrates of transporter BCRP (has a potential to increase exposure to 
substrates of these transporters, although no animal or clinical data are available to 
support these statements)
Substrates metabolized predominantly  by CYP2C19 or CYP2A6 with a narrow 
therapeutic index (that could be affe cted b y letrozole)
6.4.2.1 Corticosteroids
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to lead to 
induction of CYP3A enzymes, thereb y potentially  reducing ribociclib drug exposure to 
subtherapeutic levels. Systemic corticosteroid treatment should not be given during the study , 
except for:
Topical applications (e.g., for rash), inhaled spray s (e.g., forobstructive airway s diseases), 
eye drops or local injections (e.g., intra -articular);
A short duration (< 5 days) of sy stemic cor ticosteroids ≤ to the anti- inflammatory  potency  
of 4 mg dexamethasone (e.g. for chronic obstructive pulmonar y disease, or as an 
antiemetic)
6.4.3 Prohibited concomitant therapy
The following medications are prohibited during study  treatment in the study 
(see Table 14-1 in Appendix 14.1 ).This list is not comprehensive and is only meant to be used 
as a guide. Please contact the medical monitor with any  questions:
Strong inhibitors or inducers of CYP3A4/5 (may  significantl y increase or decrease 
ribociclib exposure, respectivel y)
Substrates of CYP3A4/5 with a narrow therapeutic index (ribociclib may  increase 
exposure to these medications resulting in toxicity  tothese medications)
Medications with a known risk for QT prolongation (may  precipitate QT prolongation and 
TdP in combination with ribociclib )
Other investigational and antineoplastic therapies
Herbal preparations/medications or dietary  supplements that ar e strong inhibitors or 
inducers of CYP3A4/5 or those with a known risk of QT prolongation . These includ ebut 
are not limited to: St. John’s wort, Kava, ephedra (ma huang), gingko biloba, 
dehy droepiandrosterone (DHEA), yohimbe, saw palmetto, black cohosh an d ginseng. 
Patients should stop using all these preparations at least 7 day s prior to first dose of study  
treatment.
6.4.4 Drugs with QT prolongation
As far as possible , avoid co-administering medications with a “Known”, “Possible” or 
“Conditional” risk of TdP ( www.crediblemeds.org ) or any  other medication with the potential 
to increase the risk of drug-related QT prolongation (e.g. via a potential DDI increasing the 
exposure of ribociclib or the exposure of the QT prolonging drug). If concomitant 
administration of drugs with a known risk of TdP is required and canno t be avoided, ribociclib
must be interrupted (see Table 6-5). If during the course of the study , concomitant 
administration of a drug with “Possible
risk” or “Conditional risk” of TdP is required, based on 

Novartis Confidential Page 68
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
the investigator assessment and clinical need, study  treatment may be resumed under close 
clinical and ECG monitoring to ensure patient safet y. A list of drugs associated with QT 
prolongation and/or TdP is available online ( www.crediblemeds.org ). Medications with a 
known risk for QT prolongation are prohibited during stud y treatment.
Refer to the r ibociclib [Investigator’s Brochure] and letrozole, goserelin, and leuprolide drug 
package insert in addition toAppendix 14.1 for information on possible int er actions with othe r 
drugs.
6.5 Patient num bering and treatment assignment
6.5.1 Patient numbering
Each patient is identified in the study  by a Subject Number (Subject 
No.), that is assigned when 
the patient is first enrolled for screening and is retained as the primary  identifier for the patient 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) (as assigned by Novartis to the investigative site) with a sequential patient 
number suffixed to it, so that each subject is numbered uniquel y across the entire database. 
Upon signing the informed consent form, the patient is assigned to the next sequential Subject 
No. avail able to the investigator through the Oracle Clinical RDC interface.
The investigator or designated staff will contact the IRT and provide the requested identify ing 
information for the patient to register them into the IRT system. If the patient fails to meet 
eligibility  criteria for any reason, the reason will be entered into the Screening Phase Disposition 
eCRF page. The patient will be entered as screen fa ilure in the IRT s ystem.
Once Subject No. is assigned, it must not be reused for any other subject and the Subject No. 
for that individual must not be changed, even if the patient is re -screened.
6.5.2 Treatment assignment
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be assigned via IRT 
to treatment. The investigator or his/he r delegate will call or log on to the IRT and confirm that 
the patient fulfills all the inclusion/exclusion criteria. The IRT will assign the patient to the 
ribociclib treatment and will specify a unique medication number for the first package of stud y 
rib
ociclib to be dispensed to the patient.
6.5.3 Treatment blinding
Not applicable; this is an open label study.
6.6 Stud y drug preparation and dispensation
Patients will be provided with an adequate supply  of study  drug for self-administration at home, 
including instructions for administration, until at least their next scheduled study  visit. Patients 
will receive ribociclib on an outpatient basis. The investigator shall provide the patient with 
instructions for ribociclib administration according to the protocol.
Letrozole ,and either goserelin (if applicable) or leuprolide (if applicable) should be dispensed 
and administered according to the local prescribing information and practice.

Novartis Confidential Page 69
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
The investigator or responsible site personnel must instruct the patient or caregive r to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by authorized site 
personnel only. All dosages prescribed to the patient and all dose changes during the study  must 
be recorded on the Dosage Administration Record eCRF(s).
6.6.1 Study treatment packaging and labeling
Ribociclib will be provided as global clinical open -labeled suppl y and will be packed and 
labeled under the responsibility  of Novartis, Drug Supply  Management .
Letrozole , goserelin and leuprolide will be sourced as local commercial supply  (in the locally 
approved formulation and packaging configuration) and labeled in the country  when possible.
Study  treatment labels (see Table 6 -8) will comply with the leg al requirements of each country 
and will include storage conditions, and a unique medication . Responsible site personnel will 
identify  the study  treatment package(s) to dispense by the medication number(s) assigned by 
IRT to the patient. Site personnel will add the patient number on the label. If the label has 2
parts (base plus tear-off label), immediatel y before dispensing the package to the patient, site 
personnel will detach the outer part of the label from the package and affix it to the patient’s 
source document (Drug Label Form) for that patient’s unique patient number.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the drug and the medication number but no 
information about the patient.
Table 6
-8 Packaging and labeling
Study  treatments Packaging Labeling (and dosing frequency )
Ribociclib Tablets in bottles Labeled as ‘LEE011”
Study treatment packaging has a 2 -part label.
Letrozole Refer to local product information Refer to local product information
Goserelin Refer to local product information Refer to local product information.
Leuprolide Refer to local product information Refer to local product information.
6.6.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, the study treatment sshould be stored according to the 
instructions specified on the drug labels (Table 6 -9) and in the [I nvestigator’s Brochure ].
Table 6
-9 Supply  and storage of study  treatment
Study  treatments Supply Storage
Ribociclib Centrally supplied by Novartis Refer to study treatment label
Letrozole Locally Refer to local product information
Goserelin Locally Refer to local product information
Leuprolide Locally Refer to local product information

Novartis Confidential Page 70
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
6.6.3 Study drug compliance and accountability
6.6.3.1 Study drug compliance
Compliance will be assessed by the investigator and/or study  personnel at each patient visit and 
information provided by the patient and/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each patient 
visit.
6.6.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by the field 
monitor during site visits and at the completion of the study. Patients will be asked to return all 
unused study  treatment and packaging on a regular basis, at the end of the study  or at the time 
of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability  logto the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.
6.6.3.3 Handling of other study  treatment
Not applicable.
6.6.4 Disposal and destruction
The study  drug suppl y can be destro yed at the local Novartis facility , Drug Supply  group or 
third party, as appropriate . Study  drug destruction at the investigational site will only be 
permitted if authorized by Novar tis in a prior agreement and if permitted by  local regulations.
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be sup
ported in the p atient’s source 
documentation. The table indicates which assessments produce data to be entered into the 
clinical database (D) or remain in source documents only  (S)(“Category ” column).
Note:
During screening visits, lab assessments including white blood cell (WBC) count, absolute 
neutrophil count (ANC), absolute lymphocy te count, hemoglobin, platelets, INR, ALT, 
AST, total bilirubin (or direct bilirubin ifGilbert ’sSyndrome ), serum creatinine, 
electrol ytes (potassium, sodium, calcium corrected for serum albumin ,and magnesium) are 
required to be collected within 14 day s of C1D1 for eligibility  assessment .
During treatment phase, only selected labs assessments are required to be collected in the
clinical database at the patient scheduled visits: WBC, ANC, absolute lymphocy tecount , 

Novartis Confidential Page 71
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
hemoglobin, platelets, AST, ALT, ALP, total bilirubin ,and direct bilirubin (if clinicall y 
indicated ). Electrol ytes should be monitored atthe beginning of each cycle before resuming 
ribociclib dose during the first 6 cycles and as clinically  indicated thereafter. The results 
should not be captured in clinical database. Eventual abnormal electroly te lab results should 
be reported as AEs at the investigator’s discretion .
ECG will be performed at screening (within 5 days of C1D1), C1D15, C2D1, then as 
clinically  indicated , and EOT .
If treatment is withheld at any time during the study , all study  visits, safety  assessments, 
and efficacy  assessme nts should be adjusted accordingl y to match the treatment cycle s.
For all visits, there is a +/-3 day window on assessments to take into account scheduling 
over public holiday s, if not explicitly  specified otherwise .

Novartis Confidential Page 72
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Table 7-1 Visit evaluation schedule (Core Phase )Category
Reference to 
Protocol Section
Screening 
PhaseCore Treatment PhaseEnd of study  
treatment 
(EOT) within 7
days from the 
last dose of 
study
treatmentSafety  follow 
upwithin 30 
daysof last 
dose of study  
treatment
Visit nameScreening 
(-28 Days 
to Day 1)
C1D1
C1D15
C2D1
C2D15
C3D1
C4D1
C5D1
C6D1 -C11D1
C12D1 and 
subsequent 
cycles (up to 
cycle 36)
Screening
Study Informed 
ConsentD 7 ×
IRT Screening 
(after ICF 
signature)D 7.1.2 ×
Patient History
Demography D 7.1.2 ×
Inclusion / 
Exclusion criteriaD 5.1 ×
Medical History D 7.1.2 ×
Diagnosis and 
extent of cancerD 7.1.2 ×
Prior 
antineoplastic 
therapy -
medicationD 7.1.2 ×

Novartis Confidential Page 73
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404Category
Reference to 
Protocol Section
Screening 
PhaseCore Treatment PhaseEnd of study  
treatment 
(EOT) within 7
days from the 
last dose of 
study
treatmentSafety  follow 
upwithin 30 
daysof last 
dose of study  
treatment
Visit nameScreening 
(-28 Days 
to Day 1)
C1D1
C1D15
C2D1
C2D15
C3D1
C4D1
C5D1
C6D1 -C11D1
C12D1 and 
subsequent 
cycles (up to 
cycle 36)
Prior 
antineoplastic 
therapy -
radiotherapyD 7.1.2 x
Prior 
antineoplastic 
therapy -surgeryD 7.1.2 x
Prior and 
concomitant 
medicationD 7.1.2 ×
Continuous –up to 30 days after last dose
Surgical and 
Medical 
proceduresD 7.1.2 ×
Continuous –up to 30 days after last dose
IRT
Eligibility 
checklist (within 
IRT)S 7.1.2×
IRT -ribociclib 
administrationS 7× × × × × ×
2 cycle
supply 
(e.g. 6, 8, 
10) ×
3 cycle 
supply (12, 
15, 18…)×

Novartis Confidential Page 74
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404Category
Reference to 
Protocol Section
Screening 
PhaseCore Treatment PhaseEnd of study  
treatment 
(EOT) within 7
days from the 
last dose of 
study
treatmentSafety  follow 
upwithin 30 
daysof last 
dose of study  
treatment
Visit nameScreening 
(-28 Days 
to Day 1)
C1D1
C1D15
C2D1
C2D15
C3D1
C4D1
C5D1
C6D1 -C11D1
C12D1 and 
subsequent 
cycles (up to 
cycle 36)
Physical Examination
Physical 
examinationS 7.2.2.1× × × × × × ×
Every 2 
cycles
(6, 8, 10) ×
Every 3
cycles
(12,15, 
18…)×
ECOG 
performance 
statusD 7.2.2.4× × × × × × ×
Every 2 
cycles
(6, 8,10)×
Every 3 
cycles (12, 
15, 18...)×
Height D 7.2.2.3 ×
WeightD 7.2.2.3 × × × ×
Every 2 
cycles
(6, 8,10)×
Every 3
cycles (12, 
15, 18…)×
Vital signsD 7.2.2.2 × × × × × x ×
Every 2 
cycles (6, 
8,10)×
Every 3 
cycles (12, 
15, 18…)× 

Novartis Confidential Page 75
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404Category
Reference to 
Protocol Section
Screening 
PhaseCore Treatment PhaseEnd of study  
treatment 
(EOT) within 7
days from the 
last dose of 
study
treatmentSafety  follow 
upwithin 30 
daysof last 
dose of study  
treatment
Visit nameScreening 
(-28 Days 
to Day 1)
C1D1
C1D15
C2D1
C2D15
C3D1
C4D1
C5D1
C6D1 -C11D1
C12D1 and 
subsequent 
cycles (up to 
cycle 36)
Laboratory  assessments (local)
Hematology 
(selected 
parameters: 
WBC, ANC, 
lymphocytes, 
platelets, 
hemoglobin)D 7.2.2.5.1 × (-14 
Days to 
Day 1)× × × × × × ×
(cycle 6 
only), 
then as 
clinically 
indicated)as clinically 
indicated×
Chemistry 
(see Table 7 -5)D 7.2.2.5.2 × (-14 
Days to 
day 1)× × × × × × ×
(cycle 6 
only), 
then as 
clinically 
indicated)as clinically 
indicated×
Coagulation
(see Table 7 -5)D 7.2.2.5.3 × As clinically indicated ×
Tumor Assessment
Tumor 
AssessmentD 7.2.1 × Recommendation: every 12 weeks from start of study treatment can be 
performed at different intervals according to the local standard of care×

Novartis Confidential Page 76
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404Category
Reference to 
Protocol Section
Screening 
PhaseCore Treatment PhaseEnd of study  
treatment 
(EOT) within 7
days from the 
last dose of 
study
treatmentSafety  follow 
upwithin 30 
daysof last 
dose of study  
treatment
Visit nameScreening 
(-28 Days 
to Day 1)
C1D1
C1D15
C2D1
C2D15
C3D1
C4D1
C5D1
C6D1 -C11D1
C12D1 and 
subsequent 
cycles (up to 
cycle 36)
Cardiac Assessment
ECG (standard 
12 lead)D 7.2.2.6 ×
(-5 Days to 
Day 1)× × As clinically indicated ×
Safety
Serum 
Pregnancy test
(only 
premenopausal 
patients) D 7.2.2.5.4 x x
Urine pregnancy 
test (only 
premenopausal 
patients)D 7.2.2.5.4 x
every cycle
Adverse events D 8.1×
Continuous –up to 30 days after last dose of study treatment
Patient Reported Outcome
FACT-B (female 
patients only)D 7.2.3× × × × × ×
Every 2 
cycles (6, 
8, 10)x
Every 3 
cycles (12, 
15, 18…)×

Novartis Confidential Page 77
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404Category
Reference to 
Protocol Section
Screening 
PhaseCore Treatment PhaseEnd of study  
treatment 
(EOT) within 7
days from the 
last dose of 
study
treatmentSafety  follow 
upwithin 30 
daysof last 
dose of study  
treatment
Visit nameScreening 
(-28 Days 
to Day 1)
C1D1
C1D15
C2D1
C2D15
C3D1
C4D1
C5D1
C6D1 -C11D1
C12D1 and 
subsequent 
cycles (up to 
cycle 36)
Treatment
LetrozoleD 6 ×
(Daily)
RibociclibD 6 ×
(Daily: Day 1 -21)
Goserelin (men 
/premenopausal 
women only)D 6 x x x x x x
every 
cyclex
every cycle
Leuprolide (men 
/premenopausal 
women only)D 6 x x x x x x
every 
cyclex
every cycle
Discontinuation
Antineoplastic 
therapies since 
discontinuation 
of study 
treatmentD 7 ×
End of phase 
dispositionD 7 × ×

Novartis Confidential Page 78
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Table 7-2 Visit evaluation schedule (Extension Phase)Category
Reference 
to Protocol SectionExtension Treatment PhaseEnd of study  
treatment 
(EOT) within 7 
days from the 
last dose of 
study  
treatmentSafety  follow 
up within 30 
days of last 
dose of study  
treatment
Visit name
E-C1D1
  E-C4D1
  E-C7D1
E-C10D1 and  
subsequent 
cycles
Concomitant medication 
(only if related to (s)AE)D 7.1.2 X
Continuous –up to 30 days after last dose
Surgical and Medical 
procedures (only if 
related to (s)AE)D 7.1.2 X
Continuous –up to 30 days after last dose
IRT
IRT –ribociclib 
administrationS 7 X
Every 3 cycles dispense 3 cycle supply (Cycle 1, 4, 7, 10…)
Safety
Adverse eventsD 8.1 X
Continuous –up to 30 days after last dose of study treatment
Pregnancy Serum Test
(only premenopausal 
patients)S/D 7.2.2.5.4 X
Pregnancy urine test
(only premenopausal 
patients)S/D 7.2.2.5.4 X
every cycle
Confirmation of Clinical 
Benefit (assessed by 
investigator)D 7 X
Every 3 cycles (1, 4, 7, 10…)

Novartis Confidential Page 79
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404Category
Reference 
to Protocol SectionExtension Treatment PhaseEnd of study  
treatment 
(EOT) within 7 
days from the 
last dose of 
study  
treatmentSafety  follow 
up within 30 
days of last 
dose of study  
treatment
Visit name
E-C1D1
  E-C4D1
  E-C7D1
E-C10D1 and  
subsequent 
cycles
Treatment
LetrozoleD 6 X
(Daily)
RibociclibD 6 X
(Daily: Day 1 -21)
Goserelin 
(men/premenopausal 
only)D 6 X
(Monthly)
Leuprolide 
(men/premenopausal 
only)D 6 X
(Monthly)
Discontinuation
Antineoplastic therapies 
since discontinuation of 
study treatmentD 7 X
Endof phase disposition D 7 X

Novartis Confidential Page 80
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
7.1.1 Molecular pre -screening
Not applicable.
7.1.2 Screening
After signing the study  ICF, the screening assessments will be done within 1 to 28 days prior 
to start of study  treatment or within 5 day s of start of study  treatment for selected assessments 
(i.e., ECG; see Table 7 -1for list of assessments to be performed).
Note: Any screening assessment that is done outside the screening window (Day  -28 to Day 
1 or Day  -5 to Day  1 for ECG assessment as applicable) must be repeated prior to C1D1 .
If patient meets all inclusion and no exclusion criteria, the screening labs can be used for 
baseline if patient is dosed within 14 days of the screening visit. If patient cannot be dosed 
within 14 days of screening, then the labs should be repeated the day before pati
ent starts dosing 
(see baseline visit in Table 7-1)
Any blood work alread y completed during the regular work -up of the patient within 5 calendar 
days before signing the main study  ICF can be considered a s the screening assessments for this 
study .Tests not considered standard practice should only be performed after the patient has 
signed ICF.
Re-screening of patients is only allowed once per patient if the patient was not registered as 
entering the treatm ent phase before (i.e. IRT assignment). In this case the Subject No. assigned 
to the patient initially  will be used and the patient will be identified with this number throughout 
his/her entire participation to the study .
For laboratory  evaluations used todetermine eligibility , a repeated evaluation within the 
screening window is permitted for screening results out of the defined range. If the repeated 
laboratory  result meets the criteria, that result may be used to determine eligibility . If the 
repeated laboratory  result does not meet the criteria, the patient will be considered a screening 
failure. In case rescreening occurs, all evaluations re-assessed should meet the eligibility  criteria.
Any imaging assessments alread y completed during the regular work -up of the patient within 
28 days prior to start of study  treatment, including before signing the main study  ICF can be 
considered as the baseline images for this study .
7.1.2.1 Eligibility  screening
Following registering in the IRT for screening, patient eligibil ity will be checked once all 
screening procedures are completed. The eligibility check will be embedded in the I RT system. 
Please refer and compl y with detailed guidelines in the I RT manual.

Novartis Confidential Page 81
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
7.1.2.2 Information to be collected on screening failures
Patients who si gn an informed consent but fail to be started on treatment for an y reason will be 
considered a screen failure. The reason for not being started on treatment will be entered on the 
Screening Phase Disposition Page.
The following eCRF pages will be collected on screen failures:
Demographic information
Informed consent
Inclusion/Exclusion
Death
Withdrawal of consent, if applicable, must also be completed. No other data will be entered 
into the clinical database for patients who are screen failures, unless the patient experienced 
a Serious Adverse Event during the Screening Phase (see Section 8for SAE reporting 
details). If the patient fails to be enrolled, the IRT must be notified within 2 days of the 
screen fail that the patient was not enrolled.
7.1.2.3 Patient demographics and other baseline characteristics
The data that will be collected on patien t characteristics at screening includes:
Demograph y (Date of birth and initials (where permitted), sex, race, ethnicity )
Diagnosis and extent of cancer (including staging at study  entry  and histology /cytology )
Medical history  (e.g., important medical, surgical, and allergic conditions from the patient’s 
medical history  which could have an impact on the patient’s evaluation) / current medical 
conditions (e.g., all relevant current medical conditions which are present at the time of 
signing informed conse nt). Ongoing medical conditions, symptoms and disease which are 
recorded on the Medical History  eCRF should include the toxicity  grade.
All prior antineoplastic therapies including surgical interventions and chemo -, biologic -, 
immunologic
-and radiation -therapies provided as treatment for cancer prior to the 
administration of study  drug.
All medications taken within 30 day s before the first dose is administered must be recorded 
on the Prior and Concomitant medication eCRF page and updated on a continual basis if 
there are an y new changes to the medications.
Surgeries and Medical Procedures prior to Informed Consent are recorded on the Medical 
History  eCRF. The Surgical and Medical Procedures after signing Informed Consent are 
recorded on Surgical and Medical Procedures e CRF.
Patient- reported outcome Functional Assessment of Cancer Therap y –Breast (FACT -B)
questionnaire (See Section 7.2.3 ).
Furthermore the following assessments will be performed:
Vital signs
Height, weight
Physical examination
Performance status (ECOG)

Novartis Confidential Page 82
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Laboratory  evaluations (hematology ,INR, chemistry )
ECG
Radiological assessments (e.g. CT Scan)
7.1.3 Run- in period
Not Applicable.
7.1.4 Treatment period
Core Phase
Patients will be treated with ribociclib + letrozole (goserelinor leuprolide will be added to this 
combination in men and premenopausal women )until disease progression, unacceptable 
toxicity , death, or discontinuation from the study treatment due to any other reason. For details 
of assessments, refer to Table 7 -
1.
Extension Phase
Patients will be treated with ribociclib + letrozole (goserelin or leuprolide will be added to this 
combination in premenopau
sal patients and men) until disease progression, unacceptable 
toxicity , death, or discontinuation from the study treatment due to any  other reason. For details 
of assessments, refer to Table 7 -2.
7.1.5 Discont inuation of study treatment
Patients may  voluntaril y discontinue from the study treatment for an y reason at an y time.
If a patient decides to discontinue from the study treatment (
Core or Extension Phase) , the 
investigator must make a reasonable effort (e.g. telephone, e-mail, letter) to understand the 
primary  reason for this decision and record this information in the patient’s chart and on the 
appropriate eCRF pages. They  may be considered withdrawn if they state an intention to 
withdraw, fail t o return for visits, or become lost to follow- up for an y other reason.
The investigator may  discontinue study  treatment (Core or Extension Phase) for a given 
patient if, on balance, he/she believes that continuation would be detrimental to the 
patient’s we ll-being.
Patients will discontinue from the Core Phase 18 months after L PFV. I n the event stud y 
patients are still deriving benefit at the end of the Core Phase and ribociclib is not 
approved or available and reimbursed , pati ents may  be transitioned to th eExtension Phase 
andcontinue to receive the study  treatment until progression, intolerance, death, or 
physician/patient decision; only  safety and clinical benefit as assessed b y investigator will 
be collected.
During the Extension Phase, if ribociclib is approved and reimbursed, patients will be 
trans itioned to prescription or drug access/support program(s) according to local laws and 
regulations.
The study  will end after completion of the Extension P hase and all remaining patients will 
discontinue from the study . Patients who complete this Extension Phase, and continue to 
derive clinical benefit from the treatment based on t he investigator’s evaluation will

Novartis Confidential Page 83
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
receive ribociclib from prescription (if approved and reimbursed) , another Post -Trial 
Access (PTA) program, or other drug access/support program(s).
Patients may  voluntarily  withdraw from the study  or be dropped from it at the discretion of the 
investigator at an y time.
Patients may  be withdrawn from the study  treatment if an y of the following occur:

Novartis Confidential Page 84
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Adverse Event
Lost to follow -up
Physician decision
Progressive Disease
Protocol deviation
Study  terminated by  sponsor
Technical problems
Patients must be withdrawn from the stud y treatment if an y of the following occur:
Pregnancy
Death
Subject/Guardian decision
In addition to the general withdrawal criteria, the following study  specific criteria will also 
require stud y treatment discontinuation:
Adjustments to study treatment due to toxicity that result in discontinuation. Please refer to 
Section 6.3
Use of prohibited medication. Please refer to Section 6.4.3
Any other protocol deviation that results in a significant risk to the patient’s safet y.
Patients who discontinue study  treatment should undergo an End of Treatment (EOT) visit 
followed b y a 30 -day safety  follow -up.
At EOT visit, all the assessments as listed in Table 7-1will be performed. If the decis ion to 
discontinue the patient occurs at a regularl y scheduled visit, that visit may serve as the EOT 
visit rather than having the patient return for an additional visit.
The investigator or his/her delegate must also contact the IRT to register the patient’s 
discontinuation from study  treatment within 2 day s of EOT visit .
7.1.6 Withdrawal of consent
Patients may voluntaril y withdraw 
consent to participate in the study  for any reason at any time. 
Withdrawal of cons ent occurs onl y when a patient:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data.
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the patient’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be conside red missing. Further attempts to 
contact the patient are not allowed unless safety findings require communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient’ s study  withdrawal should be made as detailed in the
assessment table. Novartis will continue to keep and use collected study  information (including 

Novartis Confidential Page 85
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
any data resulting from the analysis of a patient’s samples until their time of withdrawal) 
according to a pplicable law.
7.1.7 Follow up for s afety  evaluations
All patients who complete the Core Phase of the study  but donot transition to the Extension 
Phase must have safet y evaluations completed within 30 daysafter the last dose of study 
treatment (ribociclib + letrozole + either goserelin or leuprolide ).Patients who continue to the 
Extension Phase will complete safety  evaluations within 30 days after the last dose of study 
treatment of the Extension P hase.
Data collected should be added to the Adverse Events eCRF and the Concomitant Medications 
eCRF.
7.1.8 Lost to fo llow- up
Forpatie ntswhose status is unclear because they fail toappear forstudy  visits without stating 
anintention towithdraw consent, theinvestigator should show "due diligence" bycontacting 
thepatient, family orfamily physician asa
greed in theinfor medconsent andbydocum enting 
inthesource docu ments 
steps taken tocontact thepatient, e.g. dates oftelephone calls, 
registered letters,etc.Apatie ntsho uldnot be considered losttofollow -upuntil duediligence 
hasbeen completed. Patients losttofollow upshould berecorded assuch ontheappropriate 
Disposition eCRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Efficacy  assessments
Tumor response will be assessed locally  according to the Novartis guideline version 3.2 
(Appendix 14.3) based on RECI ST 1.1 (Eisenhauer et al 2009 ). The imaging assessment 
collection plan is presented in Table 7-3.There will be no central review of imaging assessments.
Table 7
-3 Imaging A ssessment Collection Guidance
Procedu re Screening: day −28 to day  1 Treatment phase* End of treatment*
CT or MRI (Chest, 
Abdomen, Pelvis)Mandated Recommend every 12 weeks 
or at different intervals 
according to local standards 
of care during treatment 
phaseMandated
Brain CT or MRI Only if suspected brain 
metastasesAs clinically indicated As clinically indicated
Whole body bone 
scan**Mandated As clinically indicated As clinically indicated
Bone X -ray, CT or 
MRIOnly if skeletal abnormalities 
identified by whole body bone 
scan (or skeletal survey) at 
screening, which are not 
visible in the chest, abdomen, 
pelvis CT/MRI.If bone lesion at screening, 
recommend every 12 weeks 
or at different intervals 
according to local standards 
of care during treatment 
phaseMandated only if bone 
lesion at screening

Novartis Confidential Page 86
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Procedu re Screening: day −28 to day  1 Treatment phase* End of treatment*
Skin visual 
inspection and 
measurement Only if skin lesions at 
screeningRecommend every 12 weeks 
or at different intervals 
according to local standards 
of care during treatment 
phaseMandated if skin 
lesions at screening
CT or MRI of any 
disease outside of 
chest, abdomen 
and pelvis (e.g., 
neck)Only if suspected lesion at 
screeningIf lesion identified at baseline, 
recommend 12 weeks or at 
different intervals according to 
local standards of care during 
treatment phaseMandated if lesion at
screening
*Tumor evaluation at EOT is required for patients who discontinue study treatment before the first scheduled 
post-baseline tumor assessment (week 12) and for patients whose previous tumor assessment did not 
demonstrate PD and was done more than 28 days prior to end of treatment visit.
** Whole body bone scan according to institutional guidelines (e.g. Tc -99 bone scan, whole body bone MRI, 
sodium fluoride positron emission tomography (NaF PET) or fluorodeoxyglucose (FDG) PET).
Baseline /Screening imaging assessments
Imaging assessments will be performed at screening/baseline within 28 days of start of 
treatment (Day  -28 to Day  - 1 prior to Cy cle 1 Day 1).
Any imaging assessments alread y completed during the regular work -up of the patient within 
28 days prior to start of treatment, including before signing the main study  ICF, can be 
considered as the baseline images for this study. Any imaging assessments obtained after stud y 
treatment cannot be considered baseline images. The following assessments are required at 
screening/baseline:
Ches t, abdomen and pelvis CT or MRI
Brain CT or MRI, if clinically  indicated
Whole body  bone scan
Localized bone CT, MRI or x -ray, for any  lesions identified on the whole body  bone scan 
that are not visible on the chest, abdomen and pelvis CT or MRI
Skin visual inspection and measurement (onl y if skin lesions at screening)
CT or MRI  of other metastatic sites (e.g. neck), if clinically  indicated
If a patient is known to have a contraindication to CT intravenous (IV) contras t media or 
develops a contraindication during the trial, a non-contrast CT of the chest (MRI  is not 
recommended due to respiratory  artifacts, however 
if CT is not feasible per local regulations, 
MRI  can be performed instead) plus a contrast -enhanced MRI  (if possible) of the abdomen and 
pelvis should be performed.
If brain metastases are suspected at baseline, brain MRI  or CT should be completed. Contrast 
enhanced brain MRI  is preferred, however, if MRI contrast is contraindicated, then MRI  without 
contrast or CT with/without contrast is acceptable.
A whole body  bone scan should be performed per institutional standard of care [e.g., Tc-99 
bone scan, whole body  bone MRI , Fluorodeox yglucose positron emission tomograph y (FDG -
PET) or sodium fluoride (NaF) PET]. L ocalized CT, MRI  or X -rays should be acquired for all 
skeletal lesions identified on the screening whole body  bone scan, which are not visible on the 
chest, abdomen and pelvis CT/MRI .

Novartis Confidential Page 87
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
If clinically indicated, CT or MRI  of other areas (e.g., neck) of diseas e as appropriate should be 
performed.
If skin lesions are present at screening, lesion will be m easured and visuall y monitored.
Any potentially  measurable lesion that has been previously  treated with radiotherap y should be 
considered as a non-measurable lesion. However, if a lesion previously  treated with 
radiotherap y has clearly  progressed since the radiotherapy , it can be considered as a measurable 
lesion.
Chest x -rays and ultrasound should not be used to measure tumor lesions.
Post -baseline imaging asses sments
Imaging assessments as described in Table 7 -
3should be performed at the timepoints specified 
using the same imaging modality  used at baseline, irrespective of study  treatment interruption 
or actual dosing (see Table 7-1). Imaging assessments for response evaluation will be performed 
in recommended timeframe of every  12 weeks or at different intervals according to the local 
standard of care after 
screening/baseline, until disease progression, death, lost to follow -up or 
withdrawal of consent. Imagin g assessments should be scheduled using the first dose date as 
the reference date (not the date of the previous tumor assessment), and should be respected 
regardless of 
whether treatment with study  treatment is temporarily  withheld or unscheduled 
assessmen ts performed.
Additional imaging assessments may be performed at any time during the study  at the 
investigator’s discretion to support the efficacy  evaluations for a subject, as necessary. Clinical 
suspicion of disease progression at any time requires a physical examination and imaging 
assessments to be performed promptly  rather than waiting for the next scheduled imaging 
assessment.
Each lesion that is measured at baseline must be measured by the same method (either same 
imaging method or by visual inspect ion and measurement and when possible, the same local 
radiologist/ph ysician throughout the study  so that the comparison is consistent. If an off-
schedule imaging assessment is performed because progression is suspected, subsequent 
imaging assessments shoul d be performed in accordance with the original imaging schedule.
Combined PET/CT may be used only if the CT is of similar diagnostic quality  as a CT 
performed without PET, including the utilization of I V contrast media. At the discretion of the 
Investigators, FDG -PET scans may be performed to document progressive disease per RECI ST 
1.1 (Appendix 14.3).
Confirmation of Clinical Benefit
During the Extension Phase, at every 3 months visit the investigator is required to confirm that 
the patient continues to receive clinical benefit and may  continue receiving study  treatment.
7.2.2 Safety  and tolerability assessments
Safety will be monitored by  assessing phy sical exam, vital signs, he matological and chemistry 
labs as well as collecting of the adverse events at every  visitduring Core Phase (Table 7-1). For 
patients who continue study  participation during Extension Phase, (S)AEs and related 

Novartis Confidential Page 88
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
asses sments and, pregnancy  test will be performed (Table 7-2). For details on AE collection 
and reporting, refer to Section 8.
Premenopausal women must complete the following pregnancy tests:
Screening 
–Serumpregnancy  test done locally
Every  4 weeks during treatment –urine pregnancy test. Can be administered at patient’s 
home
End of Treatment visit –serum pregnancy  test done locall y
Premenopausal women who administer urine pregnancy  testing at home should complete a 
simple diary  with the dates and the outcome of the urine pregnancy  tests while on study 
treatment. In case of a positive pregnancy  test, the instructions in Section 8.4 should be followed.
7.2.2.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremiti es, vascular and neurological. If indicated based on medical history and/or s ymptoms, 
rectal, external genitalia, breast, and pelvic exams 
will be performed. Information about the 
physical examination must be present in the source documentation at the study site. Physical 
examination is to be performed according to the visit schedule as outlined in
Table 7-1.
Significant findings that were present prior to the signing of informed consent must be included 
in the Medical History  page on the patient’s eCRF. Significant new findings that begin or 
worsen after informed consent must be recorded on the Adverse Event page of the patient’s 
eCRF.
7.2.2.2 Vital signs
Vital signs include blood pressure (supine position prefer red when ECG is collected), pulse 
measurement, and bod y temperature .
7.2.2.3 Height and weight
Height will be measured at screening .
Body weight (in indoor clothing, but without shoes) will be measured at screening and at 
subsequent time points as specified in Table 7 -1.
7.2.2.4 Performance status
ECOG Performance status scale will be used as described in the Table 7 -
4.
Table 7
-4 ECOG performance status
Grade ECOG status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature e.g., light house work, office work

Novartis Confidential Page 89
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Grade ECOG status
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair
5 Dead
7.2.2.5 Laboratory  evaluations
Local site laboratories will be used for the analy sis of scheduled hematology, biochemistry ,and 
other blood specimens collected as part of safet y monitoring. All unscheduled blood testing will 
also be performed locall y. The time windows granted for laborator y evaluations are identical to 
the corresponding visit time windows for each visit (refer to Section 7.1).
Laboratory  abnormalities that are considered clinically  significant, induce clinical signs or 
symptoms, require concomitant therap y or require dose adjustments in ribociclib treatment (see 
Section 8.1 ) constitut e an 
adverse event (AE) and must be reported as an AE on the AE eCRF 
page.
Laboratory  values obtained at the screening visit will be used to assess eligibility  to meet 
Inclusion criteria. If patient meets all inclusion and no exclusion criteria, the screen ing labs can 
be used for baseline if patient is dosed within 14 days of the screening visit. If patient cannot 
be dosed within 14 days of screening , then the labs should be repeated the day before patient 
starts dosing (see baseline visit in Table 7-1).
Only  selected laboratory  parameters (see Table 7 -5) will be collected on the eCRF.
Table 7
-5 Local Clinical laboratory parameters collection plan
Test 
CategoryTest Name
Hematology WBC, ANC, absolute lymphocyte count , hemoglobin, platelets
Chemistry Screening ALT (SGPT), AST (SGOT), calcium corrected for serum albumin , creatinine or 
creatinine clearance , potassium, sodium, magnesium, total bilirubin ( or direct 
bilirubin if Gilbert’s syndrome)
Scheduled 
visitsAlkaline phosphatase, ALT (SGPT), AST (SGOT), total bilirubin ,direct bilirubin
(if clinically indicated )
Note: potassium, sodium, calcium corrected for serum albumin, and magnesium 
are to be monitored but are not captured in the eCRF. Abnormal electrolyte lab 
results should be reported as AEs at the investigator’s discretion .
Coagulation International normal ized ratio [INR]
Pregnancy Serum and Urine 
7.2.2.5.1 Hematology
Hematology  tests are to be performed according to the Visit Evaluation Schedules outlined in 
Table 7-1. For details of the Hematology  panel refer to Table 7-5 .
7.2.2.5.2 Clinical chemistry
Chemistry  tests are to be performed according to the Visit Evaluation Schedules outlined in 
Table 7-1. For details of the Chemistry  panel refer to Table 7-5.

Novartis Confidential Page 90
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
7.2.2.5.3 Coagulation
INR is to be performed according to the Visit Evaluation Schedules outlined in Table 7-1.
7.2.2.5.4 Pregnancy and Hormonal Levels
Pregnancy  tests are to be performed according to the Visit Evaluation Schedules outline din 
Table 7-1 and Table 7 -2
A positive urine test is required to be confirmed by an immediate serum pregnancy  test.A 
positive pregnancy  test requires immediate interruption of study treatment until the assessment 
is confirmed. If positive, the patient must be discontinued from the study .
FSH and estradiol will be collected locally  and used for screening 
and confirmation of 
menopausal status and clinically  monitored as indicated. FSH and estradiol results are not 
recorded in theeCRF .
7.2.2.6 Cardiac assessments
7.2.2.6.1 Electrocardiogram (ECG)
Standard 12 lead ECG assessments will be performed locally  at screening, C1D15, C2D1, and 
thereafter as clinically indicated, and EOT visit (see Table 7-1). There will be no central review 
of ECGs. QT interval corrected by 
Fridericia ’sformula (QTcF) will be used in this trial for trial 
eligibility  and safet y assessments.
If an abnormal ECG or QTcF value of ≥ 481 ms is obtained at any time after C1D1, study 
treatment must be interrupted, repeat ECG and follow management guidelines detailed in Table 
6-5.
An unscheduled ECG may be repeated at the discretion of the investigator at any time during 
the study and as clinically  indicated. Local cardiologist ECG assessment may be performed at 
any time during the study at the discretion of the investigator.
Interpretation of the tracing must be made by a
 qualified physician and documented on the ECG 
eCRF page. Ea ch ECG tracing should be labeled with the study number, patient initials (where 
regulations permit), patient number, date, and kept in the source documents at the study  site. 
Clinically  significant abnormalities present when the patient signed informed consent should 
be reported on the Medical History  eCRF page. Clinically  significant findings must be 
discussed with Novartis prior to enrolling the patient in the study . New or worsened clinicall y 
significant findings occurring after informed consent must be recorded on the Adverse Events 
eCRF page.
7.2.3 Patient reported outcomes
The FACT -B will be used to explore patient -reported outcome measures of health- related 
quality -of-life, functioning, disease symptoms and treatment -related side effects in selected 
countri esincluding United States, Canada, United Kingdom, France, Italy and Spain . The 
FACT -B (Brad y MJ 1997) is a recognized, reliable and valid instrument frequently  used in 
clinical trials of patients with advanced or metastatic breast cancer.

Novartis Confidential Page 91
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Due to the nature of the questionnaire and validation , only females will be asked to complete 
this questionnaire.
The FACT -B qualit y of life questionnaire (see Appen dix 14.2) will be administered at study  
site before any study  drug administrations at the visits indicated in Table 7-1and Table 7 -6
utilizing electr onic device for data collection. Collection of the FACT -B PRO hasup to -3 day  
window unless otherwise indicated.
All questionnaires should be administered in the patient’s local language at the beginning of the 
study  visit prior to any interaction with the study  investigator to avoid biasing the patient’s 
perspective. This is to avoid potentially  biasing patients or their responses to study 
questionnaires. Patients should be given sufficient space and time to complete the study  
questionnaire and the admini stered questionnaire should be reviewed for completeness. If 
missing responses are noted, patients should be encouraged to complete any missing responses. 
Attempts should be made to collect responses to the questionnaire for all patients, including 
from those who discontinue prior to the study  evaluation completion visit, however, if patients 
refuse to complete the questionnaire, this should be documented in study source records. A 
patient’s refusal to complete the study  questionnaire is not considered a pr otocol deviation.
Completed questionnaires, including both responses to the questions and any unsolicited 
comments written by  the patient, must be reviewed and assessed by  the investigator before the 
clinical examination for responses which may indicate potential AEs or SAEs. This review 
should be documented in study  source records.
If an AE 
or SAE is confirmed then the physician should record the event as instructed in Section 
8of this protocol. I nvesti gators should not encourage the patients to change responses reported 
in questionnaires.
Table 7-
6 Patient reported outcomes collection plan
Patient 
Questionnaires Cycle Day Time
FACT-B Cycles 1 to 6 Every cycle during the first 6 cycles At the beginning of the 
study visit prior to any 
interaction with the 
study investigation.Cycle 7 and 
subsequent 
cyclesEvery 2 cycles: Cycle 8,10,12
Every 3 cycles after that: 15, 18, etc.
End of treatment Day of end of treatment assessment
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 

Novartis Confidential Page 92
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events eCRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s eCRF. Adverse event monitoring should 
be continued for at least 30 days (or 5 half-lives, whichever is longer) following the last dose 
of study  treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possib le, rather than individual underly ing signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.
Adverse events will be assessed and graded according to the Common Terminology  Criteria for 
Adverse Events (CTCAE) version 4.03. Grade 1 to 5 will be used to characterize the severit y 
of the Adverse Event.
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderate, severe, 
and life-threatening, death related to the AE corresponding to Grades 1 - 5, will be used. 
Information about an y deaths (related to an Adverse Event or not) will also be collected though 
a Death form.
The occurrence of adverse events should be sought by  non-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screening process or between visits, or through physi cal examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1 -5)
2.Itsduration (Start and end dates)
3.Its relationship to the study treatment (Reasonable possibility  that AE is related: No,
      Yes, investigational treatment, Yes, the study  treatment (non- investigational), Yes, both 
and/or indistinguishable)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
and which seriousness criteria have been met.
7.
Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown).
If the event worsens the event should be reported a second time in the eCRF noting the start 
date when the event worsens in toxicity . For grade 3 and 4 adverse events only, if improvement 
to a lower grade is determined a new entr y for this event should be reported in the eCRF noting 
the start date when the event improved from having been Grade 3 or Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adve rse Event 
eCRF.

Novartis Confidential Page 93
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by use of appropriate 
method (for example, as per RECI ST criteria for solid tumors or as per Che son's guidelines for 
hematological malignancies), should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events eCRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an a bnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities that do not meet the definition of an adverse event should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality  may be required b y 
the protocol in which case the lab abnormality  would still, by definition, be an adverse event 
and must be reported as such.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospitalization or prolongati on of existing hospitalization,
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:

Novartis Confidential Page 94
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (i.e. to per form study  related assessments)
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under stud y and has not worsened since signing the informed consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
8.2.2 Reporting
To ensure patient safet y every  SAE, regardless of suspected causality , occurring after the patient 
has provided informed consent and until at least 30 days after the patient has stopped study  
treatment must be reported to Novartis within 24 hours of learning of its occurrence.
Any additional information for the SAE including complications, progression of the initial SAE, 
and recurrent e pisodes must be reported as follow -up to the original episode within 24 hours of 
the investigator receiving the follow -up information. A SAE occurring at a different time 
interval or otherwise considered completely  unrelated to a previousl y reported one should be 
reported separatel y as a new event.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to Novartis if the investigator suspects a causal relati onship to the study  treatment.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis. Detailed 
instructions regarding the SAE submission process and requirements for signatures areto be 
found in the investigator folder provided to each site.
Follow -up information is submitted in the same way as the original SAE Report. Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation .
If the SAE is not previously  documented in the [Investigator’s Brochure] or Package Insert 
(new occurrence) and is thought to be related to the Novartis study  treatment, an oncology 
Novartis Chief Medical Office and Patient Safety  (CMO&PS) department associate may 
urgently  require further information from the investigator for Health Authority  reporting. 
Novartis may need to issue an Investigator Notification (IN), to inform all investigators 
involved in any study with the same drug that this SAE has been reported. Suspected 
Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the 
competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC 
or as per national regulatory  requirements in participating countries.

Novartis Confidential Page 95
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
8.3 Emergency  unblinding of treatment assignment
Not Applicable.
8.4 Pregnancies
This trial is planned for men ,post-menopausal women or premenopausal women with ovarian 
suppression, so no pregnanc iesare expected for study  patients. However, in the rare cases when 
this occurs, to ensure patient safet y, each pregnancy  occurring while the patient is on study 
treatment must be reported to Novartis within 24 hours of learning of its occurrence. The 
pregnancy  should be followed up to determine outcome, including spontaneous or voluntar y 
termination, details of the birth, and the presence or absence of any birth defects, congenital 
abnormalities, or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology Novartis Chief Medical Office and Patient Safety  (CMO&PS) . 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment any pregnancy outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [Investigator ’s 
Brochure ](IB). Additional safet y information collected between IB updates will be 
communicated in the form of Investigator Notifications. This information will be included in 
the patient informed consent and should be discussed with the patient during the study  as needed.
8.6 D
ata Monitoring Committee
Not Applicable.
8.7 Steering Committee
The steering committee (SC) will be established comprising investigators participating in the 
trial, and Novartis representatives from the Clinical Trial Team.
The SC will ensure transparent management of the study  according to the protocol through 
recommending and approving modifications as circumstances require. The SC will review 
protocol amendments as appropriate. Together with the clinical trial team, the SCwill also 
develop recommendations for publications of study  results including authorship rules. The 
details of the role of the SC will be defined in a Steering Committee charter.

Novartis Confidential Page 96
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
9 Data collection and management
9.1 Data confidentiality
Information about study  patients will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
What protected health information (PHI) will be collected from patients in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect oruse PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For patients that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permissi on to collect follow -up safet y information (e.g. has the subject 
experienced an y new or worsened AEs) at the end of their scheduled study period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and eCRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study ,consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be trace able to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm the ir 
consistency  with the eCRF entries. Novartis monitoring standards require full verification for 
the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the eCRFs 
are performed according to the study -specific monitoring plan.

Novartis Confidential Page 97
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
9.3 Data collection
This study  will use Electronic Data Capture (EDC) and the designated investigator staff will 
enter the data required by the protocol into the Electronic Case Report Forms (eCRF). The 
eCRFs have been built using fully validated secure web-enabled software that conforms to 21 
CFR Part 11 requirements, Investigator site staff will not be given access to the EDC system 
until they have been trained. Automatic validation programs check for data discrepancies in the 
eCRFs and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF is complete, 
accurate, and that entry  and updates are performed in a timely  manner.
9.3.1 IRT data collection
Patient eligibility  and enrollment will be tracked using an Interactive Response Technology . 
The data will be entered by the designated investigator staff. The sy stem will be supplied by  a 
vendor, who will also manage the database for that system.
9.3.2 FACT-B questionnaire data collection
FACT -B questionnaire data will be entered using ePRO. The data will be entered by the patients
at the clinic . The system will be supplied by a vendor, who will also manage the database for 
that sy stem.
The use of electronic data collection of clinical outcome assessments (eCOA), including PROs, 
has been endorsed as standard. The use of both eCOA and paper PRO collection of the same 
COA measure ina single study  is not endorsed. However, paper PRO may be utilized as a 
backup should there be a failure with the electronic version/s ystem.
All questionnaires should be administered in the patient’s local language prior to any interaction 
with the study  investigator. This is to avoid potentially  biasing patients or their responses to 
study  questionnaires.
9.4 Database management and quality  control
Novartis personnel (or designated CRO) will review the data entered by investigational staff 
for completeness and accuracy . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classif ication 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
PRO data will be collected electronically  and processed centrally  and the results will be sent 
electronically  to Novartis .

Novartis Confidential Page 98
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Data about all study  treatments dispensed to the patient will be tracked using an Interactive 
Response Technology . The IRT system will be supplied by  a vendor(s), who will also manage 
the database. The data will be sent electronically  to Novart is personnel (or designated CRO) .
The occurrence of any protocol violations will be determined. After these actions have been 
completed and the data has been verified to be complete and accurate, the database will be 
declared locked made available for data analysis. Authorization is required prior to making an y 
database changes to locked data, by joint written agreement between the Global Head of 
Biostatistics and Data Management and the Global Head of Clinical Development.
After dat abase lock, the investigator will receive a CD -ROM or paper copies of the patient data 
for archiving at the investigational site.
10 Statistical methods and data analy sis
Novartis and/or a designated CRO will perform all analyses. Any data analy sis carried out 
independentl y by the investigator should not be presented or published before the final anal ysis 
is completed. The data from all centers that participate in this trial will be combined in the 
analyses.
Final analyses will be performed when all patients 
have been followed for 30 days after they 
have either prematurel y discontinued ribociclib or been discontinued from the study  after 
completing treatment as per protocol (see Section 4.1). Data collected during the Extension 
Phase may be summarized in a separate report or publication. However, analysis may be 
performed to support regulatory  submission or safety  update if deemed necessary  before the 
final anal ysis.
Following subgroup analy ses may be performed if deemed necessary  at interim and/or final 
analysis:
Region (Latin American, Region Europe, Asia)
Country  (countries with at least 100 patients such as US, Canada, Italy , Spain, France, 
Belgium, Czech Republic)
Menopausal status (pre/ post)
Prior treatmen ts for (neo)adjuvant (no treatments, endocrine onl y, chemotherap y only, 
both (chemotherap y and endocrine treatment) )
ECOG PS (PS 0
, 1,and 2)
Location of metastasis disease (bone, liver, lung, ly mphonodes, and etc.)
Number of metastatic sites (0, 1, 2, ≥3)
Age (<65, 65 -
70, 70- 75, >75 y ears)
Gender (male and female)
Race (Asian vs. Non
-Asian)
10.1 Analysis sets
The following anal ysis sets will be used for statistical anal ysis and data reporting.

Novartis Confidential Page 99
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
10.1.1 Full A nalysis Set
The Full Analy sis Set (FAS) comprises all patients who receive at least one dose of study  
medication defined as either ribociclib or letrozole or goserelin/leuprolide ( if applicable )in the 
Core Phase .
10.1.2 Safety  setin Core Phase
The Safet y Set includes all patients who received at least one dose of study  medication sdefined 
as either ribociclib or letrozole or goserelin/ leuprolide (if applicable) . For this study , the 
definition of FAS is the same as that of Safet y set in Core Phase.
10.1.3 Safety  Set in Extension Phase
The Safet y set in the Extension Phase includes all patients who received at least one dose of 
study  medication sdefined as ribociclib or letrozole or goserelin/leuprolide (if applicable) in the 
Extension Phase .
10.1.4 Per-Protocol set
Not a pplicable.
10.1.5 Dose -determining analy sis set
Not a pplicable.
10.1.6 Pharmacokinetic analy sis set
Not applicable.
10.1.7 Other analy sis sets
The patient -reported outcomes (PRO) will be collected in subgroup of patients in selected 
countries. The PRO Analysis Set (PAS) consists of all patients in the FAS population for whom 
baseline and at least one post baseline PRO measurements are available.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed and 
summar ized descriptively for the FAS.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented.
Relevant medical histories and current medical at baseline will be summarized by system organ 
class and pr eferred term.
10.3 Treatments (study  treatment, concomitant therapies, 
compliance)
The safety  set in Core Phase will be used for all analy sis of relevant data (dosing information, 
use of concomitant therapies, etc.) in the Core Phase, and the safety set in Extension Phase will 
be used for anal ysis of all data in the Extension Phase. Categorical data will be summarized as 

Novartis Confidential Page 100
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
frequencies and percentages. For continuous data, mean, standard deviation, median, 25th and 
75th percentiles, minimum, and maximum will be presented.
Duration of study  treatment exposure, cumulative dose, dose intensit y (DI) and relative dose 
intensity  (RD I) will be summarized by  treatment. In addition, the duration of exposure to stud y 
treatment will be categorized into time intervals; frequency  counts and percentages will be 
presented for the number of patients in each interval.
The number of patients with dose adjustments (reductions, interruption, or permanent 
discontinuation) and the reasons will be summarized and all dosing data will be listed.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classifica tion sy stem.
10.4 Primary  objective
The primary objective of this study  is to further evaluate the safet y and tolerability  of ribociclib 
in combination with letrozole in men and postmenopausal women with HR+, HER2 -
aBC who 
received no prior hormonal therap y for advanced disease. For details see Section 10.5.3 .
10.4.1 Variable
To evaluate the primary  objective: the number (%) of patients who experienced adverse events 
(AEs) will be calculated for the following AE categories :
Any AEs
Grade 3/4 AEs
Serious Adverse Events ( SAEs )
AEs of Special Interest (Neutropenia (including febrile neutropenia), QT prolongation, 
hepatobiliary  AEs )
AEs leading discontinuation and deaths
AEs leading dose reductio n or dose interruption
Deaths
10.4.2 Statistical hy pothesis, model, and method of analy sis
No statistical hypotheses will be tested in this study. The primary  safety  variable 
(AEs, Grade 
3/4 AEs and SAEs, events of special interest, and AEs leading discontinuatio n and deaths) will 
be summarized by  count and percentage in safet y set.
10.4.3 Handling of missing values/censoring/discontinuations
All attempts will be made to ensure that the database contains full information for all safet y 
data. No imputation will be applied for missing data.
10.4.4 Supportive and Sensitivity analy ses
Not applicable .

Novartis Confidential Page 101
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
10.5 Secondary  objectives
10.5.1 Secondary  objective(s)
The secondary  objective of this study  is to assess the clinical efficacy  of ribociclib + letrozole
(+ goserelin or leuprolide) in Full Anal ysis Set .
The following endpoints as defined b y RECIST1.1 will be use key  secondary  objectives:
Time -to-Progression (TTP) based on investigators’ assessment
Overall response rate (ORR) for patients with measurable disease
Clinical Benefit Rate (CBR) (including patients with CR, PR, SD/NCRNPD>24 weeks)
Time to progression (TTP) is defined as time from date of start of treatment to the date of event 
defined as the first documented progression or death due to underl ying cancer ( Appendix 14.3 : 
Novartis RECI ST Guideline v 3.2). Patients with symptoms of rapidl y progressing disease 
without radiologic evidence will be classified as progression only when clear evidence of 
clinical deterioration is documented and/or patient discontinued due to ‘Disease progression’ 
or death due to study  indication. When there is no documentation of radiologic evidence of 
progression, and the patient discontinued for ‘Disease progression’ due to documented clinical 
deterioration of disease, the date of discontinuation is used as date of progression.
Overall response rate (ORR) is defined as the proportion of patients with best overall response 
of complete response (CR) or partial respons e (PR) according to RECI ST 1.1.
Clinical benefit rate (CBR) is defined as the proportion of patients with a best overall response 
of complete response (CR), or partial response (PR) or an overall lesion response of stable 
disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are 
defined accordi ng to RECI ST 1.1 (see 
Appendix 14.3 for details)
The distribution of TTP will be estimated using the Kaplan -Meier method. The median TTP 
along with 95% confidence intervals will be presented. Proportions of patients with ORR and 
CBR as assessed by investigator will be calculated and 
presented along with the approximate 
95% confidence intervals using Clopper and Pearson (1934) exact method.
In addition, PRO will be assessed using FACT -B instrument (See Section 10.5.4 ).
During Extension Phase, frequency  of AEs & SAEs will be summarized.
Theproportion of patients with clinical benefit as assessed by investigator will be reported at 
each scheduled visit during Extension Phase.
10.5.2 Other secondary  efficacy  objectives
Not applicable.
10.5.3 Safety  objectives
10.5.3.1 Analysis set and grouping for the analy ses
For safet y analysesinthe Core Phase , the Safet y Set in Core Phase will be used. For safet y 
analyses in the Extension Phase, the Safet y Set in Extension Phase will be used. All listings and 
tables will be presented.

Novartis Confidential Page 102
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
The overall observation period will be divided into three mutually  exclusive segments:
1.pre-treatment period :
Core Phase: from day of patient’s informed consent to the day before first administration of 
study  treatment.
Extension Phase: Not applicable.
2.on-treatment period :
Core Phase: For patients who discontinue after the Core Phase treatment, on-treatment period 
is defined as the time from the date of first administration of study  treatment to 30 days after 
date of last actual administration of any study treatment (includi ng start and stop date). For 
patients who transition to the Extension Phase, on -
treatment period is defined as the time from 
the date of first administration of study  treatment to date of last actual administration of any 
study  treatment in the Core Phase.
Extension Phase: from date ofthe first administration of study  treatment in the Extension Phase 
to 30 day s after date of last actual administration of any  study  treatment
3.post-treatment period :
Core Phase: starting at day 31after last administration of study treatment for patients who 
discontinue after the Core Phase treatment without transitioning to the Extension Phase. Post-
treatment period is not applicable for patients who transition to Extension Phase.
Extension Phase: starting at day  31 after last administration of study  treatment in the Extension 
Phase.
The safet y summary  tables will include assessments from the on-treatment period, unless 
otherwise specified. Further details will be included in the Statistical Analysis Plan (SAP).
All safet y data collected in the study  will be listed regardless of the study  period with data 
collected during the pre -
treatment and post- treatment period flagged.
10.5.3.2 Adverse events (A Es)
Summary  tables for adverse events (AEs) will include only AEs that started or worsened during 
the on- treatment period, the treatment- emergent AEs.
The treatment -emergent adverse events (new or worsening from baseline) will be summarized 
by system organ class and or preferred term, severity  (based on CTCAE grades), type of adverse 
event, rel ation to study  treatment
Serious adverse events, non-serious adverse events and adverse events of special interest (AESI)
during the on -treatment period will be tabulated.
All deaths (on- treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including those from the pre and post-treatment 
periods) will be listed and those collected during the pre-treatment and post-treatment period 
will be flagged.

Novartis Confidential Page 103
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
10.5.3.3 Laboratory  abnormalities
Grading of laboratory  values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) version 4.03. The calculation of CTCAE 
grades will be based on the observed laboratory  values only, clinical assessments will not be 
taken into account.
CTCAE Grade 0 will be assigned for all non- missing values not graded as 1 or higher. Grade 5 
will not be used.
The following summaries will be generated separately  for hematology , and biochemistry  tests:
Number and percentage of patients with worst post- baseline CTCAE grade (regardless of 
the baseline status). Each patient will be counted only  for the worst grade observed post-
baseline.
Shift tables using CTCAE grades to compare baseline to the worst post- baseline value 
(on-treatment).
The following listing s will be produced for the laboratory  data:
Listing of patients with laboratory  values outside the laboratory  reference ranges with 
values flagged to show the corresponding CTC grades and the classifications relative to 
the laboratory  reference ranges.
Listing of all laboratory  data with values flagged to show the corresponding CTCAE 
grades if applicable and the classifications relative to the laboratory  normal ranges
10.5.3.4 Other safety  data
Vital signs
Other safety  data (including ECGs, vital signs and weight) will be summarized and listed, 
notable values will be flagged, and any other information collected will be listed as appropriate. 
Further details will be included in the Statistical Analy sis Plan (SAP).
10.5.3.5 Supportive analy ses for secondary  objectives
Not Appl icable.
10.5.3.6 Tolerability
Tolerability  will be studied in terms of dose reductions or drug interruption due to an AE.
10.5.4 Patient -
reported outcomes
FACT -B questionnaire will be used to collect patient reported outcome data in this trial. Scores 
will be added to cre ate subscale and overall scores. A Trial Outcome Index is generated via the 
addition of the phy sical well -being, functional well-being, and breast cancer subscales.
No formal statistical tests will be performed for patient -reported outcomes (PRO) data and 
hence no multiplicity  adjustment will be applied. The PRO analysis setwill be used for 
analyzing PRO data.

Novartis Confidential Page 104
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Descriptive statistics will be used to summarize the subscale and overall scores at each 
scheduled assessment time point. Additionally , change from baseline at the time of each 
assessment will be summarized. PRO data may  be summarized by  country /region.
Patients with an evaluable baseline score and at least one evaluable post baseline score during 
the treatment period will be included in the change fr om baseline anal yses.
10.6 Exploratory  objectives
Not a pplicable.
10.7 Interim analy sis
Interim analy ses (IA) may be performed periodically . The first IA is planned to be performed 
about 12 months after FPFV, and periodicall y thereafter , if needed, to fulfill regulatory  requests, 
safet y updates, orfor publication purposes. Subgroup analy ses may be performed at interim if 
deem necessary  (based on the number of patients enrolled in each subgroup). Details of the I A 
will be provided in the SAP .
10.8 Sample size calcul ation
A sample size of 3,000 patients is planned to be enrolled in this study to detect rare AEs 
(frequency  ~0.1%) with high probability. This will allow for a greater precision when reporting 
rare, but clinicall y meaningful AEs (e.g. febrile neutropenia, QT prolongation, renal 
insufficiency , thromboembolic events, etc.) . For example, if therate of an AE is 0.1%, then the 
probability  of observing at least 1AEs out of 3000 patients is 95.0%. A sample size of 3,000 
patients will allow for a meaningful safet y analy sis of specific patient subgroup 
of particular 
interest. For example, the expected size of male patients may be 30 (~ 0.1% of total population), 
patients with ECOG PS=2 may be 150 (~5% of total population) , and patients with one prior 
line of chemot herap y may be 300 (~10% of total population) .Table 10-1 below provides a 95% 
confidence interval (CI) and the corresponding width of the 95%
 CI, with different rates of rare 
AEs observed in[LEE011A2301 ]study ) for overall population as well as for subgroups of 
various sizes.
Table 10-1 Confidence Intervals associated with A Es of interest for subgroups
Number of 
Patients Number of AE RateLower 
95% CIUpper 
95% CI Width*
QT prolongation (observed rate = 3.5% )
30 1 0.0333 0.0008 0.1722 0.1713
150 5 0.0333 0.0109 0.0761 0.0652
300 10 0.0333 0.0161 0.0604 0.0443
3000 99 0.0330 0.0269 0.0400 0.0131
Febrile neutropenia (observed rate = 1.5% )
30 0 0 0 0.1157 0.1157
150 3 0.020 0.0041 0.0573 0.0532
300 5 0.0167 0.0054 0.0385 0.0330
3000 45 0.0150 0.0110 0.0200 0.0091

Novartis Confidential Page 105
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
10.9 Power for analy sis of key secondary  variables
Not applicable .
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulat ions 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature page confirming his/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by law or regulation), IRB/IE C/REB -approved informed consent or if applicable, or, 
if incapable of doing so, after such consent has been provided by a legally  acceptable 
representative of the patient. In cases where the patient’s representative gives consent, the 
patient should be informed about the study  to the extent possib le given his/her understanding. 
If the patient is capable of doing so, he/she should indicate assent by personally  signing and 
dating the written informed consent doc ument or a separate assent form .
Informed consent must be obtained before conducting any study-specific procedures. The 
process of obtaining informed consent should be documented in the patient source documents. 
The date when a subject’s Informed Consent was actually  obtained will be captured in their 
eCRFs.
Novartis will provide to investigato rs, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator Renal insufficiency  / creatinine increase (observed rate = 0.5% )
30 0 0 0 0.1157 0.1157
150 1 0.0067 0.0002 0.0366 0.0364
300 2 0.0067 0.0008 0.0239 0.0231
3000 15 0.0050 0.0028 0.0082 0.0054

Novartis Confidential Page 106
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
must be agreed to byNovartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
Male participants will be requested to provide an information form to female partners .
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study  are outlined in Section 4.4.
11.5 Publication of study  protocol and results
Novartis is committed to following high ethical standards for reporting study  results for its 
innovative medicine, including the timel y communication and publication of clinical trial 
results, whatever 
their outcome. Novartis assures that the key  design elements of this protocol 
will be posted in a on the publicly accessible database, e.g. such as www.clinicaltrials.gov, 
before study  start. In addition, results of interventional clinical trials in adult patients are posted 
on www.novartisclinicaltrials.com, a publicly  accessible database of clinical study  results 
within 1 year of upon study  completion (i.e., LPLV), and finalization of the study  report the 
results of this study  will be either submitted for publication and/or posted in those for 
interventional clinical trials involving pediatric patients within 6 mont hs of study  completion.
Novartis follows the ICMJE authorship guidelines (//.icmje.org ) and other specific guidelines 
of the journal or congress to which the publication will be submitted.
Authors will not receive remuneration for their writing of a public ation, either 
directl y from 
Novartis or through the professional medical writing agency . Author(s) may be requested to 
present poster or oral presentation at scientific congress; however, there will be no honorarium 
provided for such presentations.
As part of its commitment to full transparency in publications, Novartis supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of interest of financial and non-financial nature by all authors, including 
medical writing/editorial support, if applicable.
For the Novartis Guidelines for the Publication of Results from Novartis -sponsored Research, 
please refer to //.novartis.com.
11.6 Stud y documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of patients. As part of par ticipating in a Novartis -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 

Novartis Confidential Page 107
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
to examine (and when required by  applicable law, to copy ) clinical records for the purposes of 
quality  assurance reviews, a udits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory  notes, memoranda, patients’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instr uments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instru ment for the stud y. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported on 
the CRF, that are derived from source documents, should be consisten t with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF should 
be dated, initialed, and explained (if necessary ) and should not obscure the original entry . For 
electronic CRFs an audit trail will be maintained by  the sy stem. The investigator should retain 
records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by applicable 
regulations and/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of the se documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retent ion for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by names 
in any documents submitted to Novartis. Signed informed consent forms and patient enrollment 
log must be kept strictl y confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at the site -prior to study  start.

Novartis Confidential Page 108
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
12 Protocol adherence
Invest igators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the study 
to request approval of a protocol deviation, as no authorized deviatio ns are permitted. If the 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC/REB it cannot be imple mented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities w here required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immedia te action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
Novartis should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. UK requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working days.

Novartis Confidential Page 109
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
13 References (available upon request)
Bachelot T, Pujade -Lauraine E, et .(2012) .Randomized phase II trial of everolimus in 
combination with tamoxifen in patients with hormone receptor -positive, human epidermal 
growth factor receptor 2 -negative metastatic breast cancer with prior exposure to aromatase 
inhibitors: a GI NECO study . J Clin Oncol. 30(22):2718 -24
Beroukhim R, Mermel C H, Porter D, et al .(2010) .The landscape of somatic cop y-number 
alteration across human cancers. Nature; 463:899 -905
Beslija S, Bonneterre J, Burstein HJ, et al. (2009) .Third consensus on medical treatment of 
metastatic breast cancer. Ann Oncol; 20: 1771
-85
Brad y MJ, et al .(1997) .Reliability  and Validity  of the Functional Assessment of Cancer 
Therap y-Breast Quality -of-life Instrument. J Clin Oncol 15:974-986
Bosco EE, Wang Y, Xu H, et al
.(2007) .The retinoblastoma tumor suppressor modifies the 
therapeu tic response of breast cancer. J Clin I nvest, 117: 218-28
Carlson RW, Theriault R, Schurman CM, et al. (2010) .Phase II trial of anastrozole plus 
goserelin in the treatment of hormone recepto r-positive, metastatic c arcinoma of the breast in 
premenopausal women. J Clin Oncol ;28(25):3917–21
Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JF, Winterbottom L, et al. (2010) .
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for 
advanced breast cancer in pre-menopausal women. Eur J Cancer ;46(16):2936–42
Clopper, Pearson (1934) .The Use of Confidence or Fiducial Limits I
llustrated in the Case of 
the Binomial. Biometrika, 26(4): 404 -413.
Cristofanilli M .(2016) .Fulvestrant plus pa lbociclib versus fulvestrant plus placebo for 
treatment of hormone -receptor -positive, HER2 -negative metastatic breast cancer that 
progressed on previous endocrine therap y (PALOMA- 3): final analy sis of the multicentre, 
double -blind, phase 3 randomised controlled trial. Lancet Oncol 2016 Apr;17(4):425-39
Dickler ,et al.(2016) .Phase III Trial Evaluating Letrozole As First -Line Endocrine Therap y 
With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone 
Receptor -Positive Advanced- Stage Breast Cancer: CAL GB 40503 (Alliance). J Clin 
Oncol ;34(22):2602-9.
Doyen J, I taliano A, Largillier R, et al. (2010). Aromatase inhibition in male breast cancer 
patients: biological and clinical implications. Ann Oncol. Jun;21(6):1243-5
EBCTCG (2000) .(Earl y Breast Cancer Trailist’ Collaborative Group). Ovarian ablation for 
early breast cancer. Cochrane Database Syst Rev; 3: CD000485
Eisenhauer EA, et al .(2009) .New response evaluation criteria in solid tumors: Revised 
RECI ST guideline (version 1.1) Eur. J. of Cancer 45:228 - 247
Ellis,RE.(1961) .The Distribution of Active Bone Marrow in the Adult, Phy. Med. Biol. 5, 
255-258
Finn RS, Slamon DJ, et al. (2009) .PD 0332991, a selective cy clin D kinase 4/6 inhibitor, 
preferentially inhibits proliferation of luminal estrogen receptor -positive human breast cancer 
cell lines in vitro. Breast Cancer Research 11:R77

Novartis Confidential Page 110
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Finn RS, Crown JP, L ang I, et al .(2015).The cy clin-dependent kinase 4/6 inhibitor 
palbociclib in combination with letrozole versus letrozole alone as first -
line treatment of 
oestrogen receptor -positive, HER2 -negative, advanced breast cancer (PALOMA -1/TRIO -18): 
a randomized phase 2 study , Lancet Oncol; 16: 25–35
Finn RS , et al .(2016) .PALOMA -2: Primary  results from a phase III trial of palbociclib (P) 
with letrozole (L ) compared with letrozole alone in postmenopausal women with ER+/HER2–
advanced breast cancer (ABC), J Clin Oncol; 34, suppl; abstr 507
Forward DP, Cheung KL, Jackson L, Robertson JF, et al. (2004) .Clinical and endocrine data 
forgoserelin plus anastrozole as secon d
-line endocrine therapy for premenopausal advanced
breast cancer. Br J Cancer ;90(3):590 –4
Giordano SH. 
(2005) . A review of the diagnosis and management of male breast cancer. 
Oncologist. 2005 Aug;10(7):471-9.
Gradishar WJ, Anderson BO, Balassanian R, et al .(2016) .Invasive Breast Cancer Version 
1.2016, NCCN Clinical Practice Guidelines in Oncology . J Natl Compr Canc Netw 14:324 -
354
Grunberg SM, Espersen BT, et al.(2010) .Evaluation of new antiemetic agents and definition 
of antineoplastic agent emetogenicity --state of the art. Support Care Cancer.;19 Suppl 1:S43 -
7.
Holm K, Borg A, et al .(2012) . Characterisation of amplification patterns and target genes at 
chromosome 11q13 in CCND1- amplified sporadic and familial breast tumours. Breast Cancer 
Res Treat (2012) 133:583 594
Hortobagy i GN. (2016) .Ribociclib as First -Line Therap y for HR -Positive, Advanced Breast 
Cancer N Engl J Med. 2016 Nov 3; 375(18):1738-1748
Hortobagy i GN. ASCO (2017) .Ribociclib as First -Line Therapy  for HR -Positive, Advanced 
Breast Cancer ASCO 2017; abstract 1038
Jeong S, Woo MM, Flocckhart DA, et al. (2009) .Inhibition of drug metabolizing cy tochrome 
p450s by  the aromatase inhibitor drug let rozole and its major oxidative metabolite 4,4’ -
methanol -bisbenzonitrile in vitro. Cancer Chemother Pharmacol; 64: 867-75
Lange CA, Yee D .(2011) .Killing the second messenger: targeting loss of cell cy cle control in 
endocrine -
resistant breast cancer. Endoc rine-Related Cancer; 18: C19 –C24
Lipton A, Demers LM, Harvey  HA, et al
.(1995) .Cance r; 75: 2132-8
Loibl S, Turner NC, Ro J, et al. (2016) . Palbociclib (PAL) in combination with fulvestrant (F) 
in pre -/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior 
progression on endocrine therap y –results from Paloma -3. J Clin Oncol 34 (suppl; abstr 524)
Martin et al .(2015) . Phase III trial evaluating the addition of bevacizumab to endocrine 
therap y as first -line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin 
(LEA) study .J Clin Oncol; 33(9):1045-52
Montagna E, Cancello G, Colleoni M. (2013) . The aromatase inhibitors (plus ovarian function 
suppression) in premenopausal breast cancer patients: Ready  for prime time? Cancer Treat 
Rev. Dec;39(8):886 -90

Novartis Confidential Page 111
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Mouridsen H, Gershanovich M, Sun Y, et al. (2001) .Superior efficacy  of letrozole versus 
tamoxifen as first
-line therap y for postmenopausal women with advanced breast cancer: 
results of a phase III study of the Internatio nal Letrozole Breast Cancer Group. J Clin Oncol; 
19: 2596-606
Musgrove EA, Caldon CE, Barraclough J, et al. (2011) .Cyclin D as a therapeutic target in 
cancer. Nat Rev Cancer; 11:558-72
National Cancer Center Network Treatment Guidelines for Breast Cancer, Version 2.2017. 
nccn.org/professionals/phy sician_gls/pdf/breast.pdf
National Cancer Center Network (NCCN) antiemesis guideline v2.2017, 
https://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf
Nichols HB, Sandler DP et al. (2015) .Risk-Benefit Profiles of Women Using Tamoxifen for 
Chemoprevention. JNCI : Jnl of National Cancer Institute. Volume 107, I ssue 1
Nishimura R, Anan K, Yamamoto Y. (2012) .A multicenter phase II trial of the LH- RH 
analogue and an aromatase inhibitor combination in premenopausal patients with advanced or 
recurrent breast cancer refractory  to an LH -RH analogue with tamoxifen: JMTO BC08
-01. J 
Clin Oncol ;30. Suppl.; abstr 588.
Novartis Pharmaceuticals (2016). MONALEESA -2 trial of Novartis' LEE011 (ribociclib) 
stopped due to positive efficacy  results at interim anal ysis in HR+/HER2- advanced breast 
cancer [PRESS release] https://novartis.com/news/media -releases/monaleesa-2- trial -novartis -
lee011- ribociclib -stopped -due- positive -efficacy Oesterreich S, Fuqua SAW (1999) Tumor 
suppre ssor genes in breast cancer. Endocr Relat Cancer; 6: 405 -19
Pagani O, et al. (2014). Exemestane with ovarian suppression in premenopausal breast cancer: 
N Engl J Med; 371(14):1358 -9
Park IH, Ro J, Lee KS, et al. (2010) .Phase II parallel group study showing comparable 
efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus 
goserelin and postmenopausal patients treated with letrozole alone as firs t-line hormone 
thera py. J Clin Oncol ;28(16):2705–11
Roche H, Thierry  D, Chieze S, et al. (2009) .Anastrozole and goserelin combination as first 
treatment for premenopausal receptor positive advanced or metastatic breast cancer: a phase II 
trial. JClin Oncol ;27:15s. Suppl.; abstr 1079.
Roila F, van der Wetering M, et al .(2016) .
2016 MASCC and ESMO guideline update for the 
prevention of chemotherapy -and radiotherap y-induced nausea and vomiting and of nausea 
and vomiting in advanced cancer patients. Ann Oncol. 27(suppl 5):v119 -v133.
Thangavel C, Knudsen E, et al .(2011) .Therapeutically  activating RB: reestablishing cell 
cycle control in endocrine therapy -resistant breast cancer. Endocrine -Related Cancer (2011) 
18 333–345
The Cancer Genome Atlas Network (2012) .
Comprehensive molecular portraits of human 
breast tumours. Nat ure; 490: 61 -70Trunet PF, Bhatnagar AS, Chaudri HA, et al .(1996) .
Letrozole (CGS20267) a new oral aromatase inhibitor for the treatment of advanced breast 
cancer in postmenopausal patients. Acta Oncol; 35 Suppl 5: 15 -8
Turner NC, et al .(2015) .Palbocicli b in hormone -receptor -positive advanced breast cancer. N 
Engl J Med; 373(3): 209 -219

Novartis Confidential Page 112
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Yao S, Xu B, Li Q, et al. (2011) . Goserelin plus letrozole as first- or second -line hormonal 
treatment in premenopausal patients with advanced breast cancer. Endocr J ;58(6):509–16

Novartis Confidential Page 113
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
14 Appendices
14.1 Appendix 1 -Concomitant Medications
In general, the use of any concomitant medication deemed necessary  for the care of the patient 
is permitted in this study , except as specificall y prohibited below. Combination administration 
of study  drugs could result in drug-drug interactions (DDI) that could potentially  lead to reduced 
activity  or enhanced toxicity  of the concomitant medication and/or ribociclib.
The following lists are not comprehensive and are only meant to be used as a guide. The lists 
are based onNovartis PK Science Memorandum , Drug -Drug Interaction and Co-Medication 
Considerations for Novartis Clinical Trials (release date: Jan 2018), which was compiled from 
the Indiana University  School of Medicine’s P450 Drug Interaction Table 
(medicine.iupui.edu/clinpharm/ddis/main -table/) and supplemented with the FDA Draft 
Guidance for Industry , Drug Interaction Studies –Study  Design, Data Anal ysis, and 
Implications for Dosing and Labeling (February  2 012) 
(fda.gov/downloads/drugs/guid ancecomplianceregulatory information/guidances/ucm292362.p
df), and the University  of Washington’s Drug Interaction Database (druginteractioninfo.org/). 
For current lists of medications that may cause QT prolongation and/or torsades de pointes 
(TdP), refer to the CredibleMeds®website crediblemeds
.org). Please contact the medical 
monitor with any  questions.
Table 14-1 List of prohibited medications during study  drug treatment
Category Drug Name
Strong CYP3A4/5 inhibitors Atazanavir/ritonavir , boceprevir, clarithromycin, cobicistat, conivaptan, 
danoprevir/ritonavir, darunavir/ritonavir, eltegravir/ritonavir, grapefruit juice, 
indinavir/ritonavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, 
nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, 
saquinavir/ritonavir, telaprevir, telithromycin, tipranavir/ritonavir, 
troleandomycin, voriconazole , indin avir, idelalisib, Ombitasvir,/ Paritaprevir, 
Ritonavir/ Dasabuvir (VIEKIRA PAK)
Strong CYP3A4/5 inducers Apalutamide, Carbamazepine3, enzalutamide, lumacaftor, mitotane, 
phenobarbital, phenytoin3, rifabutin, rifampin (rifampicin)3, St. John's wort 
(hypericum perforatum)2,3
CYP3A4/5 substrates with 
NTI1Alfentanil, astemizole, cisapride, cyclosporine, diergotamine, 
dihydroergotamine, ergotamine, fentanyl, lomitapide5, lovastatin, nicardipine, 
nisoldipine ,pimozide, quinidine, simvastatin ,sirolimus, tacrolimus
Medications with a known 
risk for QT prolongation4Amiodarone, anagrelide, arsenic trioxide, astemizole, azithromycin,bepridil 
chloroquine, cocaine chlorpromazine, cilostazol, ciprofloxacin, cisapride, 
citalopram, clarithromycin, disopyramide, dofetilide, domperidone, donepezil, 
dronedarone, droperidol, erythromycin, escitalopram, flecainide, fluconazole, 
gatifloxacin, grepafloxacin, halofantrine, haloperidol, ibutilide, levofloxacin, 
levomepromazine, levosulpiride, levomethadyl, mesoridazine methadone, 
moxifloxacin, ondansetron, oxaliplatin, papaverine HCl (intra-coronary), 
pentamidine, pimozide, probucol, procainamide, propofol, quinidine, 
roxithromycin, sevoflurane, sotalol, sparfloxacin, sulpiride, sultopride, 
terlipressin, terodiline, terfenadine, thioridazine, vandetanib

Novartis Confidential Page 114
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Category Drug Name
Herbal preparati ons/ 
medications or dietary 
supplementsHerbal preparations/medications or dietary supplements known as strong 
inducers or inhibitors of CYP3A4/5 or those with a known risk of QT 
prolongation are prohibited throughout the study. These herbal include, but are 
not limited to: St. John’s wort, Kava, ephedra (ma huang), gingko biloba, 
dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. 
Patients should stop using these herbal medications or dietary supplements 7 
days prior to first dose of study drug.
Other investigational and 
antineoplastic therapiesOther investigational therapies must not be used while the patient is on the 
study. Anticancer therapy (chemotherapy, hormonal therapy, including but not 
limited to all SERMS [including raloxifene], biologic or radiation therapy [except 
for palliative radiotherapy as outlined in the protocol] , and surgery) other than 
the study treatments must not be given while the patien t is on the study 
medication. If such agents are required,   then the patient must discontinue the 
study drug.
1NTI = narrow therapeutic index drugs whose exposure -response indicates that increases in their exposure 
levels by the concomitant use of potent inhibitors may lead to serious safety concerns (e.g., Torsades de 
Pointes), or drugs which have <2 -fold difference in the minimum toxic concentrations and minimum effective 
concentrations in the blood .
2Herbal product
3P-gp inducer
4The list provided i s as of December 2019.Check crediblemeds.org/healthcare- providers/drug -list for the most 
updated list. 
5Drug has warning for risk of hepatotoxicity
As far as possible, avoid co -administration of QT prolonging drugs or any other drugs with the potential to 
increase the risk of drug -related QT prolongation (e.g., via a potential DDI that increases the exposure of 
ribociclib or the exposure of the QT prolonging drug). A definitive list of drugs with a known risk, possible risk, 
or conditional risk of QT pro longation and/or Torsades de Pointes (TdP ) is available online at qtdrugs.org .
Source: Novartis PK Sciences Memorandum: Drug -Drug Interactions (DDI) and Co -medication Considerations 
for Novartis Clinical Trials (January 2018 ),which is compiled from Indian a University “Clinically Relevant” 
Flockhart Table™, University of W ashington Drug Interaction Database, and FDA Drug Development and Drug 
Interactions: Table of Substrates, Inhibitors and Inducers .

Novartis Confidential Page 115
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Table 14-2 List of medications to be used with caution during study  drug 
treatment
Category Drug Name
Moderate CYP3A4/5 
inhibitorsAprepitant, a mprenavir, asafoetida resin (Ferula asafoetida) cimetidine , 
crizotinib , diltiazem, faldaprevir, imatinib, isavuconazole, netupitant, nilotinib,
tofisopam, Schisandra sphenanthera (nan wu wei zi) ,verapamil
Moderate CYP3A4/5 
inducersBosentan, dabrafenib, efavirenz, etravirine, genistein, modafinil, nafcillin,
telotristat, lopinavir5
Sensitive CYP3A4/5 
substrates1Alpha -dihydroergocryptine, apixaban ,aprepitant,   atorvastatin, avanafil, 
bosutinib,brotizolam, budesonide, buspirone, cannabinoids6, cannabidiol6, 
cobimetinib ,   darifenacin, dasatininb, ebastine, eletriptan, eplerenone, 
everolimus, felodipine, fluticasone, grazoprevir, ibrutnib, isavuconazole, 
ivabradine, ivacaftor ,lumefantrine, lurasidone, maraviroc, midazolam, 
midostaurin, naloxegol, neratinib, , perospirone, quetiapine, ridaforolimus , 
rivaroxaban, sildenafil, simeprevir, ,ticagrelor, tilidine,  tolvaptan, triazolam, 
ulipristal, vardenafil, venetoclax, vicriviroc, voclosporin
BSEP inhibitors Alectinib, atorvastatin, bromocriptine, candesartan, clobetasol, c lofaziminie, 
dabigatran, dipyridamole, glyburide, grazo previr, ledipasvir, mifepristone, 
pioglitazone, reserpine, rifamycin, simeprevir, telmisartan, timcodar, 
troglitazone, velpatasvir
Medications that carry a 
possible risk for QT 
prolongation2Alfuzosin, apomorphine, aripiprazole, artenimol+piperaquine ,asenapine,
atazanavir, atomoxetine,  bedaquiline, bendamustine, bortezomib, bosutinib , 
buprenorphine, cabozantinib, capecitabine, ceritinib, clomipramine, crizotinib, 
clozapine, cyamemazine (cyam epromazine), dabrafenib, dasatinib, degarilix, 
delamanid, desipramine, dexmedetomidine, dolasetron, efavirenz, eliglustat, 
epirubicin, eribulin mesylate , ezogabine (retigabine) , famotidine, felbamate, 
fingolimod, flupentixol, gemifloxacin, granisetron, hydrocodone -ER, iloperidone, 
imipramine (melipramine), isradipine, ketanserin, lapatinib, lenvatinib, 
leuprolide, loperamide, lithium, melperone, midostaurin, mifepristone, 
mirabegron, mirtazapine, moexipril/HCTZ, necitumumab, ,nilotinib, norfloxacin, 
nortriptyline, nusinersen, ofloxacin, olanzapineosimertinib,  oxytocin, 
paliperidone, palonosetron, panabinostat, pasireotide, pazopanib, perflutren 
lipid microspheres, perphenazine, pilsicainide, pimavanserin, pipamperone,
promet hazine, prothipendyl, quetiapine, ranolazine rilpivirine, risperidone, 
romidepsin, sertindole, sorafenib, sunitinib, tamoxifen, telavancin,tetrabenazine,
tipiracil/trifluridine, tizanidine, tolterodine, toremifene,trimipramine, tropisetron, 
vardenafil, vemurafenib, venlafaxine, vorinostat, ziprasidone
MATE1 /2substrates3Acyclovir, c ephalexin, cimetidine, fexofenadine, ganciclovir, glycopyrronium , 
metformin, pindolol , plisicainide, ranitidine, topotecan, varenicline
OCT 1/2 substrates4Amantadine, carboplatin, cisplatin, cephalexin, cephradine, ipratropium, 
lamivudine, linagliptin, metformin, oxaliplatin, oxybutynin, phenformin,
picoplatin, pilsicainide , pindolol, ranitidine ,sorafenib, tropisetron, trospium, 
umeclidinium ,,and zidovudine
BCRP substrates Daunorubicin, dolutegravir, doxorubicin, hematoporphyrin, imatinib, 
methotrexate, mitoxantrone, pitavastatin, rosuvastatin ,irinotecan, ethinyl 
estradiol, sulfasalazine , sofosbuvir, tenofovir, topotecan, venetoclax.

Novartis Confidential Page 116
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Category Drug Name
1Sensitive substrates: Drugs whose plasma AUC values have been shown to increase 5-fold or higher when 
co-administered with a potent inhibitor.
2The list provided is as of January 2018. Check https www crediblemeds.org/healthcare -providers/drug -list for 
the most updated list.
3MATE1 and MATE2 share considerable substrate specificity. 
4OCT1 and OCT2 share considerable substrate specificity.
5 Lopinavir and atazanvir is prohibited when combined with ritonavir (see Table 14 -1)
6Based data that,exposure of cannabidiol (CBD), tetrahydrocannabinol (THC), 11 -hydroxy THC ,increased by 
~2-3 folds when co -administered with ketoconazole (CYP3A4 inhibitor); Stott et al, Springerplus. 2013; 2: 236
Source: Novartis PK Sciences Memoran dum: Drug -Drug Interactions (DDI) and Co -medication Considerations 
for Novartis Clinical Trials (January 2018 ),which is compiled from Indiana University “Clinically Relevant” 
Flockhart Table™, University of Washington Drug Interaction Database, and FDA Dr ug Development and Drug 
Interactions: Table of Substrates, Inhibitors and Inducers .

Novartis Confidential Page 117
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
14.2 Appendix 2 – Patient Reported Outcomes FA CT-B

Novartis Confidential Page 118
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404

Novartis Confidential Page 119
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404

Novartis Confidential Page 121
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
GBM Glioblastoma multiforme
MRI Magnetic resonance imaging
LPLV Last patient last visit
OS Overall survival
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown

Novartis Confidential Page 122
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
14.3.1 Introduction
The purpose of this document is to provide the working definitions and rules necessary  for a 
consistent and efficient analy sis of efficacy  for oncology  studies in solid tumors. This document 
is based on the RECI ST criteria for tumor responses (Therasse, et al 2000) and the revised 
RECI ST 1.1 guidelines ( Eisenhauer, et al 2009 ).
The efficacy  assessments described in Section 14.3.2 and the definition of best response in 
Section 14.3.17 are based on the RECIST 1.1 criteria but also give more detailed instructions 
and rules for determination of best response. Section 14.3.18 is summarizing the “time to event” 
variables and rules which are mainl y derived from internal discussions and regulatory 
consultations, as the RECI ST criteria do not define these variables in detail. Section 14.3.29 of 
this guideline describes data handling and programming rules. This section is to be referred to 
in the SAP (Statistical Analy sis Plan) to provide further details needed for programming.
14.3.2 Efficacy  assessments
Tumor evaluations are made based on RECIST criteria ( Therasse, et al 2000 ), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205-16 and revised RECI ST guidelines (version 1.1) (Eisenhauer, et al 2009) European 
Journal of Cancer; 45:228 -
247.
14.3.3 Definitions
14.3.4 Disease measurability
In order to evaluate tumors throughout a study , definitions of measurability  are required in order 
to classify  lesions appropriately  at base line. In defining measurability , a distinction also needs 
to be made between nodal lesions (pathological l ymph nodes) and non -nodal lesions.
Measurable disease - the presence of at least one measurable nodal or non-nodal lesion. 
If the measurable disease i s restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology /histology .
For patients without measurable disease see Section 14.3.26
Measurable lesions (both nodal and non -nodal)
Measurable non- nodal - As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thickness or 10mm 
whichever is greater -e.g. the minimum non -nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.
Lytic bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the so ft 
tissue component meets the definition of measurability .
Measurable nodal lesions (i.e. ly mph nodes) - Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Lymph nodes measuring 10 mm and <15 mm 
are considered non-measurable. Ly mph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice thickness, are normal and not considered indicative of 
disease.

Novartis Confidential Page 123
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Cystic lesions:
Lesions that meet the criteria for radiographicall y defined simple cy sts (i.e., spherical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no 
septations, and low CT density  [water -like] content) should not be considered as 
malignant lesions (neither measurable nor non -measurable) since they  are, by  
definition, simple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considered as 
measurable lesions, if they meet the definition of measurability  described above. 
However, if noncy stic lesions are present in the same patient, these are pr eferred for 
selection as target lesions.
Non-measurable lesions - all other lesions are considered non -measurable, including small 
lesions (e.g. longest diameter <10 mm with CT/MRI  or pathological ly mph nodes with 
10 to < 15 mm short axis), as well as tr uly non -measurable lesions e.g., blastic bone 
lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory  breast 
disease, l ymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly  
identified by  physical exam that is not measurable by  reproducible imaging techniques.
14.3.5 Eligibility  based on measurable disease
If no measurable lesions are identified at baseline, the patient may  be allowed to enter the study 
in some situations (e.g. in Phase III studies where PFS is the primary endpoint). However, it is 
recommended that patients be excluded from trials where the main focus is on the Overall 
Response Rate (ORR). Guidance on how patients with just non- measurable disease at baseline 
will be evaluated for response and also handled in the statistical analy ses is given in Section 
14.3.26.
14.3.6 Methods of tumor measurement -general guidelines
In this document, the term “contrast” refers to intravenous (i.v.) contrast.
The following c onsiderations are to be made when evaluating the tumor:
All measurements should be taken and recorded in metric notation (mm), using a ruler or 
calipers. All baseline evaluations should be performed as closel y as possible to the 
beginning of treatment and 
never more than 4 weeks before the beginning of the 
treatment.
Imaging- based evaluation is preferred to evaluation by clinical examination when both 
methods have been used to assess the antitumor effect of a treatment.
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow-
up. Contrast
-enhanced CT of chest, abdomen and pelvis should preferably be performed 
using a 5 mm slice thickness w ith a contiguous reconstruction algorithm. CT/MRI  scan 
slice thickness should not exceed 8 mm cuts using a contiguous reconstruction algorithm. 
If, at baseline, a patient is known to have a medical contraindication to CT contrast or 
develops a contraindica tion during the trial, the following change in imaging modalit y will 
be accepted for follow up: a non- contrast CT of chest (MRI  not recommended due to 
respiratory  artifacts) plus contrast- enhanced MRI of abdomen and pelvis.

Novartis Confidential Page 124
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
A change in methodology  can be d efined as either a change in contrast use (e.g. keeping 
the same technique, like CT, but switching from with to without contrast use or vice -versa, 
regardless of the justification for the change) or a major change in technique (e.g. from CT 
to MRI , or vice -versa), or a change in an y other imaging modalit y. A change from 
conventional to spiral CT or vice versa will not constitute a major “change in method” for 
the purposes of response assessment. A c hange in methodology  will r esult by default in a 
UNK overal l lesion response assessment as per Novartis calculated response. However, 
another response assessment than the Novartis calculated UNK response may be accepted 
from the investigator or the central blinded reviewer if a definitive response assessment 
can b e justified, based on the available information.
FDG -PET: can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). New lesions on the basis of FDG
-PET imaging can be identified according 
to the following algorithm:
Negati ve FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion.
No FDG -PET at baseline with a positive FDG- PET at follow -up:
If new disease is indicated by  a positive PET scan but is not confirmed by  CT (or 
some other conventional technique such as MRI) at the same assessment, then 
follow -up assessments by  CT will be needed to determine if there is truly  
progression occurring at that site. In all cases PD will be the date of confirmation 
of new disease b y CT (or some othe r conventional technique such as MRI) rather 
than the date of the positive PET scan. If there is a positive PET scan without any  
confirmed progression at that site by  CT, then a PD cannot be assigned.
If the positive FDG -PET at follow -up corresponds to a p re-existing site of 
disease on CT that is not progressing on the basis of the anatomic images, this is 
not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are 
clearl y defined and surrounded by aerated lung. However, CT is preferable.
Physical exams: Evaluation of lesions by  physical examination is accepted when lesions 
are superficial, wi th at least 10mm size, and can be assessed using calipers.
Ultrasound: When the primary  endpoint of the study  is objective response evaluation, 
ultrasound (US) should not be used to measure tumor lesions, unless pre -specified by  the 
protocol. I t is, howeve r, a possible alternative to clinical measurements of superficial 
palpable l ymph nodes, subcutaneous lesions and thy roid nodules. US might also be useful 
to confirm the complete disappearance of superficial lesions usually  assessed by  clinical 
examination.
Endoscopy and laparoscopy: The utilization of endoscopy  and laparoscopy  for objective 
tumor evaluation has not y et been full y and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may  only be 
available in some centers. Therefore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in specialized centers. However, such 
techniques can be useful in confirming complete pathological res ponse when biopsies are 
obtained.

Novartis Confidential Page 125
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Tumor markers: Tumor markers alone cannot be used to assess response. However, 
some disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer, 
PSA for prostate cancer, alpha -FP, LDH and Beta- hCG for testicular cancer) can be 
integrated as non -target disease. If markers are initially  above the upper normal limit they  
must normalize for a patient to be considered in complete clinical response when all 
lesions have disappeared.
Cytology and histology: C ytology  and histology  can be used to differentiate between PR 
and CR in rare cases (i.e., after treatment to differentiate between residual benign lesions 
and residual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation of ne oplastic nature of any  effusion that appears or worsens during treatment 
is required when the measurable tumor has met the criteria for response or stable disease. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
diffe rentiation between response and stable disease (an effusion may  be a side effect of the 
treatment) or progressive disease (if the neoplastic origin of the fluid is confirmed).
Clinical examination : Clinical lesions will only  be considered measurable when t hey are 
superficial (i.e., skin nodules and palpable l ymph nodes). For the case of skin lesions, 
documentation by  color photography , including a ruler to estimate the size of the lesion, is 
recommended.
14.3.7 Baseline documentation of target and non -target lesio ns
For the evaluation of lesions at baseline and throughout the study , the lesions are classified at 
baseline as either target or non -target lesions:
Target lesions: All measurable lesions (nodal and non -nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and 
their suitability  for accurate repeated measurements (either by  imaging techniques or 
clinically ). Each target lesion must be uniquely  and sequentially  numbered on the eCRF 
(even if it resides in the same organ).
Minimum target lesion size at baseline
Non-nodal target : Non- nodal target lesions identified by  methods for which slice 
thickness is not applicable (e.g. clinical examination, photograph y) should be at least 10 
mm in longest diameter. See Section 14.3.4.
Nodal target : See 
Section 14.3.4 .
A sum of diameters (long axis for non -nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD) . The baseline sum of 
diameters will be used as reference by which to characterize the objective tumor response. Each 
target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.

Novartis Confidential Page 126
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Non-target lesions : All other lesions are considered non- target lesions, i.e. lesions not 
fulfilling the criteria for target lesions at baseline. Presence or absence or worsening of 
non-target lesions should be assessed throughout the study ; measurements of these lesions 
are not requir ed. Multiple non-target lesions involved in the same organ can be assessed as 
a group and recorded as a single item (i.e. multiple liver metastases). Each non -target 
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.
14.3.8 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameters for all target lesions will be calculated (at 
baseline and throughout the study ). At each assessment response is evaluated first separately 
for the target (Table 14-3) and non-target lesions (Table 14 -4) identified at baseline. These 
evaluations are then used to calculate the overall
lesion response considering both the target and 
non-target lesions together ( Table 14 - 5) as well as the presence or absence of new lesions.
14.3.9 Follow -up and recording of lesions
At each visit and for each lesion the actual date of the scan or procedure which was used for the 
evaluation of each specific lesion should be recorded. This applies to target and non-target 
lesions as well as new lesions that are detected. At the assessment visit all of the separa te lesion 
evaluation data are examined by the investigator in order to derive the overall visit response. 
Therefore all such data applicable to a particular visit should be associated with the same 
assessment number.
14.3.10 Non
-nodal lesions
Following treatment, lesions may  have longest diameter measurements smaller than the image 
reconstruction interval. Lesions smaller than twice the reconstruction interval are subject to 
substantial “partial volume” effects (i.e., size may be underestimated because of the dista nce of 
the cut from the longest diameter; such lesions may appear to have responded or progressed on 
subsequent examinations, when, in fact, they  remain the same size).
If the lesion has completely disappeared, the lesion size should be reported as 0 mm.
Measurements of non-nodal target lesions that become 5 mm or less in longest diameter are 
likely  to be non -reproducible. Therefore, it is recommended to report a default value of 5 mm, 
instead of the actual measurement. This 
default value is derived from the 5 mm CT slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement 
should be given for all lesions larger than 5 mm in longest diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where th e lesion cannot be reliably measured for reasons other than its size (e.g., 
borders of the lesion are confounded by neighboring anatomical structures), no measurement 
should be entered and the lesion cannot be evaluated.

Novartis Confidential Page 127
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
14.3.11 Nodal lesions
A nodal lesion less t han 10 mm in size by short axis is considered normal. Lym ph nodes are not 
expected to disappear completely , so a “non- zero size” will alway s persist.
Measurements of nodal target lesions that become 5 mm or less in short axis are likely  to be 
non-reproduci ble. Therefore, it is recommended to report a default value of 5 mm, instead of 
the actual measurement. This default value is derived from the 5 mm CT slice thickness (but 
should not be changed with varying CT slice thickness). Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of diameters for target 
lesions, which may  be required subsequentl y for response determination.
14.3.12 Determination of target lesion response
Table 14-3 Response criteria for target lesions
Response Criteria Evaluation of target lesions
Complete Response (CR): Disappearance of all non -nodal target lesions. In addition, any pathological lymph 
nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1
Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as 
reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, 
taking as reference the smallest sum of diameter of all target lesions recorded at 
or afte r baseline. In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm 2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions 
which would qualify for PD .
Unknown (UNK) Progression has not been documented and one or more target lesions have not 
been assessed or have been assessed using a different method than baseline.3
1.SOD for CR may not be zero when nodal lesions are part of target lesions
2.Follow ing an initial CR, a PD cannot be assigned if all non -nodal target lesions are still not present and all 
nodal lesions are <10 mm in size. In this case, the target lesion response is CR
3.In exceptional circumstances an UNK response due to change in metho d could be over -ruled by the 
investigator or central reviewer using expert judgment based on the available information (see Notes on target 
lesion response and methodology change in Section 14.3.6 ).
Notes on target lesion response
Reappearance of lesions: I f the lesion appears at the same anatomical location where a target 
lesion had previousl y dis appeared, it is advised that the time point of lesion disappearance (i.e., 
the “0 mm” recording) be re-evaluated to make sure that the lesion was not actually  present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investigator/radiologist has to decide between the following 
possib ilities:
The lesion is a new lesion, in which case the overall tumor assessment will be considered 
as progressive disease

Novartis Confidential Page 128
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the eCRF and the tumor assessment will remain 
based on the sum of tumor measurements as presented in Table 14-3 above (i.e., a PD will 
be determined if there is at least 20% increase in the sum of diam eters of allmeasured 
target lesions, taking as reference the smallest sum of diameters of all target lesions 
recorded at or after baseline with at least 5 mm increase in the absolute sum of the 
diameters). Proper documentation should be available to suppo rt this decision. This 
applies to patients who have not achieved target response of CR. For patients who have 
achieved CR, please refer to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if still small, is considered a PD.
Missing measurements: In cases where measurements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for 5 target lesions at baseline is 
100 mm at basel ine and the sum of diameters for 3 of those lesions at a post -baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 
in other cases where a PD cannot definitel y be attributed, the target lesion response would 
be UNK.
Nodal lesion decrease to normal size: When nodal disease is included in the sum of 
target lesions and the nodes decrease to “normal” size they  should still have a 
measurement recorded on scans. This measurement should be reported even when the 
nodes are normal in order not to overstate progression should it be based on increase in the 
size of nodes.
Lesions split: In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (long axis -
non-nodal lesion, short axis -nodal lesions) 
of the two split lesions should be added together and the sum recorded in the diameter 
field on the case report form under the original lesion number. This value will be included 
in the sum of diameters when deriving target lesion response. The individual split lesions 
will not be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced: Conversel y, itis also possible that two or more lesions which were 
distinctly  separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may  be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coalesced such that they 
are no longer separable, the maximal diameters (long axis - non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for t arget lesions. On the case report form, the diameter of the “merged lesion” 
should be recorded for the size of one of the original lesions while a size of “0”mm should 
be entered for the remaining lesion numbers which have coalesced.
The measurements for n odal lesions , even if less than 10 mm in size, will contribute to 
the calculation of target lesion response in the usual way  with slight modifications.
Since lesions less than 10 mm are considered normal, a CR for target lesion response 
should be assigned 
when all nodal target lesions shrink to less than 10 mm and all non -
nodal target lesions have disappeared.

Novartis Confidential Page 129
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Once a CR target lesion response has been assigned a CR will continue to be appropriate 
(in the absence of missing data) until progression of target lesions.
Following a CR, a PD can subsequently  only be assigned for target lesion response if 
either a non- nodal target lesion “reappears” or if any  single nodal lesion is at least 10 mm 
and there is at least 20% increase in sum of the diameters of all nod al target lesions 
relative to nadir with at least 5 mm increase in the absolute sum of the diameters.
A change in method for the evaluation of one or more lesions will usually lead to an UNK 
target lesion response unless there is progression indicated b y the remaining lesions which 
have been evaluated b y the same method. In exceptional circumstances an investigator or 
central reviewer might over -rule this assignment to put a non -UNK response using expert 
judgment based on the available information. E.g. a c hange to a more sensitive method 
might indicate some tumor shrinkage of target lesions and definitel y rule out progression 
in which case the investigator might assign an SD target lesion response; however, this 
should be done with caution and conservativel y as the response categories have well 
defined criteria.
14.3.13 Determination of non -target lesion response
Table 14-4 Response criteria for non -target lesions
Response Criteria Evaluation of non-target lesions
Complete Response (CR): Disappearance of all non -target lesions. In addition, all lymph nodes assigned a 
non-target lesions must be non -pathological in size (< 10 mm short axis)
Progressive Disease (PD): Unequivocal progression of existing non -target lesions.1
Non-CR/Non-PD: Neither CR nor PD
Unknown (UNK) Progression has not been documented and one or more non -target lesions have 
not been assessed or have been assessed using a different method than 
baseline2.
1.The assignment of PD solely based on change in non -target lesions in light of target lesion response of CR, 
PR or SD should be exceptional. In such circumstances, the opinion of the investigator or central reviewer does 
prevail.
2.It is recommended that t he investigator and/or central reviewer should use expert judgment to assign a Non -
UNK response wherever possible (see notes section for more details)
Notes on non -target lesion response
The investigator and/or central reviewer can use expert judgment to assign a non- UNK 
response wherever possible, even where lesions have not been fully  assessed or a different 
method has been used. In many  of these situations it may  still be possible to identify  
equivocal progression (PD) or definitively  rule this out (non- CR/Non -PD) based on the 
available information. In the specific case where a more sensitive method has been used 
indicating the absence of any  non-target lesions, a CR response can also be assigned.

Novartis Confidential Page 130
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions 
returned to normal size (i.e. < 10 mm). If an y of the non -target lesions are still present, or 
there are an y abnormal nodal lesions (i.e. 10 mm) the response can onl y be ‘ Non-
CR/Non -PD’ unless there is unequivocal progression of the non -target lesions (in which 
case response is PD) or it is not possible to determine whether there is unequivocal 
progression (in which case response is UNK).
Unequivocal progression: To achieve “unequivocal progression” on the basis of non-
target disease there must be an overall level of substantial worsening in non -target disease 
such that, even in presence of CR, PR or SD in target disease, the overall tumor bu rden 
has increased sufficiently to merit discontinuation of therap y. A modest “increase” in the 
size of one or more non- target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of overall progression solely  onthe basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non -
target lesions, the increase in the 
extent of the disease must be substantial even in cases where there is no measurable 
disease at baseline. If there is unequivocal progression of non- target lesion(s), then at least 
one of the non -target lesions must be assigned a status of “Worsened”. Where possible, 
similar rules to those described in Section 14.3.12 for assigning PD following a CR for the 
non-target lesion response in the presence of non -target lesions nodal lesions should be 
applied.
14.3.14 New lesions
The appearance of a new lesi on is alway s associated with Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion eCRF page.
If a new lesion is 
equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it rep resents truly  new disease. If repeat scans confirm 
there is definitel y a new lesion, then progression should be declared using the date of the 
first observation of the lesion
If new disease is observed in a region which was not scanned at baseline or where the 
particular baseline scan is not available for some reason, then this should be considered as 
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for an y of thi s patient's assessment 
(see Section 14.3.15).
A lymph node is considered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size to 10 mm for the first time in the study  plus 5 
mm absolute increase.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). See 
Section 14.3.6 .
14.3.15 Evaluatio n of overall lesion response
The evaluation of overall lesion response at each assessment is a composite of the target lesion 
response, non- target lesion response and presence of new lesions as shown below in Table 14 -
5.

Novartis Confidential Page 131
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Table 14-5 Overall lesion response at each assessment
Target lesions Non-target lesions New Lesions Overall
lesion response
CR CR No CR1
CR Non-CR/Non-PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1.This overall lesion response also applies when there are no non-target lesions identified at baseline.
2.Once confirmed PR was achieved, all these assessments are considered PR.
3.As defined in Section 14.3.8 .
If there are no baseline scans available at all, then the overall lesion response at each assessment 
should be considered Unknown (UNK).
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determinatio n, it is recommended 
that the residual lesion be investigated (fine needle aspirate/biopsy ) to confirm the CR.
14.3.16 Efficacy  definitions
The following definitions primarily relate to patients who have measurable disease at baseline. 
Section 14.3.26 outlines the special considerations that need to be given to patients with no 
measurable disease at baseline in order to appl y the same concepts.
14.3.17 Best overall response
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). In general, the patient's best response assignment will depend on 
the achievemen t of both measurement and confirmation criteria.
The best overall response will usually  be determined from response assessments undertaken 
while on treatment. However, if an y assessments occur after treatment withdrawal the protocol 
should specificall y describe if these will be included in the determination of best overall 
response and/or whether these additional assessments will be required for sensitivity  or 
supportive analyses. As a default, any  assessments taken more than 30 day s after the last dose 
of study  treatment will not be included in the best overall response derivation. If any alternative 
cancer therapy  is taken while on study  any subsequent assessments would ordinarily  be 
excluded from the best overall response determination. If response assessments taken after 
withdrawal from study  treatment and/or alternative therap y are to be included in the main 
endpoint determination, then this should be described and justified in the protocol.
Where a study  requires confirmation of response (PR or CR), cha nges in tumor measurements 
must be confirmed by  repeat assessments that should be performed not less than 4 weeks after 
the criteria for response are first met.

Novartis Confidential Page 132
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Longer intervals may  also be appropriate. However, this must be clearl y stated in the protocol.
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are n ot confirmed.
For non -randomized trials where response is the primary  endpoint, confirmation is needed.
For trials intended to support accelerated approval, confirmation is needed
For all other trials, confirmation of response may  be considered optional.
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one de termination of CR prior to progression where confirmation 
not required
PR = at least two determinations of PR or better at least 4 weeks apart before progression 
(and not qualify ing for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required
SD = at least one SD assessment (or better) > 6 weeks after randomization/start of 
treatment (and not qualifying for CR or PR).
PD = progression  12 weeks after randomization/ start of treatment (and not qualify ing 
for CR, PR or SD).
UNK = all other cases (i.e. not qualify ing for confirmed CR or PR and without SD after 
more than 6 weeks or early  progression within the first 12 weeks)
The time durations specified in the SD/PD/UNK definitions above are defaults based on a 6 
week tumor assessment frequency . However these may be modified for specific indications 
which are more or less aggressive. In addition, it is envisaged that the time duration may also 
take into account assessment windows. E.g. if the assessment occurs every 6 weeks with a time 
window of +/ -7 days, a BOR of SD would require a SD or better response longer than 5 weeks 
after randomization/start of treatment.
Overall lesion responses of CR must stay the same until progression sets in, with the except ion 
of a UNK status. A patient who had a CR cannot subsequently  have a lower status other than a 
PD, e.g. PR or SD, as this would imply  a progression based on one or more lesions reappearing, 
in which case the status would become a PD.
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR (30% reduction of tumor 
burden compared to baseline) at one assessment, followed by  a <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally  
disappear in which case a CR assignment is applicable. In studies where confirmation of 
response is not required after a single PR the overall lesion response should still be considered 

Novartis Confidential Page 133
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
PR (or UNK) until progression is documented or the lesion totally  disappears in which case a 
CR assignment is applicable.
Example: In a case where confirmation of response is required the sum of lesion diameters is 
200 mm at baseline and then 140 mm - 150 mm - 140 mm - 160 mm - 160 mm at the subsequent 
visits. Assuming that non -target lesions did not progress, the overall lesion response would be
PR -SD - PR -PR -PR. The second assessment with 140 mm confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 
20% compared to baseline (200 mm to 160 mm) at the following assessments.
If the patient progressed but continues study  treatment, further assessments are not considered 
for the determination of best overall response.
Note: these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may  be provided 
from different sources:
Investigator overall lesion response
Central Blinded Review overall lesion response
Novartis calculated overall lesion response (based on measurements from either 
Investigator or Central Review)
The primary  analysis of the best overall response will be based on the sequence of
investigator/central blinded review/calculated (investigator)/calculated (central) overall lesion 
responses.
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications.
Disease control rate (DCR) is the proportion of patients with a best overall response of CR or 
PR or SD. The objective of this endpoint is to summarize patients with signs of “activit y” 
defined as either shrinkage of tumor (regardless of duration) o r slowing down of tumor growth.
Clinical benefit rate (CBR) is the proportion of patients with a best overall respon se of CR or 
PR , or an overall lesion response ofSD or Non-CR/Non -PD which lasts for a minimum time 
duration (with a default of at least 24 weeks in breast cancer studies). This endpoint measures 
signs of activity  taking into account duration of disease s tabilization.
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used:
Early progression rate (EPR) is the proportion of patients with progressive disease within 
8weeks o f the start of treatment.
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study  specific. EPR is used for the multinomial designs of Dent and Zee (2001)and 
counts all patients who at the specified assessment (in this example the assessment would be at 

Novartis Confidential Page 134
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with an 
unknown (UNK) assessment at that time point and no PD before, will not be counted as early 
progressors in the anal ysis but may  be included in the denominator of the EPR rate, depending 
on the analy sis population used. Similarly  when examining overall response and disease control, 
patients with a best overall response assessment of unknown (UNK) will not be regarded as 
“responders” but may be included in the denominator for ORR and DCR calculation depending 
on the anal ysis population (e.g. populations based on an ITT approach).
14.3.18 Time to event variables
The protocol shou ld state which of the following variables is used in that study.
14.3.19 Progression -free survival
Usually  in all Oncology  studies, patients are followed for tumor progression after 
discontinuation of study  medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearl y stated in the protocol. Note that 
randomized trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression- free survival is censored at the date of last adequate 
tumor assessment.
PFS rate at x weeks is an additional measure used to quantify PFS endpoint. It is recommended 
that a Kaplan Meier estimate is used to assess this endpoint.
14.3.20 Overall survival
All patients should be followed until death or until patient has had adequate follow -up time as 
specified in the protocol whichever comes first. The follow -up data should contain the date the 
patient was last seen alive / last known date patient alive, the date of death and the reason of 
death (“Stud y indication” or “Other”).
Overall survival (OS) is defined as the time from date of randomization/start of treatment to 
date of death due to an y cause. If a patient is not known to have died, survival will be censored 
at the date of last known date patient alive.
14.3.21 Time to progression
Some studies might consider only death related to underly ing cancer as an event which indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as 
PFS except for death unrelated to underl ying cancer.
Time to progression (TTP) is the time from date of randomization/start of treatment to the 
date of event defined as the first documented progression or death due to underly ing cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate tum or 
assessment.

Novartis Confidential Page 135
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
14.3.22 PFS2
A recent EMA guidance (EMA 2012) recommends a substitute end point intermediate to PFS 
and OS called PFS2, a surrogate for OS when OS cannot be measur
ed reliably , which assesses 
the impact of the experimental therapy  on next- line treatment. The main purpose of this 
endpoint is to assess long term maintenance strategies, particularly  of resensitizing agents and 
where it is necessary  to examine the overall “field of influence”.
PFS2, which could be termed PFS deferred, PFS delay ed, tandem PFS, or PFS version 2.0, is 
the time from date of randomization/start of treatment to the date of event defined as the first 
documented progression on next- line treatment or death from any cause. The censoring rules 
for this endpoint will incorporate the same principles as those considered for PFS in this 
document, and in addition may involve other considerations which will need to be detailed in 
the protocol.
Please note that data collection for the PFS2 is limited to the date of progression and not specific 
read of the tumor assessments.
It is strongl y recommended that the teams consult regulatory  agencies for scientific advice given 
the limited experience with the use of this endpoint in regulatory setting in light of 
methodological issues w.r.t. censoring foreseen.
14.3.23 Time to treatment failure
This endpoint is often appropriate in studies of advanced disease where early discontinuation is 
typicall y related to intolerance of the study  drug. In some protocols, time to treatment failure 
may be considered as a sensitivity  analysis for time to progression. The list of discontinuation 
reasons to be considered or not as treatment failure may be adapted according to the specificities 
of the study  or the disease .
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date of progression, date of death due to any cause, or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment 
failure for patients who did not experience treatment failure will be censored at last adequate 
tumor assessment.
14.3.24 Duration of response
The analy sis of the following variables should be performed with much caution when restricted 
to responders since treatment bias could have been introduced. There have been reports where 
a treatment with a significantly  higher response rate had a significantly shorter duration of 
response but where this probabl y primaril y reflected selection bias which is explained as 
follows: I t is postulated that there are two groups of patients: a good risk group and a poor risk 
group. Good risk patients tend to get into response readily  (and relativel y quickly ) and tend to 
remain in response after they  have a response. Poor risk patients tend to be difficult to achieve 
a response, may have a longer time to respond, and tend to relapse quickly  when they do respond. 
Potent agents induce a response in both good risk and poor risk patients. Less potent agents 
induce a response mainly in good risk patients only. This is described in more detail by Morgan 
(1988)

Novartis Confidential Page 136
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
It is recommended that an analysis of all patients (both responders and non-responders) be 
performed whether or not a “responders onl y” descriptive anal ysis is presented. An analy sis of 
responders should only be performed to provide descriptive statistics and even then interpreted 
with caution by evaluating the results in the context of the observed response rates. If an
inferential comparison between treatments is required this should only be performed on all 
patients (i.e. not restricting to “responders” only ) using appropriate statistical methods such as 
the techniques described in Ellis, et al (2008) . It should also be stated in the protocol if duration 
of response is to be calculated in addition for unconfirmed res
ponse.
For summary  statistics on “responders” only the following definitions are appropriate. (Specific 
definitions for an all-patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study  is usuall y taken into account in the anal ysis).
Duration of overall response (CR or PR) : For patients with a CR or PR (which may  have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end date 
and censoring is defined the same as that for time to progression.
The following two durations might be calculated in addition for a large Phase III study  in whic h 
a reasonable number of responders is seen.
Duration of overall complete response (CR) : For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that fo r time to progression.
Duration of stable disease (CR/PR/SD) : For patients with a CR or PR (which may have to be 
confirmed) or SD the start and end date as well as censoring is defined the same as that for time 
to progression.
14.3.25 Time to response
Time to over all response (CR or PR) is the time between date of randomization/start of 
treatment until first documented response (CR or PR). The response may  need to be confirmed 
depending on the ty pe of study  and its importance. Where the response needs to be confirm ed 
then time to response is the time to the first CR or PR observed.
Although an analysis on the full population is preferred a descriptive analysis may be performed 
on the “responders” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response in Section 14.3.23. I t is recommended that an 
analysis of all patients (both responders and non-responders) be performed whether or not a 
“responders onl y” descriptive analysis is presented. Where an inferential statistical comparison 
is required, then all patients should definitely  be included in the analysisto ensure the statistical 
test is valid. For anal ysis including all patients, patients who did not achieve a response (which 
may have to be a confirmed response) will be censored using one of the following options.

Novartis Confidential Page 137
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
at maximum follow -up (i.e. FPFV to LPLV used for the anal ysis) for patients who had a 
PFS event (i.e. progressed or died due to an y cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subsequently  respond. Since the 
statistical analy sis usually  makes u se of the ranking of times to response it is sufficient to 
assign the worst possible censoring time which could be observed in the study  which is 
equal to the maximum follow- up time (i.e. time from FPFV to L PLV)
at last adequate tumor assessment date other wise. In this case patients have not y et 
progressed so they  theoretically  still have a chance of responding
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis con siderations including (if appropriate) 
censoring rules apply  for this endpoint described for the time to overall response endpoint.
14.3.26 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as the latest of 
all measurement dates (e.g. X -ray, CT-scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise -if overall lesion response is progression -the assessment date is 
calculated as t he earliest date of all measurement dates at that evaluation number.
In the calculation of the assessment date for time to event variables, any unscheduled 
assessment should be treated similarly  to other evaluations.
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the following start date should be used:
Date of first documented response is the assessment date of the first overall lesion 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively , when this status is later confirmed.
End dates
The end dates which are used to calculate ‘time to event’ variables are defined as follows:
Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded on the study  evaluation completion page or the survival follow -up 
page).
Date of progression is the first assess ment date at which the overall lesion response was 
recorded as progressive disease.

Novartis Confidential Page 138
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was made before an event or a censoring reas on 
occurred. In this case the last tumor evaluation date at that assessment is used. If no post -
baseline assessments are available (before an event or a censoring reason occurred) the 
date of randomization/start of treatment is used.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus 
the protocol specified time interval for assessments. This date may  be used if back-dating 
is considered when the event occurred bey ond the acceptable time window for the next 
tumor assessm ent as per protocol (see Section 14.3.26).
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact is defined as the last date the patient was known to be alive. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment 
date. If available, the last known date patient alive from the survival follow -up page is 
used. If no survival follow- up is available, the date of discontinuation is used as last 
contact date.
Date of se condary  anti- cancer therap y is defined as the start date of an y additional 
(secondary ) antineoplastic therap y or surgery .
14.3.27 Handling of patients with non -measurable disease only  at baseline
It is possible that patients with only non- measurable disease present at baseline are entered into 
the study , either because of a protocol violation or by design (e.g. in Phase III studies with PFS 
as the primary  endpoint). In such cases the handling of the response data requires special 
consideration with respect to inclu
sion in any analysis of endpoints based on the overall 
response evaluations.
It is recommended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoints.
Although the text of thedefinitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response for patients with non-
measurab le disease is derived slightly  differently  according to 
Table 14 -6.
Table 14
-6 Overall lesion response at each assessment: patients with non -target 
disease only
Non-target lesions New Lesions Overall lesion response
CR No CR
Non-CR/Non-PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section 14.3.8 .

Novartis Confidential Page 139
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 
only non - measurable disease may  be highlighted in an appropriate fashion e.g. in particular by 
display ing the specific numbers with the non- CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression needs to be taken into account.
For ORR it is recommended that the main (I TT) analy sis includes data from patients with only 
non-measurable disease at baseline, handling patients with a best response of CR as “responders” 
with respect to ORR and all other pat ients as “non -responders”.
For PFS, it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non-measurable disease at baseline, with possible sensitivity analyses which 
exclude these particular patients. Endpoints such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients with only non-measu rable 
disease.
14.3.28 Sensitivity analy ses
This section outlines the possible event and censoring dates for progression, as well as addresses 
the issues of missing tumor assessments during the study . For instance, if one or more 
assessment visits are missed prior to the progression event, to what date should the progression 
event be assigned? And should progression event be ignored if it occurred after a long period 
of a patient being lost to follow -up? It is important that the protocol and RAP specify  the 
primary analy sis in detail with respect to the definition of event and censoring dates and also 
include a description of one or more sensitivity  analy ses to be performed.
Based on definitions outlined in Section 14.3.25, and using the draft FDA guideline on 
endpoints 
(Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 2005) 
as a reference, the following analy ses can be considered:
Table 14-7 Options for event dates used in PFS, TTP, duration of response
Situation Options for end -
date (progression or 
censoring)1
(1) = default unless specified differently  in the 
protocol or RAPOutcome
A No baseline assessment (1)Date of randomization/start of treatment3Censored
B Progression at or before next scheduled 
assessment(1) Date of progression
(2) Date of next scheduled assessment2Progressed
Progressed
C1 Progression or death after exactly  one
missing assessment(1)Date of progression (or death)
(2) Date of next scheduled assessment2Progressed
Progressed
C2 Progression or death after two or more
missing assessments(1) Date of last adequate assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored

Novartis Confidential Page 140
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Situation Options for end -date (progression or 
censoring)1
(1) = default unless specified differently  in the 
protocol or RAPOutcome
E Treatment discontinuation due to ‘Disease 
progression’ without documented 
progression, i.e. clinical progression 
based on investigator claim(1) Ignore clinical progress ion and follow 
situations above
(2) Date of discontinuation (visit date at which 
clinical progression was determined)As per above 
situations
Progressed
F New anticancer therapy given (1) Ignore the new anticancer therapy and follow
situations above (ITT approach)
(2) Date of last adequate assessment prior to new 
anticancer therapy
(3) Date of secondary anti -cancer therapy
(4) Date of secondary anti -cancer therapyAs per above 
situations
Censored
Censored
Event
G Deaths du e to reason other than 
deterioration of ‘Study indication’(1) Date of last adequate assessment Censored 
(only TTP and 
duration of 
response)
1.=Definitions can be found in Section 14.3.25 .
2.=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in
Section 14.3.25 .
3.=The rare exception to this is if the patient dies no later than the time of the second schedule d assessment as 
defined in the protocol in which case this is a PFS event at the date of death.
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and wh y options (1) are not used for situations C, E and (if applicable) F.
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using options (1) for situations C1 and C2, i.e.
(C1) taking the actual progression or death date, in the case of only one missing 
assessment.
(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or missing assessments (situation C2), option (3) may  be considered jointly 
with option (1) in situation C1 as sensitivity  analysis. A variant of this sensitivity  analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Di sease progression’ without documented 
progression :By default, option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment. However, option (2) may 
be used as sensitivity  analy sis. If progression is claimed based on clinical deterioration instead 
of tumor assessment by e.g. CT-scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration.

Novartis Confidential Page 141
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1) (ITT) is the recommended approach; events 
documented after the initiation of new cancer therap y will be considered for the primary 
analysis i.e. progressions and deaths documented after the initiation of new cancer therapy 
would be included as events. This will require continued follow -up for progression after the 
start of the new cancer therapy . In such cases, it is recommended that an additional sensitivity  
analysis be performed by censoring at last adequate assessment prior to initiation of new cancer 
therap y.
Option (2), i.e. censoring at last adequate assessment may be used as a sensitivity  analy sis. If a 
high censoring rate due t o start of new cancer therapy is expected, a window of approximately 
8 weeks performed after the start of new cancer therap y can be used to calculate the date of the 
event or censoring. This should be clearl y specified in the anal ysis plan.
In some specifi c settings, local treatments (e.g. radiation/surgery ) may not be considered as 
cancer therapies for assessment of event/censoring in PFS/TTP/DoR analysis. For example, 
palliative radiotherap y given in the trial for analgesic purposes or for lytic lesions at risk of 
fracture will not be considered as cancer therap y for the assessment of BOR and PFS analyses. 
The protocol should clearly  state the local treatments which are not considered as antineoplastic 
therapies in the PFS/TTP/DoR analy sis.
The protocol should state that tumor assessments will be performed every  x  w eeks until 
radiological progression irrespective of initiation of new antineoplastic therapy . It is strongl y 
recommended that a tumor assessment is performed before the patient is switched to a new 
cancer therap y.
Additional suggestions for sensitivity analyses
Other suggestions for additional sensitivity  analyses may include analy ses to check for potential 
bias in follow -up schedules for tumor assessments, e.g. by assigning the dates for censorin g and  
events only  at scheduled visit dates. The latter could be handled by  replacing in Table 14 -7the 
“Date of last adequate assessment” by the “Date of previous scheduled assessment (from 
baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly  
followed from baseline, immediately
 before or on the date of the last adequate tumor 
assessment.
In addition, analy ses could be repeated using the Investigators’ assessments of response rather 
than the calculated response. The need for these types of sensitivity  anal yses will depend on the 
individual requirements for the specific study  and disease area and have to be specified in the 
protocol or RAP documentation.
14.3.29 Data handling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).

Novartis Confidential Page 142
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
14.3.30 Study/project specific decisions
For each study  (or project) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
14.3.31 End of treatment phase completion
Patients may voluntarily withdraw from the study  treatment or may be taken off the study 
treatment at the discretion of the investigator at any time. For patients who are lost to follow -
up, the investigator or designee should show "due diligence" by documenting in the source 
documents steps taken to contact the patient, e.g., dates of telephone calls, registered letters, etc.
The end of treatment visit and its associated assessments should occur within 7 da ys of the last 
study treatment.
Patients may  discontinue study  treatment for an y of the following reasons:
Adverse event(s)
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Progressive disease
Study  terminated b y the sponsor
Non-compliant with study  treatment
No longer requires treatment
Treatment duration completed as per protocol (optional, to be used if only  a fixed number 
of cy cles is given)
Death is a reason which “ must ” lead to discont inuation of patient fr om trial.
14.3.32 End of post -treatment follow -up (study  phase completion)
End of post-treatment follow -up visit will be completed after discontinuation of study  treatment 
and post -treatment evaluations but prior to collecting survival follow-up.
Patients may  prov ide study  phase completion information for one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy

Novartis Confidential Page 143
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Protocol deviation
Technical problems
Subject/guardian decision
Death
Progressive disease
Study  terminated by  the sponsor
14.3.33 Medical validation of programmed overall lesion response
In order to be as objective as possible the RECI ST programmed calculated response assessment 
is very strict regarding measurement methods (i.e. any assessment with more or less sensitive 
method than the one used to assess the lesion at baseline is considered UNK) and not available 
evaluations (i.e. if any target or non-target lesion was not evaluated the whole overall lesion 
response is UNK unless remaining lesions qualified for PD). This contrasts with the slightly  
more flexible guidance given to local investigators (and to the central reviewers) to use expert 
judgment in determining response in these type of situations, and therefore as a consequence 
discrepancies between the different sources of response assessment often arise. To ensure the 
quality  of response assessments from the local site and/or the central reviewer, the responses 
may be re -evaluated by clinicians (based on local investigator data recorded in eCRF or based 
on central reviewer data entered in the database) at Novartis or external experts. In addition, 
data review reports will be available to identify  assessments for which the investigators’ or 
central reader’s opinion does not match the programmed calculated response based on RECIS T 
criteria. This may be queried for clarification. However, the investigator or central reader’s 
response assessment will never be overruled.
If Novartis elect to invalidate an overall lesion response as evaluated by the investigator or 
central reader upon internal or external review of the data, the calculated overall lesion response 
at that specific assessment is to be kept in a dataset. This must be clearl y documented in the 
RAP documentation and agreed before database lock. This dataset should be create d and stored 
as part of the ‘raw’ data.
Any discontinuation due to ‘Disease progression’ without documentation of progression by 
RECI ST criteria should be carefull y reviewed. Only patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or stud y evaluation.
14.3.34 Programming rules
The following should be used for programming of efficacy  results:

Novartis Confidential Page 144
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
14.3.35 Calculation of ‘time to event’ variables
Time to event = end date -start date + 1 (in day s)
When no post-baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as end date (duration = 1 day ) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negat ive.
14.3.36 Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 14.3.25). If all measurement dates have no 
day recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
14.3.37 Incomplete dates for last known date patient alive or death
All dates must be completed with day, month and year. If the day is missing, the 15thof the 
month will be used for incomplete death dates or dates of last contact.
14.3.38 Non- target lesion response
If no non -target lesions are identified at baseline (and therefore not followed throughout the 
study ), the non-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
14.3.39 Study/project specific programming
The st andard anal ysis programs need to be adapted for each study /project.
14.3.40 Censoring reason
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.
For survival the following censoring reasons are possible:
Alive
Lost to follow -up
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:
Ongoing without event
Lost to follow -up

Novartis Confidential Page 145
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
Withdrew consent
Adequate assessment no longer available*
Event documented after two or more missing tumor assessments (optional, see Table 14 -7)
Death due to reason other than underl ying cancer (only used for TTP and duration of 
response)
Initiation of new anti-cancer therapy
*Adequate assessment is defined in Section 14.3.25 . This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut-off 
(or prior to any other 
censoring reason) corresponding to the unavailability  of two or more planned tumor 
assessments prior to the cut-off date. The following clarifications concerning this reason should 
also be noted:
This may  be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study  evaluation completion page), when patients are not 
followed for progression after treatment comple tion or when onl y UNK assessments are 
available just prior to data cut -off).
The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -
cancer therapy) has occurred more than the specified period following the last adequate 
assessment.
This reason will also be used to censor in case of no baseline assessment.
14.3.41 References (available upon request)
Dent S, Zee (2001) application of a new multin omial phase II stopping rule using response 
and earl y progression, J Clin Oncol; 19: 785
-791
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECI ST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228 -47
Ellis S, et al (2008) Analysis of duration of response in oncology trials. Contemp Clin Trials 
2008; 29: 456-465
EMA Guidance: 2012 Guideline on the evaluation of anticancer medicinal products in man
FDA Guidelines: 2005 Clinical Trial Endpoints for the Appro val of Cancer Drugs and 
Biologics, April 2005
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May  2007
Morgan TM (1988) Analy sis of duration of response: a problem of oncology  trials. Cont Clin 
Trials; 9: 11-18
Therasse P, Arbuck S, Eisenhauer E, et al (2000) New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205 -16

Novartis Confidential Page 146
Amended Protocol Version 04 (Clean) Protocol No. CLEE011A2404
14.4 Appendix 4 -Bone Marrow Reserve in A dults
Table 14-8 Bone Marrow Reserve in A dults
MARROW DISTRIBUTION OF THE ADULT
SITEMARROW
wt. (g)FRACTION 
RED 
MARROW 
AGE 40RED 
MARROW 
wt. (g)
AGE 40% TOTAL RED 
MARROW
CRANIUM 
AND
MANDIBLEHead:
Cranium
Mandible165.8
16.40.75
0.75136.6
124.3
12.313.1 13.1
HUMERI, 
SCAPULAE, 
CLAVICLESUpper Limb Girdle :
2 Humerus, head & 
neck
2 Scapulae
2 Clavicles26.5
67.4
21.60.75
0.75
0.7586.7
20.0
50.5
16.28.3 8.3
STERNUM 
AND
RIBSSternum
Ribs:
1 pair
2
3
4
5
6
7
8
9
10
11
1239.0
10.2
12.6
16.0
18.6
23.8
23.6
25.0
24.0
21.2
16.0
11.2
4.60.6
All 0.423.4
82.6
4.1
5.0
6.4
7.4
9.5
9.4
10.0
9.6
8.5
6.4
4.5
1.82.3
7.910.2
PELVIC 
BONESSacrum
2 os coxae194.0
310.60.75
0.75145.6
233.013.9
22.3 36.2
FEMUR 2 Femoral head
and neck53.0 0.75 40.0 3.8
Adapted from R.E. ELLIS: The Distribution of Active Bone Marrow in the Adult, Phy. Med. 
Biol. 5, 255 -258, 1961
